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Abstract 
 
Propelled by the significant socio-economic issues presented by obesity and an ageing 
population, research has identified links between physical activity, metabolism and 
disease, and quality of life. Our overall aim was to implement an empirically informed, 
palatable acute endurance exercise intervention that elicits beneficial hormonal responses 
with the potential for improved health/quality of life across the lifespan. Two groups of 
similar male participants (Study 1: n = 6; age, 28 ± 5 yrs.; BMI, 25 ± 4 kg/m2 - Study 2: 
n = 7; age, 26 ± 7 yrs.; BMI, 25 ± 4 kg/m2) performed equal work (varying duration) 
moderate (80 % GET) (M) and heavy (30 % ) (H) (Study 1), and H and very heavy (60 
% ) (VH) (Study 2) acute constant work-load cycle ergometer exercise trials, 
respectively (Chapter 3). Analysis of bioptic material indicated increased mRNA 
(GAPDH normalised) in skeletal muscle for IL-6: baseline (B) vs. M (P = 0.006), H (P < 
0.001) and VH (P < 0.001), and M vs. VH (P = 0.02); TNFα: B vs. VH (P = 0.04) and 
SOCS3 B vs. M (P = 0.02) and VH (P = 0.04). Exercise was without effect in 
subcutaneous adipose tissue (Chapter 4). The systemic concentrations of IL-6 increased 
and remained elevated for 24 hrs. in response to exercise. The increase was greatest 
following M (P = 0.001). IGF-I and cortisol concentrations declined by 60 min post-
exercise (P = 0.001 and P = 0.04, respectively) (M, H and VH). GH increased to peak at 
the end of exercise (P < 0.001) (M, H and VH) (Chapter 5). To investigate the effect of 
age, groups of male participants (Study 3: 20 - 30 yrs., n = 8; 30 - 40 yrs., n = 10; 40 - 50 
yrs., n = 8; 50 - 60 yrs., n = 8) performed a similar 30 min bout of heavy (30 % ) domain 
exercise (Chapter 6). The systemic concentrations of IL-6 displayed a bi-phasic profile in 
all groups. IL-6 increased during exercise at 10 min and then 60 min post-exercise (P < 
0.001). Insulin and leptin declined during exercise in all groups (P < 0.001 and P = 0.002, 
respectively). Adiponectin was unchanged. GH increased similarly in all groups to peak 
again at the end of exercise (P < 0.001). IGF-I was unchanged. Concentrations were 
consistently higher in the 20 – 30 group however (P = 0.001). Cortisol declined similarly 
post-exercise in all groups (P < 0.001). We suggest that the oxygen uptake dynamics 
approach used here should be used when investigating physiological phenomenon 
potentially sensitive to skeletal muscle metabolic threshold events. We conclude that the 
exercise-induced hormone and cytokine responses studied in recreationally active health 
males between 20 and 60 yrs. age most likely reflects the requirements of metabolism. 
Further work should assess the effectiveness of this modified approach against resistance 
exercise in a training study format. 
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Chapter 1. Literature review 
 
1.1. Age-related skeletal muscle functional decline 
 
The increase in the prevalence of skeletal muscle functional decline with age and the 
globally increasing numbers of the ‘oldest old’ is of major socio-economic significance 
(World Health Organization, 2012). In the United Kingdom alone, the number of people 
aged 85 and over doubled from 0.7 million to over 1.4 million between 1985 and 2010 
and this number is projected to increase to 3.5 million by 2035 (Office for National 
Statistics, 2012). For this reason there has been a concerted drive to understand the 
mechanisms behind the skeletal muscle functional decline that occurs with increasing age 
(Mitchell et al., 2012). Of particular importance are the mechanisms governing the loss 
of skeletal muscle strength ‘Dynapenia’ (Clark and Manini, 2008; 2010; 2012) and the 
contributions of age-related reductions in skeletal muscle mass ‘Sarcopenia’ (Rosenberg, 
1989; 1997), declining levels of physical activity (Amati et al., 2009; Cobley et al., 2015; 
Wullemset al., 2016), increasing adipose tissue mass (obesity) (Visser, 2011) and 
inflammation (Franceschi and Campisi, 2014). Nair (2005) suggested that the reduction 
in skeletal muscle mass/strength, in combination with reduced endurance, is responsible 
for reduced voluntary physical activity levels in ageing individuals. The result is a 
reduction in total energy expenditure and weight gain through adipose tissue 
accumulation (Nair, 2005). Increased adipose tissue mass (subcutaneous, visceral and 
skeletal muscle infiltrated) is a burden to locomotion, potentially reducing voluntary 
physical activity further, and sustains skeletal muscle functional decline through 
infiltrating macrophage mediated-release of pro-inflammatory cytokines (such as 
Tumour necrosis factor-alpha (TNF), Interleukin-6 (IL-6), Interleukin-1 (IL-1)) and 
proteins leptin, adiponectin and resistin (Neels and Olefsky, 2006; Tilg and Moschen, 
2006; Antuna-Puente et al., 2008). These processes promote a pathological spiral of 
skeletal muscle functional decline, adipose tissue gain and inflammation (figure 1.1). 
Given the current increase in the proportion of older individuals on a worldwide scale, 
and a high incidence of poor quality of life in old age, it is essential to establish whether, 
with a better understanding of the mechanisms involved, these detrimental changes can 
be positively influenced. 
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Figure 1.1. Adapted from Zamboni et al., (2008). Inter-relationships between adipose tissue and skeletal 
muscle with advancing age. 
 
1.1.1. The ageing process: hormone and cytokine adaptations 
 
The natural aging process is accompanied by a decline in endocrine function involving 
both the responsiveness of tissues and a reduction in the secretion of hormones (Lamberts 
et al., 1997) such as testosterone, oestrogen, Growth hormone (GH) and Insulin-like 
growth factor-I (IGF-I) (Baumgartner et al., 1999; Chahal and Drake, 2007; Giovannini 
et al., 2008). In addition, there maybe increased levels of pro-inflammatory cytokines 
such as TNF and IL-6 (Visser et al., 2002). On top of this, modifications in the central 
mechanisms controlling the temporal organisation of hormone release can result in 
detrimental rearrangements of circadian hormonal and non-hormonal rhythms (Chahal 
and Drake, 2007; Aguilera, 2011). An abrupt reduction in oestrogen production 
(menopause) in women results in an increase in abdominal adipose tissue mass (Cooke 
and Naaz, 2004) and loss of strength (Lowe et al., 2010). Similar effects are observed in 
men due to a gradual, but progressive decline in testosterone (andropause) (Gray et al., 
1991). In older individuals the amplitude, but not the number of GH pulses per day can 
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be reduced by as much as 50 % (Veldhuis et al., 2005). This progressive decline in GH 
secretion (somatopause) has been shown to cause a reduction in protein synthesis, lean 
body mass, bone mass, and a decline in immune function (Corpas et al., 1993). The 
considerable influence IGF-I has over skeletal muscle mass through hypertrophy 
(Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB)/Mammalian target of 
rapamycin (mTOR)) and inhibition of atrophy (PI3K/PKB/mTOR/Forkhead box 
(FOXO)) has been well documented (Latres et al., 2005; Glass, 2010b; Fernandes et al., 
2012). The anabolic and lipolytic effects of GH are mediated by circulating or paracrine 
IGF-I, and IGF-I declines in parallel with GH (Corpas et al., 1993). The Hypothalamic-
pituitary-adrenal (HPA) axis and its end product, the pleiotropic glucocorticoid cortisol, 
mediate the relationship between stressful life experiences and health outcomes (Krøll, 
2010; Aguilera, 2011; Lucassen et al., 2013). Data from Van Cauter et al., (1996) 
suggested daily mean cortisol concentrations increase by 20 – 50 % between the age of 
20 and 80 yrs., with the evening nadir in serum cortisol concentrations greater and earlier 
in older individuals. 
 
Nutrition and anabolism, and the associated physiological adaptations are influenced by 
a number of hormones including insulin, leptin and adiponectin. These in turn are altered 
with age. Data from Bryhni et al., (2010) suggest that insulin release is blunted with 
advancing age, indicated by impaired processing of pro-insulin to insulin, but this is not 
unequivocal. For instance, a preserved sensitivity to insulin, indicated by a insulin 
concentrations similar to those in younger adults (Paolisso et al., 1996) is widely 
acknowledged to be a key factor in the healthy ageing phenotype in centenarians (Arai et 
al., 2009; van Heemst, 2010). The systemic concentration of leptin declines throughout 
life independent of Body mass index (BMI) and other endocrine changes (Isidori et al., 
2000). Interestingly, women generally have higher systemic leptin concentrations, which 
decline at a greater rate during ageing, than men. Commonly, a fall in leptin concentration 
is observed around the time of menopause (Isidori et al., 2000). Conversely, adiponectin 
concentrations have been shown to increase with age (Adamczak et al., 2005; Isobe et al., 
2005; Kizer et al., 2010) but more dramatically in women around menopause (Isobe et 
al., 2005). 
 
It has been suggested that an increase in the leptin to adiponectin ratio reflects insulin 
resistance and the risk of vascular disease (Finucane et al., 2009). This is based on the 
causal relationship between obesity and insulin resistance, and a proportional increase in 
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systemic leptin concentrations and adipose tissue mass (Lönnqvist et al., 1995), which 
are associated with a decrease in systemic adiponectin concentrations (Arita et al., 1999). 
Similarly, a decrease in the ratio of GH to cortisol has been suggested to reflect body 
compositional changes favouring accumulation of visceral adipose tissue mass in both 
the young (Misra et al., 2008) and old (Nass and Thorner, 2002). A reduction in lipolytic 
capacity due to declining systemic GH concentrations is a contributory agent in the age-
related increase in adipose tissue mass, as is prolonged exposure to elevated systemic 
cortisol concentrations (Nass and Thorner, 2002). Given the central role obesity and 
inflammation play in the pathogenesis of a number of chronic conditions that increase 
with age, the leptin to adiponectin ratio and GH to cortisol ratio may provide a useful 
index of age-related dysfunction. 
 
1.1.2. The relationship between Inflammation, inflammageing and increasing adipose 
tissue mass 
 
Inflammation and the inflammatory response are essential physiological processes, 
ensuring survival by defending against infection and enabling recovery from injury. The 
inflammatory response involves a variety of cells, organs and organ systems (Gruys et 
al., 2005; Serhan et al., 2007). An age-related increase in the production of inflammatory 
compounds occurs in the immune system (Vescovini et al., 2007; Larbi et al., 2008), brain 
(Licastro et al., 2003), adipose tissue (Hotamisligil, 2006) and muscle (Greiwe et al., 
2001). The up-regulation of the inflammatory state with increasing age has been termed 
‘inflammageing’ (Franceschi et al., 2000; Cevenini et al., 2013; Franceschi and Campisi, 
2014). The result is a chronic systemic low-grade pro-inflammatory state that appears to 
be associated with the pathogenesis of cancer (Schottelius and Dinter, 2006; Aggarwal 
and Gehlot, 2009), the metabolic syndrome (Camera et al., 2008), insulin resistance 
(Reaven and Chen, 1988; Goodpaster et al., 2000; 2003), Type 2 diabetes mellitus 
(T2DM) (Pradhan et al., 2001; Festa et al., 2002) and Cardio-vascular disease (CVD) 
(Libby, 2002; 2006). 
 
Increasing adipose tissue mass is characterised by adipocyte hypertrophy and is often 
associated with elevated levels of circulating inflammatory markers or chronic 
inflammation. Increased systemic concentrations of inflammatory markers (leptin, 
TNF, IL-6) reflect an ‘overflow’ of these proteins and subsequent health implications 
(Trayhurn, 2005; Goossens, 2008; Kwon and Pessin, 2013). During adipocyte 
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hypertrophy the capacity for lipid storage is stretched which may impair further lipid 
storage, resulting in ectopic fat deposition and insulin resistance as other tissues are 
exposed to an excessive influx of lipids (Lettner and Roden, 2008). Adipocyte 
hypertrophy induces relative hypoxia in clusters of adipocytes distant from the capillary 
network, inducing changes in gene expression with up-regulation of inflammatory 
proteins, a shift from aerobic to anaerobic metabolism with increased lactate production, 
and importantly, insulin resistance and the development of adipose tissue fibrosis 
(Trayhurn, 2013). Adipocyte hypertrophy also induces the expression of chemo-attractant 
proteins (Cancello et al., 2005) resulting in infiltration of the adipose tissue bed by 
inflammatory (M1) macrophages (Weisberg et al., 2003; Xu et al., 2003; Lumeng et al., 
2007), and a corresponding increase in macrophage secretion of cytokines pro-
inflammatory TNF and IL-6, amongst others, (Manderson et al., 2007) thereby fuelling 
the inflammatory environment. Pedersen (2009) recently proposed the ‘diseasome’ of 
physical inactivity in which chronic diseases including T2DM, CVD and cancer, 
associated with an enhanced risk of premature morbidity, are linked by visceral and 
ectopic fat accumulation and therefore systemic and chronic inflammation resulting from 
physical inactivity. 
 
1.2. Exercise as a therapeutic intervention 
 
Notwithstanding the significant drive to investigate the mechanisms behind the age-
related decline in skeletal muscle mass and, more recently, strength, it appears we are still 
some way from translating research findings into primary care diagnosis and 
interventions in clinical practice (Sayer, 2010; von Haehling et al., 2010; Sayer, 2014). 
However, towards this aim, the European working group on sarcopenia in older people 
(EWGSOP) have produced a diagnostic algorithm based on measurements of 
performance, skeletal muscle mass and function (Cruz-Jentoft et al., 2010), which has 
been validated for use in clinical practice (Da Silva Alexandre et al., 2014). From the 
perspective of interventions, research has shown progressive resistance training is 
effective in increasing skeletal muscle mass (hypertrophy) and strength in the older 
individuals (Borst, 2004; Liu and Latham, 2009; Peterson et al., 2010; 2011; Degens, 
2012) and has been advocated as an effective intervention for skeletal muscle functional 
decline by the American College of Sports Medicine (ACSM) (Chodzko-Zajko et al., 
2009), American Heart Association (AHA) (Nelson et al., 2007) and others (Marcell, 
2003; Abellan van Kan et al., 2009). However, progressive resistance training alone does 
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not offer a complete solution to address the multifactorial aetiology of skeletal muscle 
functional decline, especially given the complex influence of co-morbidities such as obesity 
(Stenholm et al., 2008; Zamboni et al., 2008; Waters and Baumgartner, 2011), or by contrast, 
the nutritional abnormalities prevalent in older individuals (low calorie and protein intake) 
(Bartali et al., 2006; Phillips, 2015) against the background of altered hormone and cytokine 
profiles and low-grade systemic inflammation (inflammageing) (Franceschi et al., 2000; 
Cevenini et al., 2013; Franceschi and Campisi, 2014) described above. As such, a 
multimodal lifestyle approach incorporating physical activity (endurance/aerobic and 
strength/power), nutrition (optimum calorific quantity and nutritional makeup) and key 
pharmaceutical therapies appears logical (Waters et al., 2010). Evidence suggests that 
including an endurance exercise component in such an approach might prove effective in 
reducing visceral and ectopic fat accumulation and therefore may go some way to 
addressing the systemic and chronic inflammation resulting from physical inactivity. 
Such an exercise component might also provide a sufficient stimulus for improvement in 
cardio-respiratory fitness, in addition to minor improvements in or maintenance of 
skeletal muscle strength and power, potentially promoting functional improvements in 
the performance of activities of daily living. 
 
Research has identified that skeletal muscle and adipose tissue function as endocrine 
organs (Trayhurn, 2005; Pedersen and Febbraio, 2008; Pedersen, 2013), collectively 
secreting hundreds of hormones, cytokines and other proteins that act as chemical 
messengers governing essential biological processes (Bortoluzzi et al., 2006; Alvarez-
Llamas et al., 2007; Lehr et al., 2012). Pedersen and colleagues proposed the term 
‘myokines’, for hormones, cytokines and other proteins released by skeletal muscle fibres 
as a result of contractile activity (Pedersen et al., 2003). Similarly, hormones, cytokines 
and other proteins secreted by adipose tissue are collectively known as ‘adipokines’ 
(Trayhurn and Wood, 2004). Recent research suggests that myokines play a role in 
mediating the beneficial effects of endurance exercise (Pedersen, 2009; Pedersen and 
Febbraio, 2012). Adipokines, on the other hand, regulate energy metabolism (Yu and 
Ginsberg, 2005; Ronti et al., 2006), and therefore contribute to inflammatory mechanisms 
resulting from the storage of excess adipose tissue (Tilg and Moschen, 2006; Arai et al., 
2011). A number of proteins such as IL-6 and TNF are secreted by both skeletal muscle 
and adipose tissue, and as such have been suggested to be involved in the cross-talk 
between these tissues, termed ‘the adipose-muscular axis’ (Argilés et al., 2004; Tomas et 
al., 2004). Myokines and adipokines communicate via autocrine, paracrine (Argilés et al., 
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2004; Tomas et al., 2004; Pedersen, 2009) as well as endocrine signalling mechanisms 
(Pedersen et al., 2003; Calabrò et al., 2009) indicating the complex regulatory system 
governing adaptations in these tissues. Endurance exercise may be considered as an 
effective exercise component in a multimodal lifestyle approach addressing age-related 
skeletal muscle functional decline only if it can be proven that such a component confers 
positive benefits. It is therefore imperative that we gain a better understanding of how the 
secretomes of skeletal muscle and adipose tissue respond to this form of exercise, the 
associated mechanisms, and how systemic concentrations vary as a result. 
 
1.2.1. Skeletal muscle derived ‘myokine’ interactions 
 
Skeletal muscle primarily functions to contract, which provides stability and facilitates 
movement, but this tissue also has a major role in glucose metabolism, being responsible 
for ~ 75 % of whole-body insulin-stimulated glucose uptake (Shulman et al., 1990; 
Corcoran et al., 2007). Skeletal muscle contractions also stimulate the secretion of 
myokines. The pleiotropic cytokine IL-6 (Poupart et al., 1987) was the first protein to be 
designated as a myokine (Pedersen et al., 2003; 2004; 2007) and is the most widely 
studied. Within 30 min of the onset of endurance exercise the rate of transcription, 
translation and release of IL-6 from skeletal muscle is dramatically increased, particularly 
when the exercise is sustained at a high level and muscle glycogen content is reduced 
(Keller et al., 2001; Steensberg et al., 2002). In skeletal muscle IL-6 acts in an autocrine 
manner, signalling through Glycoprotein 130 receptor-beta (GP130R)/Interleukin-6 
receptor-alpha (IL-6Rα) (‘classical’ signalling), resulting in activation of the Adenosine 
monophosphate-activated protein kinase (AMPK) and/or PI3K signalling pathways that 
result in increased glucose uptake and fat oxidation (Pedersen and Fischer, 2007) (figure 
1.2). Interleukin-6 may even have a role in modulating the choice of substrate in skeletal 
muscle during exercise by altering Pyruvate dehydrogenase (PDH) complex via AMPK 
(Biensø et al., 2014). Evidence suggests the c-Jun NH2-terminal kinase (JNK)/Activator 
protein-1 (AP-1) pathway maybe a primary signalling pathway controlling IL-6 
transcription in contracting skeletal muscle (Whitham et al., 2012), and that IL-6 
expression depends on an Inositol trisphosphate (IP3)-dependent Calcium (Ca2+) signal, 
acting as an early step, promoting a positive IL-6 loop via the Janus kinase 2 
(JAK2)/Signal transducer and activator of transcription 3 (STAT3) pathway (Bustamante 
et al., 2014). Paradoxically, IL-6 is also pro-inflammatory. In pro-inflammatory (M1) 
macrophages within the adipose tissue bed, IL-6 activates IKappa-B kinase kinase 
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complex (IKK)/Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), 
which leads to the production of inflammatory cytokines, primarily TNF, but also 
Interleukin-1-beta (IL-1) (Weisberg et al., 2003; Xu et al., 2003). Recent evidence 
suggests IL-6 and TNF behaviour is mediated by A disintegrin and metalloprotease-17 
(ADAM17) (Edwards et al., 2008; Gooz, 2010). Cleavage of the membrane-bound IL-
6Rα by ADAM17 constitutes a rapid and irreversible regulatory switch (Düsterhöft et al., 
2014) that facilitates IL-6 ‘trans-signalling’ (Rose-John, 2012), a process shown to 
promote the transition from acute to chronic inflammation (Jones and Rose-John, 2002; 
Jones et al., 2001; 2005; Rose-John et al., 2006; Rabe et al., 2008a). 
 
Classical IL-6 signalling and activation of JAK2/STAT3 signalling pathway results in the 
rapid induction of Suppressor of cytokine signalling-3 (SOCS3) (Starr et al., 1997; Hilton, 
1999; Babon and Nicola, 2012). Suppressor of cytokine signalling-3 inhibits IL-6 
signalling via negative feedback regulation, by high-affinity binding with both JAK and 
GP130 simultaneously (Babon et al., 2012). The ‘SOCS box’ domain, present on all 
Suppressor of cytokine signalling (SOCS) proteins, then facilitates proteasomal 
degradation of IL-6 through interaction with Cullin-5 (CUL-5) and the formation of an 
E3 ubiquitin-ligase complex (Starr et al., 1997; Hilton et al., 1998; Babon and Nicola, 
2012). 
 
Suppressor of cytokine signalling-3 also regulates the response to cytokines, growth 
factors, and hormones that signal independently of GP130, namely the Interleukin-12 
receptor (IL-12R), Granulocyte-colony stimulation factor (G-CSF), leptin and insulin. 
SOCS3 is induced by and binds to the leptin receptor, thereby limiting leptin action 
(Bjørbaek et al., 1998; 1999; 2000; Eyckerman et al., 2000). In obesity, the expression of 
SOCS3 in the Central nervous system (CNS) is increased. Suppressor of cytokine 
signalling-3 expression, induced by elevated concentrations of IL-6 and TNF impairs 
insulin signalling in peripheral organs by binding to the Insulin receptor (IR) or the Insulin 
receptor substrate (IRS) proteins Insulin receptor substrate-1 (IRS1) and Insulin receptor 
substrate-2 (IRS2), leading to their ubiquitination and degradation, or by preventing 
receptor tyrosine phosphorylation (Rui et al., 2002; Ueki et al., 2004; 2005; Shi et al., 
2006). 
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Figure 1.2. Reproduced from Pedersen and Febbraio (2012). Skeletal muscle as an endocrine organ. 
Interleukin‑6 is involved in AMPK‑mediated fat oxidation and also enhances insulin‑stimulated glucose 
uptake. Interleukin‑6 appears to have systemic effects on the liver and adipose tissue and increases insulin 
secretion via upregulation of Glucagon-like peptide-1 (GLP-1). Interleukin‑6 has been suggested to 
promote hypertrophy though satellite cell proliferation. Arrows - positive, activating functions. T-lines - 
inhibitory functions. 
 
1.2.2. Adipose tissue derived ‘adipokine’ interactions 
 
Adipose tissue insulates the body, stores excess energy in the form of Triacylglyceride 
(TAG), assists in mediating glucose homeostasis and synthesises and secretes adipokines 
(figure 1.3). Over 50 adipokines have been identified to date (Trayhurn and Wood, 2004), 
of which leptin and adiponectin, are the most widely studied. Dysregulation of adipokine 
actions promote local and systemic inflammation, and co-morbidities including insulin 
resistance and T2DM (Bays, 2011; Kwon and Pessin, 2013). Mature adipocytes form the 
major component of adipose tissue, releasing the adipokines leptin and adiponectin 
(Yadav et al., 2013). The history of leptin can be traced to two murine strains (ob/ob and 
db/db) discovered in 1950 and 1965 with identical phenotypes including: morbid obesity, 
  35 
insulin resistance, infertility and lethargy (reviewed by Coleman, 2010). The role of leptin 
in energy balance/body mass control is mediated by expression of the long isoform of the 
leptin receptor (Leptin Receptor b (LepRb)) in the hypothalamus (Meister, 2000), and 
increased leptin is associated with feelings of satiety (Cohen et al., 2001; Villanueva and 
Myers, 2008). Leptin Messenger ribonucleic acid (mRNA) is expressed in both skeletal 
muscle (Wang et al., 1998; Guerra et al., 2007) and adipose tissue (Kielar et al., 1998; 
Lefebvre et al., 1998) and is secreted by adipocytes in proportion to adipose tissue mass, 
suggesting leptin acts as an ‘adipostat’, informing the brain of adipose tissue mass, thus 
regulating energy balance (Zhang et al., 1994; Pelleymounter et al., 1995; Halaas et al., 
1995). 
Figure 1.3. Adapted from Trayhurn (2013). Major physiological and metabolic processes with which 
adipose tissue is involved through the secretion of adipokines from adipocytes. 
 
Leptin binding activates JAK2/STAT3 and PI3K signalling pathways to increase 
metabolic rate and sympathetic tone and suppress appetite, thereby decreasing body fat 
mass (Spiegelman and Flier, 2001; Morris and Rui, 2009) (figure 1.4). Adiponectin 
functions in opposition to leptin, reducing metabolic rate and stimulating appetite 
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(Kadowaki et al., 2008). Kraus et al., (2002) demonstrated strong differentiation-
dependent leptin secretion and PI3K mediated negative autocrine effects on insulin action 
in highly insulin-responsive SV40T-immortalised brown adipocytes from the FVB strain 
of mice. Acute leptin treatment of mature adipocytes dose- and time-dependently 
stimulated phosphorylation of STAT3 and Mitogen-activated protein kinase (MAPK). 
Acute pretreatment of fully differentiated brown adipocytes with leptin (100 nm) 
significantly diminished insulin-induced glucose uptake in a time-dependent manner. The 
response correlated with a ~ 35 % reduction in insulin-stimulated insulin receptor kinase 
activity, and ~ 60 % and 40 % reductions in insulin-induced IRS1 tyrosine 
phosphorylation and binding to the regulatory subunit p85 of PI3K, respectively (Kraus 
et al., 2002). Resistance to the appetite suppressive action of leptin ‘leptin resistance’ 
resulting in increased expression of leptin mRNA in adipose tissue (Lönnqvist et al., 
1995; Klein et al., 1996) and increased systemic leptin concentrations (Maffei et al., 1995; 
Considine et al., 1996; Diamond et al., 2004), is a primary risk factor for obesity. 
Proposed mechanisms for leptin resistance are impaired leptin transport across the Blood-
brain-barrier (BBB) (El-Haschimi et al., 2000), hyperleptinaemia-induced SOCS3 (Kievit 
et al., 2006), defective autophagy (Quan and Lee, 2013) and endoplasmic reticulum stress 
(Morris and Rui, 2009; Ozcan et al., 2009). 
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Figure 1.4. Adapted from Meier and Gressner (2004). Action of leptin on the hypothalamus, pancreas, liver 
and skeletal muscle. 
 
Adiponectin was originally discovered by four distinct groups (Scherer et al., 1995; Hu 
et al., 1996; Maeda et al., 1996; Nakano et al., 1996). Similar to leptin, the adipostat 
functions of adiponectin are primarily achieved by regulating neuronal activity in the 
hypothalamus via binding to the adiponectin receptors (Adiopnectin receptor 1 
(AdipoR1) and Adiponectin receptor 2 (AdipoR2)) (Guillod-Maximin et al., 2009). In 
addition to insulin and IGF-I mediated expression in adipose tissue (Halleux et al., 2001), 
adiponectin is also expressed in skeletal muscle (Krause et al., 2008). Adiponectin signals 
through AMPK and Peroxisome proliferator-activated receptor-alpha (PPAR) by 
binding to AdipoR1 in skeletal muscle and AdipoR2 in the liver (Yamauchi et al., 2003a; 
Civitarese et al., 2004) (figure 1.5), primarily to improve insulin sensitivity, increase fuel 
oxidation and reduce TAG content (Yamauchi et al., 2001; 2003b). Adiponectin has been 
shown to exert significant and diverse autocrine/paracrine effects, including regulating 
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its own expression (Wu et al., 2003; Fu et al., 2005; Lin and Li, 2012). Adiponectin gene 
expression in murine 3T3-L1 fibroblasts promotes cell proliferation and differentiation 
from pre-adipocytes into adipocytes, augments programmed gene expression responsible 
for adipogenesis, and increases lipid content and insulin responsiveness of the glucose 
transport system in adipocytes (Fu et al., 2005). Wu et al. (2003) incubated isolated 
epididymal rat adipocytes with the globular domain of recombinant adiponectin, which 
increased Thr-172 phosphorylation and catalytic activity of AMPK and enhanced the Ser-
79 phosphorylation of Acetyl CoA carboxylase (ACC). Glucose uptake was increased in 
adipocytes without stimulating tyrosine phosphorylation of the IR or IRS1, and without 
enhancing phosphorylation of PKB on Ser-473. Further, adiponectin enhanced insulin-
stimulated glucose uptake at sub-maximal insulin concentrations and reversed the 
inhibitory effect of TNF. These findings suggest normal leptin and adiponectin function 
is essential in regulating the accumulation of body fat and sensitivity to insulin. Although 
it is becoming evident that exercise can have a positive effect on lipid metabolism, the 
impact that it has on the adipokines adiponectin and leptin is less clear. It has been 
suggested that the positive benefits of exercise on systemic concentrations of both leptin 
(decrease) and adiponectin (increase) are realised principally through a reduction in 
adipose tissue mass (Fatouros et al., 2005; Blüher et al., 2006; Simpson and Singh, 2008). 
This is clearly an avenue worthy of further investigation. 
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Figure 1.5. Adapted from Kadowaki and Yamauchi (2005). Adiponectin activation of Adenosine 
monophosphate-activated protein kinase (AMPK) and Peroxisome proliferator-activated receptor-alpha 
(PPAR) in the liver and skeletal muscle. 
 
1.2.3. The influence of endurance exercise on systemic protein abundance 
 
Ostrowski et al., (1998a; 1998b; 1999; 2001) identified the exercise-induced systemic 
abundance and skeletal muscle expression kinetics of TNF, IL-1, Interleukin-10 (IL-
10), IL-6, Interleukin-15 (IL-15), Interleukin-1 receptor-antagonist (IL-1ra), Soluble 
tumour necrosis factor receptor-1 (sTNFr1), Soluble tumour necrosis factor receptor-2 
(sTNFr2), Interleukin-8 (IL-8), Macrophage inflammatory protein-1-alpha (MIP-1) and 
Macrophage inflammatory protein-1-beta (MIP-1) during and after bouts of acute 
endurance running. The response appeared analogous to the acute phase response to 
trauma. Research focused on exercise-induced skeletal muscle fibre damage as the 
stimulus for the response (Pedersen et al., 1998; Croisier et al., 1999; Malm, 2001) and 
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the possibility that exercise might provide a model with which to study inflammation 
(Pedersen and Nieman, 1998; Friedland et al., 1992; Shephard, 2001). Further 
investigation identified skeletal muscle contractile activity as the source of increased 
systemic concentrations of proteins such as IL-6 (Steensberg et al., 2000). Differences 
between the cytokine cascade induced by exercise and infection were identified. 
Typically, exercise does not induce a rise in the systemic concentrations of pro-
inflammatory cytokines TNFα and IL-1β (Pedersen and Febbraio, 2008). Interleukin-6 
was designated a pleotropic cytokine (Pedersen et al., 2001) with a pro-inflammatory role 
in disease and an anti-inflammatory role as a myokine induced through exercise (Pedersen 
et al., 2003; 2004; 2007). Interleukin-6 is thought to be beneficial during endurance 
exercise, due to its ability to diminish systemic concentrations of TNFα (Starkie et al., 
2003) and to increase lipolysis in adipose tissue (van Hall et al., 2003), thus sparing 
glycogen as an energy source and, over time, potentially reducing inflammation via a 
reduction in adipose tissue mass. Further, systemic anti-inflammatory effects of IL-6 have 
been observed (Tilg et al., 1997; Steensberg et al., 2003). Fischer (2006) suggested that a 
reduction in basal IL-6 is a characteristic of the normal adaptation to training, whereas 
high basal systemic IL-6 concentrations are closely associated with physical inactivity. 
Indeed, life-long endurance activity has been shown to be associated with significantly 
lower basal inflammatory markers C-reactive protein (CRP) and IL-6 (Mikkelsen et al., 
2013). 
 
1.2.3.1. Insulin 
 
Insulin was first successfully isolated in 1922 (Banting and Best, 1922) and was the first 
protein to have its entire primary amino-acid structure sequenced (Sanger, 1949; Ryle et 
al., 1955). Between 1961 and 1967 significant steps were made in the synthesis of 
biologically active forms of the protein (Du et al., 1961; Kung et al., 1963; Wang et al., 
1965; Katsoyannis, 1966; 1967). The primary sequence of human insulin shares 50 % 
amino-acid identity in the Alpha () and Beta () domains with IGF-I and Insulin-like 
growth factor-II (IGF-II) (Rinderknecht and Humbel, 1976; 1978). Insulin action is 
initiated by binding to the IR (Kahn, 1985; Freychet et al., 1971; Cuatrecasas, 1972). Both 
the IR and the IGF-I receptor (IGF-IR) belong to the Receptor tyrosine kinase (RTK) 
family (Hubbard and Till, 2000). The IR is ubiquitously expressed in human tissues, with 
the highest expression levels in adipose tissue, liver and skeletal muscle (Kahn et al., 
1981).  
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Insulin is secreted by clusters of pancreatic -cells located in the islets of Langerhans in 
response to elevated concentrations of glucose in the blood (Newsholme et al., 2014). 
Glucose-stimulated insulin secretion is a biphasic response comprising an initial phase 
which develops rapidly but lasts only a few minutes, followed by a second sustained 
phase (Luzi and DeFronzo, 1989; Curry et al., 1968; Cerasi and Luft, 1967). The insulin 
response promotes glucose uptake in skeletal muscle, adipose tissue and the liver, 
therefore acting towards maintaining a constant concentration in the blood. The binding 
of insulin with its receptor results in auto-phosphorylation of tyrosine kinase residues 
(Kasuga et al., 1982) that in turn lead to recruitment and phosphorylation of IRS1, 
phosphorylation and activation of PI3K, PKB and Atypical protein kinase C isoforms λ 
and ζ (PKC-λ/ζ), which result in Glucose transporter type 4 (GLUT4) translocation and 
glucose transport into the cell (Taniguchi et al., 2006; Thirone et al., 2006) (figure 1.6). 
In adipose tissue, insulin has an anti-lipolytic effect, stimulating free fatty acids uptake 
and lipogenesis (Duncan et al., 2007). Insulin reduces hepatic glycogenolysis (Wahren 
and Ekberg, 2007) and promotes amino-acid transport, lipid metabolism, glycogen 
synthesis, gene transcription and Messenger ribonucleic acid (mRNA) turnover, and 
protein and Deoxyribonucleic acid (DNA) synthesis in liver and muscle (Cheatham and 
Kahn, 1995). Insulin resistance is a condition in which skeletal muscle, liver and adipose 
tissue demonstrate reduced responsiveness to insulin. Insulin resistance is a key factor in 
the pathogenesis of T2DM and the metabolic syndrome (Facchini et al., 2001). A recent 
report suggests three distinct mechanisms linking obesity to insulin resistance and a 
predisposition to T2DM: 1) increased production of adipokines/cytokines and a reduction 
in adiponectin concentration, 2) ectopic fat deposition in the liver and skeletal muscle, 
and 3) mitochondrial dysfunction and compromised -cell function (Eckel et al., 2011). 
 
Systemic concentrations of insulin have been shown to increase following acute bouts of 
resistance exercise (Kraemer and Castracane, 2014). By contrast, during prolonged 
endurance exercise, circulating insulin levels decline with time in healthy individuals 
(Hansen et al., 2012). It has been suggested that the concentration of insulin circulating 
in the blood is related to the intensity and duration of exercise, determined by the rate of 
glucose production and utilisation (Sigal et al., 1994; 2000), mediated by the 
catecholamine response during intense exercise (Marliss et al., 1991; 1992; Sigal et al., 
1996; Marliss and Vranic, 2002). 
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Figure 1.6. Adapted from The Medical Biochemistry Page (no date). The insulin-signalling system affects 
numerous intracellular processes. Arrows - positive, activating functions. T-lines - inhibitory functions. 
 
1.2.3.2. Insulin-like growth factor-I 
 
Insulin-like growth factor-I was initially termed Somatomedin C (Daughaday et al., 
1972). The name insulin-like growth factor was proposed in 1976 following the discovery 
of the proteins’ non-suppressible insulin-like activity (Rinderknecht and Humbel, 1976). 
Insulin-like growth factor-I is an essential mediator of normal postnatal growth, cell 
proliferation, differentiation and survival. Its constitutive expression is tissue-specific 
(liver and skeletal muscle) and influenced by hormonal (e.g. insulin and growth 
hormone), nutritional (glycaemic levels) and developmental regulators (figure 1.7). It 
mediates its effects through binding to its cell surface receptor, a 350 kDa protein similar 
to the insulin receptor, composed of two ligand-binding -subunits and two trans-
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membrane -subunits with integral tyrosine kinase activity. Additionally, IGF-I can bind 
to the insulin receptor and vice versa, albeit with lower affinity. Insulin-like growth 
factor-I is an important metabolic biomarker associated with a variety of health- and 
exercise-related outcomes (Nindl, 2010). Insulin-like growth factor-I regulates glucose 
homeostasis by stimulating glucose uptake in skeletal muscle (Berg and Bang, 2004). In 
contrast, GH antagonises the hepatic and peripheral effects of insulin on glucose 
metabolism (Møller and Jørgensen, 2009). Insulin-like growth factor-I and GH are tightly 
linked. In adults GH exerts a potent anabolic influence through IGF-I, known as the 
Growth hormone/Insulin-like growth factor-I (GH/IGF-I) axis (Butler and Le Roith, 
2001). Growth hormone regulates the hepatic synthesis of IGF-I and Insulin-like growth 
factor binding protein-3 (IGFBP-3), the major IGF carrier and modulator of systemic 
IGF-I action. Insulin-like growth factor-I, in turn, regulates GH secretion via negative 
feedback (Frystyk, 2004; 2010). The main mechanisms through which IGF-I exerts its 
considerable influence over skeletal muscle mass is hypertrophy (Glass, 2010a) and 
inhibition of atrophy (Latres et al., 2005; Fernandes et al., 2012). Insulin-like growth 
factor-I secreted locally i.e. by skeletal muscle, and not systemic IGF-I is suggested to be 
primarily responsible for the anabolic response to exercise (LeRoith et al., 2001; Velloso, 
2008). The relationship between local and systemic IGF-I in mediating the outcomes of 
exercise are still not fully understood, as investigations into the effect of exercise on 
systemic concentrations of IGF-I has yielded inconsistent results (Frystyk, 2010; Nindl 
and Pierce, 2010), but local IGF-I may augment systemic concentrations (Adams, 2002; 
Berg and Bang, 2004; Nindl, 2010). Nemet et al., (2002; 2006) described a biphasic 
systemic IGF-I response to exercise, with a small but significant increase during the first 
10 - 20 min followed by a decline as exercise progresses. Data from high and low intensity 
short duration (10 min) exercise (Schulze et al., 2002) and longer duration (30 min) heavy 
exercise bouts (Zaldivar et al., 2006) support this, as do data resulting from bouts of short 
duration maximal exercise (De Palo et al., 2008; Zebrowska et al., 2009). 
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1.2.3.3. Growth hormone 
 
Growth hormone is secreted in a pulsatile fashion by the anterior pituitary gland 
(Hindmarsh et al., 1997) and has a key regulatory role in controlling the hepatic release 
of the IGF-II and IGF-II (Rodriguez et al., 2007), co-ordinating the postnatal growth of 
multiple target tissues, including skeletal muscle (Florini et al., 1996) (figure 1.7). Growth 
hormone deficiency is associated with impairment of growth, e.g. Laron Dwarfism 
(Godowski et al., 1989), a cluster of cardio-vascular risk factors such as altered body 
composition with increased body fat, insulin resistance, adverse lipid profile, reduced 
physical performance, reduced bone mineral density and impaired quality of life 
(Papadogias et al., 2003), whilst excessive GH secretion early in life typically results in 
pituitary gigantism, and later somatotroph adenomas and acromegaly (Lindholm, 2006). 
Systemic concentrations of GH are augmented by a variety of stimuli, of which endurance 
exercise has been shown to be extremely potent (Sutton and Lazarus, 1976; Felsing et al., 
1992; Pritzlaff et al., 1999). Increases in systemic GH concentrations have been observed 
after as little as 10 min of cycle ergometer exercise (Felsing et al., 1992). Felsing et al., 
(1992) hypothesised that systemic GH concentrations would only increase if a threshold 
of work intensity corresponding to the Anaerobic threshold (ATh) was exceeded. Indeed, 
data illustrated that GH was significantly elevated after only 5 min of high intensity 
exercise, whilst 10 min of low intensity exercise was without effect (Felsing et al., 1992). 
The exercise-induced increase in systemic GH concentration is suggested to spare blood 
glucose by increasing gluconeogenesis and mobilising free fatty acids from adipose tissue 
(Hunter et al., 1965a; 1965b). However, it is thought that the latter maybe restricted 
during very strenuous exercise due to reduced blood flow to adipose tissue depots. 
Interestingly, ageing and obesity result in a reduction in both basal and exercise-induced 
GH concentrations (Chahal and Drake, 2007; Hansen et al., 2012). These findings 
highlight the importance of identifying an endurance exercise component that promotes 
increases in systemic GH concentrations to maximise benefits in target groups. 
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Figure 1.7. Adapted from Clemmons (2006a). Schematic diagram of insulin, growth hormone and insulin-
like growth factor-I regulation. In the liver, insulin enables increased IGF-I synthesis in response to GH. 
Insulin-like growth factor-I exerts negative feedback on GH production in the pituitary. In muscle, insulin 
and growth hormone increase protein synthesis, and transport of amino acids; insulin also increases 
transport of glucose. + variables that stimulate GH secretion, - variables that inhibit GH secretion. 
 
1.2.3.4. Cortisol 
 
The glucocorticoid cortisol is secreted following stimulation of the Hypothalamic-
pituitary-adrenal (HPA) axis in a tightly controlled manner (Lightman et al., 2008; 
Russell et al., 2010) (figure 1.8). Systemic concentrations reflect a combination of the 
normal diurnal pulsatile cortisol secretion and that secreted through transient activation 
of the HPA axis during times of perceived or actual physical or psychological stress: the 
fight or flight response, an essential mechanism that promotes adaptation and survival via 
responses of the neural, cardio-vascular, autonomic, immune and metabolic systems 
(Charmandari et al., 2005). Once released, cortisol is taken up by skeletal muscle, adipose 
tissue and the liver. In these tissues cortisol mediates critical physiological processes that 
aid exercise and recovery, e.g. skeletal muscle proteolysis and Amino-acid metabolism, 
and the adipose tissue hydrolysis of TAG into free fatty acids and glycerol (Symonds and 
Lomax, 1992; McMurray, and Hackney 2000; Viru and Viru, 2004; Hackney, 2006). 
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High circulating levels of cortisol may stimulate gluconeogenesis in the liver, providing 
additional carbohydrate for energy production (Viru and Viru, 2004). Excessive cortisol 
secretion (hypercortisolism) has been implicated in the muscle weakness and increased 
central adiposity/obesity characteristic of Cushing’s Disease (Medline Plus, no date). 
Further, Cree et al., (2010) found that physical inactivity and induced hypercortisolism 
increased intramuscular TAG content and skeletal muscle insulin resistance in previously 
healthy males. Investigation into the effect of exercise on systemic concentrations of 
cortisol has yielded inconsistent results due, it is been suggested, to confounding variables 
such as time of day, circadian rhythms, psychological stress and training (Howlett, 1987; 
Hill et al., 2008). However, data suggest endurance exercise at an intensity greater than 
~ 50 - 60 % max results in cortisol release proportional to exercise intensity (Luger 
et al., 1987; Hill et al., 2008; Shojaei et al., 2011), while exercise below this level 
promotes a decline in systemic cortisol concentrations (Davies and Few, 1973; Bloom et 
al., 1976), potentially reflecting the underlying circadian rhythm (Howlett, 1987). 
Interestingly, studies by Rosa et al., (Rosa et al., 2011; 2012) indicate that systemic 
cortisol concentrations are reduced following an acute bout of ‘concurrent’ training, a 
combination of endurance [cycling] and resistance training. 
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Figure 1.8. Adapted from Inder and Wittert (2005). Regulation of the hypothalamic-pituitary-adrenal axis. 
Neuronal and neuro-transmitter input to Hypothalamic corticotropic-releaseing hormone (CRH) and 
Arginine vasopressin (AVP)-containing neurons result in release of these hormones into the hypothalamic-
hypophysial portal system. This causes an increase in secretion of Adrenocorticotropic hormone (ACTH) 
from the pituitary, which in turn stimulates cortisol release from the adrenal cortex. Cortisol acts at both 
the pituitary and hypothalamic level via negative feedback to inhibit ACTH, CRH and AVP. 
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1.3. Overall aim, goal and chapter objectives 
 
Research propelled by the significant socio-economic issues presented by an ageing 
population has identified links between physical inactivity, metabolism and disease. Less 
active lifestyles and over-nutrition, result in dysregulation of metabolism and the 
progression of a chronic inflammatory state (immunometabolism). As we age a similar 
inflammatory process (inflammageing) contributes to the decline in the quality and 
quantity of skeletal muscle (dynapenia/sarcopenia), functional capability and quality of 
life. Our overall aim is to implement an empirically informed, palatable acute endurance 
exercise intervention that elicits beneficial hormonal responses with the potential for 
improved health/quality of life across the lifespan. 
 
It is clear that exercise recommendations shuld be based on sound molecular and 
biochemical analyses. The goal of this thesis is therefore to clarify hormone and cytokine 
responses to endurance exercise with regard to skeletal muscle metabolic threshold 
events, by using an ‘exercise-domain’ based approach, thereby improving our 
understanding of the mechanisms behind the responses, and refining the potential for 
endurance exercise to deliver health benefits. Our objectives are: 1) to compare data from 
a cycle ergometer maximum rate of oxygen uptake ( max) test, conducted using 
principles and techniques associated with oxygen uptake dynamics research, with that 
from three acute ‘domain-based’ constant work-load cycle ergometer exercise 
interventions of varying intensity, but equal total work done (Chapter 3), 2) to establish 
the changes in the mRNA expression of selected hormones and cytokines that occur 
locally in skeletal muscle and subcutaneous adipose tissue (Chapter 4) and 3) systemically 
(Chapter 5), as a function of our acute ‘domain-based’ constant work-load cycle 
ergometer exercise interventions in recreationally active young males, and 4) to establish 
the the impact of age (20 - 60 yrs.) on the systemic hormone and cytokine response to an 
acute heavy domain constant work-load cycle ergometer exercise intervention in 
recreationally active males (Chapter 6). 
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Chapter 2. General methods 
 
Information supplementary to these methods is present in Appendixes (A - E). 
 
2.1. Laboratory 
 
Experimental work was undertaken in the laboratories of Manchester Metropolitan 
University (MMU). Experimental work performed between September 2005 and 2008 
was performed in the Laboratories housed collectively within the Old Physiology 
Laboratory, Department of Exercise and Sport Science, Alsager Campus, MMU 
Cheshire. Following relocation of the Institute for Biomedical Research into Human 
Movement and Health (IRM) to MMU in Central Manchester in 2008, further 
experimental work was performed in the Laboratories housed within the IRM facility on 
1st floor, John Dalton Tower, All Saints Campus, MMU. 
 
2.1.1 Health and safety 
 
Experimental work conformed to the MMU Heath and Safety guidelines. Procedure 
documents Health and Safety Procedures for the Exercise Physiology Laboratories, and 
Health and Safety Procedures for the Biochemistry, Molecular Biology, Cell and Tissue 
Culture Laboratories and Imaging Facilities, local to the Department of Exercise & Sport 
Science, were consulted. 
 
2.1.2. Environmental conditions 
 
Data collated from the portable Cardio-pulmonary exercise testing system employed 
during each exercise test suggested ambient laboratory conditions during exercise testing 
varied as follows: Temperature 21  1 (range 19 – 25) C, Relative humidity 44  8 (range 
22 – 56) % and Barometric Pressure 746  10 (range 726 - 764) mmHg. Integrated 
building management and air conditioning systems ensured appropriate ambient 
conditions were maintained in other laboratory areas used (data not available). 
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2.2. Participants 
 
2.2.1. Ethical approval 
 
The MMU Department of Exercise & Sport Science Ethics Committee granted ethical 
approval for each of the studies performed. The procedures described herein therefore 
conform to the ethical regulations for the use of humans in research as laid out by the 
committee. 
 
2.2.2. Participant recruitment 
 
Participants were recruited by word of mouth, and through e-mail and poster advertisements 
targeting male members of the MMU staff/student body. Potential participants were invited 
to visit the laboratory. During this initial visit each participant was verbally informed of the 
requirements of the study for which they wished to volunteer, and their attention was drawn 
to relevant local ethical committee approval documentation. Participants who did not satisfy 
any of the exclusion criteria, and were willing to participate, were asked to sign the relevant 
informed consent document. Participants received additional written information for 
reference purposes and a copy of their signed informed consent form. 
 
2.2.2.1. Exclusion criteria 
 
 Female 
 History of smoking 
 Age < 18 or > 40 (Chapters 3, 4 and 5), Age < 20 or > 60 (Chapter 6). 
 
Having any of the following: 
 
 Inflammatory disease 
 Chronic disease with regular clinical treatment 
 Muscle or bone disease 
 Bone fractures within the last twelve months 
 Metabolic or hormonal disorders 
 Blood clotting disorders 
 Epilepsy 
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2.2.3. Initial measurements: body mass, stature and body mass index 
 
The body mass and stature of each participant was measured following informed consent. 
Body mass was measured using precision scales (SECA beam balance 709, SECA, 
Hamburg, Germany) with the participant in minimal clothing and without shoes. Stature 
was measured using a wall-mounted stadiometer (Harpenden with Veeder-Root high 
speed counter, Holtain Ltd, Crymych, Wales). The participant was positioned bare-foot 
with their back against the stadiometer, heals pressed firmly against the heal stop and 
head in the Frankfort horizontal plane. The participant was instructed to breathe in, 
following which the stature value was read from the counter mechanism. Body mass 
index (BMI) was calculated subsequently from the body mass and stature values using 
the formula BMI = body mass (kg)/stature (m)2 (Eknoyan, 2008). 
 
2.2.4. Participant preparation 
 
Participants were asked to comply with a series of requests prior to visiting the laboratory 
for data collection. The requests were made to ensure all participants were in a similar 
physiological state. Participants were asked to abstain from exercise, caffeine and alcohol 
consumption during the 24 hr. period immediately prior to visiting the laboratory, and to 
fast during the 12 hr. period immediately prior to visiting the laboratory. In addition, 
participants were asked to consume only a prescribed volume of water within five minutes 
of waking, prior to visiting the laboratory. To facilitate this each participant was provided 
with their own individual plastic water bottle on which was placed a mark corresponding 
to a water volume of 5 ml/kg body mass. Participants were asked to refill and reuse the 
bottle prior to each subsequent laboratory visit. 
 
2.3. Electronically-braked cycle ergometry 
 
An electronically-braked cycle ergometer (Ergoline ER800, Jaeger, GmbH, Würzburg, 
Germany) was used for all exercise tests. The resistance applied to the flywheel is 
independent of cadence, thus providing a constant work-load regardless of small 
variations in pedal frequency. Saddle and handlebar height, and handlebar reach were 
adjusted to ensure an ergonomic fit between each participant and the ergometer. These 
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data were recorded to ensure replication of the position on subsequent visits. Participants 
were asked to remain seated at all times while pedalling. 
 
2.3.1. Maximal oxygen uptake determination protocol 
 
A maximum rate of oxygen uptake ( max) test was completed by all participants to 
enable exercise trial prescription at specific work-loads. The test commenced following 
a 60 s resting baseline expired gas sample and 4 min of cycling at 20 W/min (the lowest 
resistance available on the ergometer) to establish the resting and exercising baseline rate 
of oxygen uptake ( ). Participants cycled at 60 RPM unless otherwise specified. A 
ramp rate of 30 W/min was employed, administered by increasing the resistance by 5 
W/min every 10 s. 
 
2.3.1.1. Methodological considerations: maximal incremental exercise testing 
 
Since max may differ during different types of exercise, the max test should be 
performed within the same mode of exercise and using the same equipment e.g. treadmill, 
cycle ergometer, that will be used during subsequent periods of data collection. For 
optimal inter-individual comparisons participants should perform the test in a similar 
physiological state, e.g. rested, fasted, euhydrated and at the same time of day to avoid 
circadian effects. Consideration of these conditions is particularly important if the goal 
of the research is to characterise the effects of an exercise stimulus on local and systemic 
hormone and cytokine responses (Baldwin et al., 2000; Starkie et al., 2001). 
 
2.3.2. Criteria for a successful max test 
 
The following were used as guidelines to determine a successful max test. A plateau 
in the  data with increasing work-load was taken as the primary criterion, indicating 
a successful test. A re-test was performed if a plateau in the  data with increasing 
work-load was not observed and two out of the three secondary criteria were not met. 
 
 A plateau in the  data with increasing work-load (Taylor et al., 1955). 
 Attainment of age predicted Heart rate at max (HRmax) within 10 b/min, 
predicted using the equation 205.8 – 0.685 x age (Inbar et al., 1994). 
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 Respiratory exchange ratio (RER) of 1 or greater (Issekutz et al., 1962). 
 Rating of perceived exertion (RPE) of 18 or greater (Borg, 1970; 1982). 
 
2.3.2.1. Methodological considerations: criteria for a successful max test 
 
A major source of error in maximal exercise testing results from participant motivation, 
and failure to produce a truly maximum effort. The British Association of Sport and 
Exercise Sciences (BASES) and the American College of Sports Medicine (ACSM) 
provide guidelines on maximal exercise testing, which include assessment criteria for 
determining whether a participant reached a true maximum. In the literature a plateau in 
the  profile with increasing work-load has been the primary criterion by which 
attainment of max has been assessed (Taylor et al., 1955; Astrand, 1967). The plateau 
has been defined as an increase in oxygen uptake of < 1.5 ml/min/kg (Foster et al., 1986) 
or < 2.0 ml/min/kg (Astrand, 1960). Secondary criteria such as an RER > 1.0 (Drinkwater, 
1984; Cress et al., 1991) to > 1.15 (Shephard et al., 1968), an exercise Heart rate (HR) of 
at least 85 % of age-predicted maximum (Borg, 1982) or a HR within 10 b/min of age-
predicted maximum (Howley et al., 1995), a Blood lactate (BLa) concentration of > 5.5 
mM (von Dôbeln et al., 1967) or > 7.9 mM (Astrand 1952), and Borg’s RPE scale (Borg, 
1982; 1970) have also been used (Tanaka et al., 1997). More recently the validity of 
criteria such as these has been questioned (Howley et al., 1995; Midgley et al., 2007; 
Poole et al., 2008; Midgley et al., 2009). Given that the outcome of a max test is 
dependent on so many factors it is surprising that the exercise literature often does not 
provide sufficient information pertaining to the protocol followed to determine max. 
Similarly, it is often unclear how exercise trial intensities based on max are set. 
Where details are available, considerable variation exists in the protocols used, and there 
is also considerable inter-individual variation in max (Shephard, 1984). In cycle 
ergometry this issue is further compounded by differences in cadence. 
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2.4. Heart rate monitoring 
 
Heart rate was monitored during exercise using a short-range telemetry heart rate monitor 
(Accurex Plus, Polar Electro Oy, Kempele, Finland). Additionally, HR data 
corresponding with breath-by-breath expired gas analysis data were recorded using the 
portable cardio-pulmonary testing system described in the following section. 
 
2.5. Expired gas sampling 
 
Breath-by-breath expired gas samples were analysed during exercise using a portable 
cardio-pulmonary testing system (K4 b2, COSMED, Rome, Italy). In accordance with the 
operating instructions, the system was allowed to warm up for 45 min before calibration 
and use. A volume calibration, performed using a precision 3 l syringe, and a respiratory 
delay calibration were performed before use. Additionally, a calibration step was 
performed with room air and precision gases of known Oxygen (O2) and Carbon dioxide 
(CO2) gas concentrations (British Oxygen Company (BOC) Ltd, Guildford, UK) 
immediately prior to each individual test. Data from the K4 b2 unit were downloaded to a 
standard personal computer using appropriate software (Version 8.0b, K4 b2, COSMED, 
Rome, Italy). Data were analysed using Microsoft® Excel® 2004 for Macintosh (version 
11.2.5, Microsoft Corporation, Redmond, WA, USA). 
 
2.5.1. Methodological considerations: an oxygen uptake dynamics approach 
 
The following paragraphs summarise terms and methodological aspects of the oxygen 
uptake dynamics approach to exercise testing employed in this thesis. The reader is 
referred to Jones and Poole (2005) for a general introduction to the area of oxygen uptake 
dynamics research. 
 
2.5.1.1. The  response to constant work-load exercise 
 
Following the onset of constant work-load exercise,  increases in an exponential 
manner, incorporating three distinct phases (Whipp et al., 1982), illustrated in figure 2.1. 
The cardio-dynamic component phase, during which time  rises rapidly, lasts ~ 10 – 
30 s. During the primary component phase  rises exponentially. When the exercise 
work-load is below the anaerobic threshold (ATh), and the exercise duration is 
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sufficiently long, the final steady state phase can be observed, within which the rise in 
 appears to plateau. If the exercise work-load is above the Anaerobic threshold (ATh) 
a steady state component maybe delayed or absent as  continues to rise, a response 
termed the  slow component (Whipp and Wasserman, 1972). 
Figure 2.1. Schematic representation of the phases of the oxygen uptake response to constant work-load 
exercise. Initial (cardio-dynamic component) phase, second (primary component) phase, third (steady state 
component) phase, and the  slow component.  
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2.5.1.2. The gas exchange threshold 
 
The term Gas exchange threshold (GET) refers to the point at which there is a 
disproportionate increase in the rate of carbon dioxide production ( ) with respect to 
 during a maximal incremental exercise test (Beaver et al., 1986b). Increasing 
exercise intensity beyond a certain work-load threshold results in the accumulation of 
lactate as a result of anaerobic energy metabolism. Accompanying this increase in lactate 
is an approximately equal reduction in blood bicarbonate concentration (Wasserman et 
al., 1967; Beaver et al., 1986a). The resulting increase in CO2 production can be observed 
in the expired CO2 profile (Wasserman et al., 1973; Wasserman, 1984). The point at 
which lactate starts to increase in the blood has been termed the ATh, the Lactate 
threshold (LTh) when reference is made to acid-base status, or the GET when observed 
through monitoring of  and  respiratory profiles. 
 
2.5.1.3. Maximal lactate steady state 
 
The term Maximal lactate steady state (MLSS) refers to the highest constant work-load 
(Power output at maximal lactate steady state (P-MLSS)) at which BLa concentration, 
whilst elevated above that at rest, is maintained at a constant level. (Beneke and von 
Duvillard, 1996; Jones and Doust, 1998). Pringle and Jones (2002) suggested that the 
MLSS represents a clear demarcation in the  response to constant work-load cycle 
exercise; cycling below and at the P-MLSS results in a steady state  and the 
ventilatory equivalent ( ), while cycling just above P-MLSS resulted in a progressive 
increase in  and  and subsequent termination of exercise due to fatigue. 
 
2.5.1.4. The concept of exercise domains 
 
Whipp et al., (2005) originally explained the concept of exercise domains and the 
physiological characteristics that demarcate the domain boundaries, which are 
summarised in figure 2.2. Exercise of moderate intensity is characterised by the absence 
of metabolic acidosis. The upper boundary of this domain is marked by the GET. During 
moderate intensity, constant work-load exercise  increases as a two-phase 
exponential response attaining steady state within ~ 2 - 3 min (Whipp and Wasserman, 
1972). Exercise intensities within this domain are usually expressed as a percentage of 
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GET, e.g. 80 % GET. Heavy intensity exercise, bordering moderate, is indicated by 
sustained metabolic acidosis with increased arterial blood lactate and decreased pH. In 
this domain these parameters may become stable or return to baseline. Stepping up in 
intensity is very heavy exercise. The point denoted by MLSS indicates the boundary 
between heavy and very heavy exercise (Pringle and Jones, 2002), where increasing 
arterial blood lactate and decreasing pH ultimately culminate in voluntary cessation of 
exercise (volitional exhaustion). This point generally coincides with max. The 
exercise intensities that fall within the heavy and very heavy domains are usually 
expressed as delta () values, e.g. 30 % . 
  
˙ V O
2
  58 
Figure 2.2. Schematic representation of the exercise domains defined by the  response to constant 
work-load exercise. (a) moderate exercise domain (below GET), (b) heavy exercise domain (above the Gas 
exchange threshold (GET) but below Maximal lactate steady state (MLSS)) and (c) very heavy exercise 
domain (above MLSS but below max).    
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2.5.1.5. Determination of exercise trial intensity from raw pulmonary gas exchange data 
 
The breath-by-breath data were examined to exclude errant breaths caused by coughing, 
swallowing, etc. Data from all of the tests were linearly interpolated to provide second-
by-second values. Mean values were calculated over consecutive 10 s periods (Astorino, 
2009). The GET was determined from a cluster of measurements. Initially, it was 
determined as the point on the  profile at which there was a disproportionate increase 
in  from visual inspection of individual  and  graphs (Beaver et al., 
1986b), known as the V-slope method (figure 2.3). Should the V-slope method not prove 
deterministic, visual inspection of the ventilatory equivalents for an increase in /  
with no increase in / , and an increase in end-tidal O2 tension with no fall in end-
tidal CO2 tension (Wasserman et al., 1999) provided confirmation. The max value 
was determined as the highest 10 s average value. Exercise trial power output 
corresponding to moderate (80 % GET), heavy (30 % ) and very heavy (60 % ) exercise 
intensities were calculated by first determining the power output corresponding to the 
GET and max. Power output corresponding to 80 % of that at GET was designated 
moderate (80 % GET) intensity exercise. Similarly, power output corresponding to 30 % 
and 60 % of the difference between that at GET and max was designated heavy (30 
% ) intensity exercise and very heavy (60 % ) intensity exercise, respectively. The 
mean response time of the  response to ramp exercise (assumed to approximate 2/3 
of the ramp rate, i.e. 20 W) was taken into account in the calculation of these work-loads 
(Whipp et al., 1981). 
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Figure 2.3. The V-slope method. A disproportionate increase in  from visual inspection of individual  and  profiles (red dashed lines). The boundaries of the Moderate, 
Heavy and Very heavy exercise domains are shown (blue dashed lines), as are the threshold events that define them (GET, MLSS and max). The exercise trial intensities referred 
to throughout this thesis are shown in bold (Moderate 80 % GET, Heavy 30 %  and Very heavy 60 % ). 
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2.5.1.6. Explanation and justification for exercise trial intensities 
 
Moderate (80 % GET) exercise: exercise at this intensity provides sufficient stimulus for 
increased physiological responses while falling short of the GET and therefore, avoiding 
any contribution of energy produced via anaerobic pathways (Carter et al., 2000). 
 
Calculation: 
 
Power output at GET x 0.8 = 80 % GET (moderate) exercise resistance. 
 
Heavy (30 % ) exercise: although above the GET and therefore receiving an energy 
contribution from anaerobic pathways, exercise at this intensity is considerably below 
Maximal lactate steady state (MLSS) (approximately 54 %  (Pringle and Jones, 2002)), 
which will considerably minimise the effects of the O2-slow component and increased 
metabolic acidosis on the measured physiological variables.  
 
Calculation: 
 
((Power output at max - Power output at GET) x 0.3) + Power output at 
GET = 30 %  (heavy) exercise resistance. 
 
Very heavy (60 % ) exercise: above MLSS, exercise at this intensity produces a rapid 
increase in the O2-slow component and in metabolic acidosis. 
 
Calculation: 
 
((Power output at max - Power output at GET) x 0.6) + Power output at GET 
= 60 %  (very heavy) exercise resistance. 
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2.5.1.7. Example of calculations to determine exercise trial duration according to equal 
work done 
 
Moderate intensity:  (e.g. 100 W): 100 W x 30 min (1800 s) = 180000 J total work done. 
 
Heavy intensity:  (e.g. 200 W): Total work done at moderate intensity = 180000 J. 
180000 J/200 W = 900 s (15 min). 
 
Very heavy intensity:  (e.g. 300 W): Total work done at moderate intensity = 180000 J. 
180000 J/300 W = 600 s (10 min). 
 
2.5.1.8. Exercise trial protocols 
 
The equipment and procedures identified here have been described in detail previously. 
Participants were asked to observe the preparation guidelines with regard to fasting, 
relative hydration and abstinence described previously prior to all exercise trials. 
Participants were asked politely to ensure they arrived promptly at the appointed time for 
data collection, and to wear clothing suitable for exercise. Shortly after arriving at the 
laboratory an indwelling venous cannula was placed. Venous and finger prick blood 
samples were obtained following 10 min quiet sitting. Prior to the trial the cycle 
ergometer saddle was correctly positioned according to data recorded during the max 
test. Exercise trials commenced in earnest with the application of a load pre-determined 
to elicit the physiological response characteristic of the exercise domain (moderate, heavy 
or very heavy) in which the trial is taking place. Immediately prior to this, resting and 
exercising baseline  data were collected. Heart rate was recorded and participants 
were asked to breath into a portable cardio-pulmonary testing system during the initial 10 
min (including resting and exercising baseline  data collection) and the final two min 
of each exercise trial. Samples of skeletal muscle tissue and adipose tissue were obtained 
immediately post-exercise (exercise studies 1 and 2 only). Additional blood samples were 
obtained to establish time-course profiles. Detailed information including an overview 
schematic relating to the exercise trial protocols employed in each of the interlinking 
studies follows. 
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2.5.1.8.1. Overview of exercise studies 
 
A schematic representation of the experimental timelines for the interlinking feasibility 
and exercise studies performed in this thesis is provided in figure 2.4. Details of the 
exercise trial protocols used in exercise studies 1, 2, and 3 are provided in tables 2.1., 2.2. 
and 2.3, respectively. 
 
  
6
4
 
Figure 2.4. Experimental timelines: feasibility studies 1 and 2, and exercise studies 1, 2 and 3. Chronological order represents the minimum duration between subsequent events. IF - 
participant meeting, informed consent obtained, IM - initial measurements (participant stature and body mass), FAST - 12 hr. overnight fast, MAX -  max test, pre- and post-test 
venous and finger prick (blood glucose and blood lactate) blood samples, SM&A - skeletal muscle and subcutaneous adipose tissue biopsy, EX - randomised exercise trial. Information 
relating to feasibility studies 1 and 2 is not reported. 
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Table 2.1. Study 1 exercise trial protocols 
 
      
Time (min) Trial 
 Moderate 
(60 min) 
Heavy 
(equal work: 27:48 ± 02:31) 
   
   
0 (baseline) Blood 
Exercise trial commenced 
 
27:48 ± 02:31 (end of exercise) 
(Heavy (equal work) trial time, 
mean ± SD) 
- Blood. 
Muscle and adipose tissue 
biopsy 
30 Blood 
 
- 
60 (end of exercise) (Moderate 
trial time) 
Blood. 
Muscle and adipose tissue 
biopsy 
- 
60 (post-exercise) Blood 
 
24 hr. (post-exercise) Blood 
 
      
 
Heavy (equal work) - work done is approximately equal to that done in the moderate (60 min) trial. 
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Table 2.2. Study 2 exercise trial protocols 
 
      
Time (min) Trial 
 
Heavy  
(30 min) 
Very heavy  
(equal work: 22:29 ± 01:31) 
      
   
0 (baseline) Blood  
Exercise trial commenced 
 
22:29 ± 01:31 (end of exercise) 
(Very heavy (equal work) trial 
time, mean ± SD) 
- Blood.  
Muscle and adipose tissue 
biopsy 
30 (end of exercise) (Heavy 
trial time) 
Blood.  
Muscle and adipose tissue 
biopsy 
- 
60 (post-exercise) Blood 
 
24 hr. (post-exercise) Blood 
 
      
 
Very heavy (equal work) - work done is approximately equal to that done in the heavy (30 min) trial. 
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Table 2.3. Study 3 exercise trial protocol 
 
    
Time (min) Trial 
 Heavy (30 min) 
    
  
0 (baseline) Blood  
Exercise trial commenced  
10  Blood 
 
20  Blood 
 
30 (end of exercise) Blood.  
 
30 (post-exercise) Blood 
 
60 (post-exercise) Blood 
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2.6. Blood sampling 
 
2.6.1. Venous blood sampling 
 
Samples of whole blood were obtained via venepuncture from veins in close proximity 
to the cubital fosse of the non-dominant arm pre-exercise, during exercise and post-
exercise via indwelling venous cannula (Venflon IV Blue 22G, Beckton Dickinson (BD) 
Biosciences, Oxford, UK.). Resting baseline samples and 24 hr. post-exercise samples, 
were collected via needle (NN-2138R, Terumo, Luer 21G, Terumo Europe, 
Leuven, Belgium) and 10 ml syringe (SS-10ES, Terumo Europe, Leuven, Belgium). 
Blood samples (3 ml discard, 10 ml collection) were drawn into ice cold S-Monovette® 
tubes (02.1063.001 Serum Z/9 ml, Sarstedt AG & Co, Germany). To control for the 
influence of postural changes on body fluid distribution, the pre-exercise resting blood 
sample was taken 10 min post-cannulation, after the participant had been seated, 
motionless, for that time. Following blood draw, 10 ml sterile saline was infused to ensure 
the cannula was kept patent. Following blood clotting on ice, serum was obtained via 
centrifugation (2000 g, 6 min, 4 C). The serum was aliquoted into labelled 2 ml 
Eppendorf® tubes (0030 120.094, Eppendorf AG. Hamburg, Germany) and stored at - 
80 C until analysed. 
 
2.6.2. Capillary blood sampling 
 
Samples of whole blood were obtained from the fingertip capillary bed via finger prick pre- 
and post-exercise to enable measurements of BLa and Blood glucose (BGlu) 
concentrations. 
 
2.6.2.1. Blood lactate 
 
The concentration of BLa was measured using a YSI 1500 Sport portable BLa analyzer 
(1500, YSI Inc., Yellow Springs, Ohio, USA). This instrument uses a proprietary 
electrochemical enzymatic method for detection of lactate in 25 µl samples of whole 
blood (measurement range: 0 – 30 mmol/l, Precision: Whichever is larger, ± 2 % of 
reading or 0.1 mmol/l). Calibration checks were performed on this machine daily using a 
5 mmol/l standard (2327, YSI Inc., Yellow Springs, Ohio, USA). 
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Following the relocation of laboratory facilities to central Manchester this instrument was 
no longer available. Blood lactate concentrations were measured in approximately 5 l 
whole blood using a Lactate Pro BLa analyser and specific test strips (Lactate Pro Reagent 
Strips, Akray KDK, Koyota, Japan). This method was used for all samples collected from 
participants in the 40 - 50 yr. and 50 - 60 yr. age groups in study 3 only. The measurement 
principle employed by the instrument is based on the potassium ferricyanide and lactate 
oxidase method. Independent evaluation confirmed the validity of this device (Pyne et 
al., 2000) and the relationship of measurements to the YSI 1500 Sport (McLean and 
Smith, 2004). Equipment and calibration checks were performed on this machine daily 
using the check strip and a calibration strip associated with the specific test strips being 
used. Prior to calibration a visual check was performed to confirm serial number 
agreement between the calibration and test strips. 
 
2.6.2.2. Blood glucose 
 
The concentration of BGlu was measured using a portable BGlu analyser (11418246906, 
Accutrend® GC, Roche Diagnostics, East Sussex, UK) and test strips for quantification 
of BGlu (11443054018 BM Accutest, Roche Diagnostics, East Sussex, UK). The 
measurement principle employed by this instrument is reflectance photometry (optical 
system: LED 657 nm, measurement range: glucose 3.88 – 7.76 mmol/l). Fasting glucose 
reference values for healthy adult males are considered to be between 3.4 and 5.5 mmol/l. 
 
Following the relocation of laboratory facilities to central Manchester this instrument also 
was no longer available. Blood glucose concentrations were measured using a 
HemoCue® 201+ BGlu analyser (120713, HemoCue® AB, Ängelholm, Sweden) and 
specific HemoCue® Glucose 201 Microcuvetes (110716, HemoCue® AB, Ängelholm, 
Sweden). This method was used for all samples collected from participants in the 40 - 50 
yr. and 50 - 60 yr. age groups in study 3 only. The measurement principle employed by 
the instrument is based on a glucose dehydrogenase method. Calibration checks were 
performed on this machine daily using Level 2 controls - range 6.0 ± 0.9 mmol/l 
(146.002.002, HemoCue® AB, Ängelholm, Sweden). 
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2.6.3. Enzyme-linked immunosorbent assay analyses 
 
Serum samples were assayed for specific growth factors and cytokines. Pre-coated, 96-
well enzyme-linked immunosorbent assay (ELISA) kits were purchased for 
determination of specific protein concentrations in human serum. Kits were stored and 
utilised according to the manufacturers instructions. An automated plate reader 
(ELx800UV, BIO-TEK Instruments Inc., Winooski, Vermont, USA) was used at relevant 
wavelengths for all protein determinations. Data were analysed using Microsoft® Excel® 
2004 for Mac (version 11.2.5, Microsoft Corporation, Redmond, WA, USA). 
 
The following assays were performed: 
 
 Interleukin-6 (IL-6) (850.035.096, DIACLONE research high sensitivity IL-6, 
IDS Ltd., Tyne and Wear, UK). Standard curve range 0 – 50 pg/ml, sensitivity 0.8 
pg/ml. †, †† 
 Interleukin-1-alpha (IL-1) (583301, Cayman Chemical Company, Michigan, 
USA). Standard curve range 0 – 250 pg/ml, sensitivity 1.5 pg/ml. †† 
 Interleukin-1-beta (IL-1) (583311, Cayman Chemical Company, Michigan, 
USA). Standard curve range 0 – 250 pg/ml, sensitivity 1.5 pg/ml. †† 
 Tumour necrosis factor-alpha (TNF) (589201, Cayman Chemical Company, 
Michigan, USA). Standard curve range 0 – 250 pg/ml, sensitivity 1.5 pg/ml. †† 
 Cortisol (DX-EIA-1887, DRG Instruments GmbH Corisol ELISA, IDS Ltd., Tyne 
and Wear, UK). Standard curve range 0 – 800 ng/ml, sensitivity 2.5 ng/ml. ††, ‡, 
‡‡, ‡‡‡  
 IL-6 (BMS213INST, Bender MedSystems GmbH, Vienna, Austria). Standard 
curve range 0 – 200 pg/ml, sensitivity 0.92 pg/ml. ‡, ‡‡, ‡‡‡ 
 Growth Hormone (GH) (DX-EIA-3552, DRG Instruments GmbH hGH ELISA, 
IDS Ltd., Tyne and Wear, UK). Standard curve range 0 – 74 µIU/ml, sensitivity 
0.2 µIU/ml. ††, ‡, ‡‡, ‡‡‡ 
 Insulin-like growth factor-I (IGF-I) (EL2010, Biocode-Hycel™, IGF-I, Oxford 
Biosystems Oxford, UK). Standard curve range 0 – 1250 ng/ml, sensitivity 8 
ng/ml. †, ††, ‡, ‡‡, ‡‡‡ 
 Leptin (BMS2039INST, Bender MedSystems GmbH, Vienna, Austria). Standard 
curve range 0 – 4000 pg/ml, sensitivity 20 pg/ml. ‡, ‡‡, ‡‡‡ 
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 Adiponectin (DEE009, Demeditec Diagnostics GmbH, Kiel, Germany). Standard 
curve range 0 – 100 ng/ml, sensitivity 0.6 ng/ml. ‡, ‡‡, ‡‡‡ 
 Insulin (KAP1251, BioSource Europe S.A., Nivelles, Belgium). Standard curve 
range 0 – 237 IU/ml, sensitivity 0.15 IU/ml. ‡, ‡‡, ‡‡‡ 
 
Feasibility study 1- †, 2 - †† 
Exercise study 1 - ‡, 2 - ‡‡, 3 - ‡‡‡ 
 
2.7. Skeletal muscle and subcutaneous adipose tissue sampling 
 
Skeletal muscle and subcutaneous adipose tissue samples were obtained post-exercise via 
conchotome technique (Dietrichson et al., 1980; 1987). The procedure was performed by 
a suitably qualified, General Medical Council registered, medical doctor experienced in 
the extraction of skeletal muscle and adipose tissue. 
 
2.7.1. Skeletal muscle and subcutaneous adipose biopsy procedure 
 
The point of incision above the Vastus Lateralis was identified following a request to the 
participant to contract the muscles of the thigh. An area on the skin surface in which an 
incision would be made was shaved using a disposable prep razor (UN2000, Universal 
Hospital Supplies, Enfield, UK) and cleaned using alcohol swabs (Sterets pre-injection 
wipes, 00766691, Seton Healthcare Group plc., Oldham, UK). A sterile field was created 
and maintained using a sterile procedure pack (Vernaid wound care pack option 2, 28853, 
Vernon-Carus ltd., Preston, Lancashire, UK). The area around the incision was swabbed 
with a surgical scrub solution (Betadine Surgical Scrub, Purdue Pharma LP, Stamford, 
Connecticut, USA). Local anaesthesia of the skin and immediately underlying tissue was 
achieved using Lidocaine 2 % solution (PL01502/0021R, Lidocaine Hydrochloride, 40 
mg in 2 ml, Hamlin Pharmaceuticals Ltd., Gloucester, UK), administered via a 25G 
hypodermic needle (NN-2516R, Terumo Europe, Leuven, Belgium) and 5 ml syringe 
(SS-05ES, Terumo Europe, Leuven, Belgium). Sufficient time was allowed for the 
anaesthetic to act before a 5 mm incision was made in the skin and underlying facia using 
a sterile disposable scalpel (Size 11, Swann-Morton, General Medical, Aldershot, UK). 
The sterile biopsy conchotome (Weil-Blakesley Rongeur, 52-030-50, Gebrüder Zepf 
Medizintechnik, Tüttlingen, Germany) was inserted through the incision, manoeuvred 
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into position and used to incise tissue from the muscle belly. The instrument was removed 
and the sample prepared for storage/cell culture. 
 
Immediately after harvesting the skeletal muscle tissue sample, a sample of subcutaneous 
adipose tissue was obtained from the adipose tissue bed surrounding the site of the 
incision. Adipose tissue samples were obtained using the conchotome in a similar manner 
as the skeletal muscle samples. A rest period of at least two weeks was implemented 
between repeat skeletal muscle and adipose tissue sampling on the same limb. Care was 
taken to ensure that a distance of at least 2 cm separated the sites of samples taken from 
the same limb (Malm et al., 2000). 
 
Wound closure was undertaken using sterile adhesive strips (3M Steri-Strip, 3M 
Healthcare, St. Paul, Minnesota, USA) and overlayed with a sterile dressing (Mepore® 
Ultra, Mölnlycke Health Care AB, Göteborg, Sweden). Bleeding was minimised by the 
application of a compressive dressing (3M Coban Self-Adherent Wrap, 1584, 3M 
Healthcare, St. Paul, Minnesota, USA with Vernaid gauze swab, 28919, Vernon-Carus 
ltd., Preston, Lancashire, UK). Perfusion of the leg post-biopsy was established by 
checking the pulse at the ankle. Participants were advised that the compressive dressing 
should only be removed after a minimum period of 4 hrs. and to keep the wound dry. 
Participants were further advised to refrain from exercise for 4 days post-procedure, and 
that they must inform the principal investigator and their general practitioner should the 
wound become infected. 
 
2.7.2. Skeletal muscle and adipose tissue homogenisation 
 
Cryovials containing the skeletal muscle and adipose tissue samples were removed from 
liquid nitrogen in small batches before being homogenised in the presence of Trizol 
(TRI®) Reagent Solution (1 ml) (AM9738 Applied Biosystems, Warrington, UK.) using 
an T10 basic Ultra-Turrax Homogenizer Workcenter (3519700) fitted with a S10N-5G 
dispersing tool (3304000, IKA-Werke GmBH & Co. KG, Staufen, Germany). Visual 
inspection confirmed no visible pieces of tissue remained following the procedure. 
Cryovials were re-labelled and returned to storage at -80 °C. Between samples the 
dispersing tool was washed in sterile phosphate buffered saline (BR0014G soluble 
tablets, OXOID, Basingstoke, UK) followed by 1 ml TRI® Reagent Solution. 
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2.7.3. Ribonucleic acid isolation 
 
Cryovials containing the homogenised samples were removed from storage at -80 °C in 
small batches and allowed to thaw completely. Samples were supplemented with 0.2 ml 
Chloroform (for molecular biology, minimum 99 %, C2432-500ML, Sigma-Aldrich 
Company Ltd., Poole, UK) per 1 ml of TRI® Reagent Solution and mixed vigorously for 
20 s prior to centrifugation at 12000 g for 16 min at 4 ˚ C (3K10, SIGMA Laborzentrifugen 
GmbH, Osterode am Harz, Germany). The aqueous phase was transferred into a 1.5 ml 
RNase free microcentrifuge tube (AM12400, Applied Biosystems, Warrington, UK). 
Care was taken not to disturb the interface Deoxyribonucleic acid (DNA) layer. Original 
cryovials containing the DNA and organic phase were returned to -80 °C for storage. 
Ribonucleic acid (RNA) was precipitated from the aqueous phase using Isopropanol (2-
Propanol for molecular biology, minimum 99 %) (I9516-500 ml, Sigma-Aldrich 
Company Ltd., Poole, UK) at a ratio of 1:1. Samples were mixed by inversion twice prior 
to being centrifuged at 12000 g for 10 min at 4 °C. The supernatant was carefully removed 
and the RNA pellet was washed with 75 % Ethanol (BDH AnalaR 96 % v/v) (10476, 
VWR International Ltd., Lutterworth, UK) prior to centrifugation at 8500 g for 6 min at 
4 ˚C. Ethanol was removed and the RNA pellets were left to air dry before being re-
suspended in 100 µl RNA storage solution (AM7001, Applied Biosystems, Warrington, 
UK). Ribonucleic acid was returned to -80 °C for storage until required for further 
analyses. 
 
2.7.4. Oligonucleotide primer design and synthesis 
 
The Genome Bioinformatics Group of UC Santa Cruz website genome browser (no date) 
was used to identify the DNA sequences for the selected genes of investigation. 
Oligonucleotide primers were designed using Beacon Designer version 5.11 (PREMIER 
Biosoft International, California, USA). Oligonucleotide primers were designed to yield 
products spanning exon-intron boundaries to avoid genomic DNA contamination. The 
inclusion of three or more GC base pairs in the last 5 base pairs at the 3’ end of the primer 
was avoided in order to minimise nonspecific amplification. All primers had a nucleotide 
base length of between 18 and 22 base-pair sequences. Beacon Designer version 5.11 was 
also used to perform searches for secondary structure or inter/intra-molecular interactions 
such as hairpins, self-dimers and cross-dimers within the primer. Sequence homology 
searches were performed against the National Center for Biotechnology Information 
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(NCBI) Genbank® database (NCBI, Maryland, USA) to ensure specific amplification of 
the associated target gene. Custom oligonucleotide primers (table 2.4) were purchased 
from Sigma-Genosys (Sigma-Genosys Ltd., Suffolk, UK), or from QIAGEN (QIAGEN, 
West Sussex, UK). 
 
Table 2.4. Reverse transcription-polymerase chain reaction oligonucleotide primer 
information 
 
    
Target Gene (ref. sequence) Oligonucleotide primer Sequence (5’-3’) Supplier 
    
   
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 
F GCAGAACGGACGGAGATG 
R TCAACGGCACAGTCAAGG 
Sigma-Genosys 
IL-6 (NM_000600.3) 
F ACAACCTGAACCTTCCAAAG 
R TTCCTCACTACTCTCAAATCTG 
Sigma-Genosys 
TNFα (NM_000594) 
F CCAGGGACCTCTCTCTCTAATC 
R GCTACAACATGGGCTACAG 
Sigma-Genosys 
IGF-I (X57025) 
F GCTCTTCAGTTCGTGTGTG 
R GAAGCAGCACTCATCCAC 
Sigma-Genosys 
Insulin-like growth factor-I 
receptor (IGF-IR) (NM_000875) 
Not disclosed QIAGEN 
Suppressor of cytokine signalling 
3 (SOCS3) (NM_003955.3) 
Not disclosed QIAGEN 
Interleukin-15 (IL-15) 
(NM_000585) 
Not disclosed QIAGEN 
Tripartite motif-containing 72 
(TRIM72) (NM_001008274) 
Not disclosed QIAGEN 
Peroxisome proliferator-activated 
receptor-γ coactivator 1-alpha 
(PGC-1α) (NM_013261) 
Not disclosed QIAGEN 
Leptin (NM_000230) Not disclosed QIAGEN 
Adiponectin (NM_004797) Not disclosed QIAGEN 
Adiponectin receptor 1 
(AdipoR1) (NM_015999) 
Not disclosed QIAGEN 
   
 
F - Forward oligonucleotide primer sequence. 
R - Reverse oligonucleotide primer sequence. 
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2.7.5. Reverse transcription-polymerase chain reaction method and data analysis 
 
Ribonucleaic acid concentration and purity were assessed via ultraviolet spectroscopy 
from the optical density at 260 and 280 nm using a spectrophotometer (WPA Biowave II, 
Biochrom Ltd., Cambridge, UK). Seventy ng RNA were used per Reverse transcription-
polymerase chain reaction (RT-PCR) (7 µl of RNA at a concentration of 10 ng/µl). 
Amplification of target genes via RT-PCR was performed using a commercially available 
Power SYBR Green RNA-to-CT 1 step kit (4389986, Applied Biosystems, Warrington, 
UK) and 96-well RT-PCR plates (223-9441, Bio-Rad Laboratories Ltd., Hertfordshire, 
UK). The custom RT-PCR protocol was controlled using a Chromo4TM DNA engine 
interfaced with a laptop computer running Opticon Monitor version 3.1.32 (MJ 
Geneworks Inc, Bio-Rad Laboratories Ltd., Hertfordshire, UK). The following RT-PCR 
cycles (table 2.5) were performed in order to facilitate gene amplification. 
 
Table 2.5. Reverse transcription-polymerase chain reaction thermal cycle protocol 
 
   
Description of protocol stage Temperature and duration 
   
  
1. cDNA synthesis Incubate at 48 °C for 30:00  
2. Transcriptase inactivation Incubate at 95 °C for 10:00 
3. Denaturation Incubate at 95 °C for 00:15 
4. Annealing/extension Incubate at 60 °C for 01:00 
5. Plate read - 
6. Goto line 3 for 39 more times - 
7. Melting curve analyses 
From 50 to 95 °C read every 
1°C, hold 00:00:01 
END - 
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Opticon Monitor version 3.1.32 constructs a graphical representation of fluorescence 
yield against RT-PCR cycle. The cycle number at which fluorescence yield crossed a 
threshold line (C(t)) was obtained by manually positioning a threshold line at a point 
along the exponential rise in the fluorescence/cycle curve. The data were exported to an 
Excel® version 12.2.0 spreadsheet (Microsoft® Excel® 2008 for Mac, Microsoft 
Corporation, Redmond, WA, USA) for analyses. The Delta delta (ΔΔ) C(t) equation 
(Livak Method) was used to determine normalised gene expression: 
 
Equation 1: Delta (Δ) C(t) = mean C(t) [gene of interest at exercise condition] – 
mean C(t) [reference gene at exercise condition]. 
 
Where: mean C(t) [gene of interest at exercise condition] = The mean C(t) value (sample 
and duplicate) of the targeted gene (e.g. IL-6) in the experimental condition (e.g. RNA 
isolated from skeletal muscle or adipose tissue following moderate, heavy or very heavy 
intensity cycle ergometer exercise).  
 
Mean C(t) [reference gene at exercise condition] = The mean C(t) value (sample and 
duplicate) of reference gene (e.g. GAPDH) in the experimental condition (e.g. RNA 
isolated from skeletal muscle or adipose tissue following moderate, heavy or very heavy 
intensity cycle ergometer exercise). 
 
Equation 2: ΔC(t) = mean C(t) [gene of interest at baseline] – mean C(t) [reference 
gene at baseline]. 
 
Where: mean C(t) [gene of interest at baseline] = The mean C(t) value (sample and 
duplicate) of targeted gene (e.g. IL-6) at baseline (e.g. RNA isolated from skeletal muscle 
or adipose tissue at rest). 
 
Mean C(t) [reference gene at baseline] = The mean C(t) value (sample and duplicate) of 
reference gene (e.g. GAPDH) at baseline (e.g. RNA isolated from skeletal muscle or 
adipose tissue at rest). 
 
Equation 3: ΔΔC(t) = ΔC(t) of Equation 1 - ΔC(t) of Equation 2. 
 
Equation 4: 2^-ΔΔC(t) = [normalised expression]. 
  77 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the reference gene in 
all RT-PCR experiments (Barber et al., 2005). Expression (C(t) value) of each gene of 
interest was normalised against the corresponding GAPDH C(t) value for each sample. 
 
Sterile technique was implemented throughout. RNase contamination from work surfaces 
and equipment reserved for molecular techniques was minimised prior to use by exposure 
to RNase Zap. (AM9780, Applied Biosystems, Warrington, UK). Fluid transfer activities 
were performed using pipettes reserved exclusively for molecular biology techniques. 
These were used with sterile Aerosol resistant (ART®) pipette tips (Molecular 
BioProducts Inc., San Diego, CA, USA). 
 
2.8. Statistical analyses 
 
Statistical analyses were performed using IBM SPSS Statistics versions 19 - 21 (IBM 
Corporation, New York, USA). Checks for parametricity were performed using, where 
appropriate, Levene’s equal variance test and the Shapiro-Wilk normal distribution test 
and Mauchly’s test of sphericity. Data were log (log10) or inverse (1/datum) transformed 
where applicable to normalise non-normally distributed data. If the assumption of 
sphericity was violated the degrees of freedom were adjusted accordingly (Greenhouse-
Geisser). Non-parametric methods of statistical analyses were employed where a normal 
distribution could not be reached. Statistical significance was accepted at P ≤ 0.05. 
Bonferrini corrections were applied where appropriate. Data are represented as mean ± 
SD unless otherwise stated. 
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Chapter 3. Maximal incremental exercise vs. acute ‘domain-based’ constant work-load 
cycle ergometry: comparison of cardio-respiratory responses 
 
3.1. Abstract 
 
Oxygen uptake dynamics research characterises exercise intensity into ‘domains’, based 
upon threshold events in the profiles of the muscle metabolic and pulmonary gas 
exchange responses. We hypothesised that mean , HR and /HR data obtained 
from equal work (varying duration) moderate (80 % GET) (M), heavy (30 % ) (H) and 
very heavy (60 % ) (VH) domain cycle ergometer exercise trials would parallel those 
obtained during a max test. Two groups of young recreationally active male 
participants (Study 1: n = 6; age, 28 ± 5 yrs.; body mass, 81.1 ± 14.6 kg; stature 1.79 ± 
0.03 m; BMI, 25 ± 4 kg/m2 - Study 2: n = 7; age, 26 ± 7 yrs.; body mass, 82.9 ± 14.3 kg; 
stature 1.84 ± 0.07 m; BMI, 25 ± 4 kg/m2) performed a cycle ergometer max test (30 
W/min ramp, 60 RPM) and equal work (varying duration) M and H (Study 1), and H and 
VH (Study 2) constant work-load cycle ergometer exercise trials, respectively. Statistical 
analyses permitted the pooling of data from the H exercise trials. Power Output (PO), 
, HR and /HR exercise trial data differed significantly between trials (P < 0.02). 
Analyses comparing M, H and VH trials and max text data revieled no significant 
differences for  (P = 0.16), HR (P = 0.5) and /HR (P = 0.42) and strong positive 
correlations ( : r = 0.944, n = 25, P < 0.001; HR: r = 0.903, n = 24, P < 0.001; and 
/HR: r = 0.824, n = 24, P < 0.001). We concluded that the ‘domain-based’ constant 
work-load cycle egometer exercise trials, performed at a power output identified during 
a incremental exercise test carried out with regard to the principals of oxygen uptake 
dynamics, yield similar cardio-respiratory characteristics. 
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3.2. Introduction 
 
The study of the acute responses to physical exercise and the adaptations to regular 
physical exercise are core to exercise physiology studies. Typically, in such studies 
participants are required to perform an incremental exercise test until exhaustion, work 
pioneered by A.V. Hill and colleagues (Hill and Lupton, 1923; Hill et al., 1924). The 
primary function of this fundamental measure of exercise physiology is to quantify the 
maximum rate of oxygen uptake ( max) by an individual during exercise on e.g. a 
cycle ergometer. To obtain the max value, work-load is progressively increased until 
the participant is unable to continue due to fatigue; a point termed volitional exhaustion. 
The rate of oxygen uptake ( ), Heart rate (HR) and Power output (PO), at this point 
correspond with the maximum aerobic capacity of the participant. The max value has 
traditionally been used to set constant work-load exercise e.g. a work-load that elicits 60 
% max. More recently maximal incremental or ramp exercise tests have replaced the 
discontinuous protocols employed by Hill and colleagues as the preferred method of 
establishing key parameters of aerobic function in humans, for example work efficiency, 
the Gas exchange threshold (GET) and max (Whipp et al., 1981). 
 
The accuracy with which exercise trials are assigned to and performed by a group of research 
study participants is an important methodological consideration, effecting the quality of the 
data gathered and consequently the research findings. Oxygen uptake dynamics researchers 
suggest the traditional approach, to assign exercise intensity in relation to max, could 
result in markedly different physiological stress characteristics at what would appear to 
be identical relative exercise intensities (Whipp et al., 2005) i.e. exercise at 70 % 
max in a group of participants varying in aerobic fitness might mean one participant is 
working below his/her Anaerobic threshold (ATh) and another maybe working above 
his/her ATh. Whipp et al., (2005) suggests that this issue can be overcome by assigning 
exercise intensity with reference to exercise ‘domain-based’ threshold events in the 
profiles of the muscle metabolic and pulmonary gas exchange responses, as described in 
Chapter 2 ‘General methods’. Section 2.5.1. ‘Methodological considerations: an oxygen 
uptake dynamics approach’. 
 
We suggest that this approach maybe more appropriate in the study of endurance 
exercise–induced hormone and cytokine changes than traditional methods given that the 
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Messenger ribonucleic acid (mRNA) of many metabolically sensitive proteins are 
expressed in skeletal muscle and/or adipose tissue in response to exercise. Zaldivar et al., 
(2006) employed this approach by investigating the effect of 30 minute bouts of heavy 
cycle ergometry exercise on the expression of pro- and anti-inflammatory cytokines and 
growth factors in leukocytes following exercise. It appears however, that a comparison 
has not be performed to assses the relationship between physiological data resulting from 
a cycle ergometer max test, performed in a manner capable of distinguishing oxygen 
uptake dynamics and therefore exercise domains, and constant work-load cycle ergometer 
exercise trials, conducted at an intensity specifically to elicit cardio-respiratory 
characteristics reflective of those domains. The objective of this chapter is therefore to 
compare data from a cycle ergometer max test, conducted using principles and 
techniques associated with oxygen uptake dynamics research, with that from three acute 
‘domain-based’ constant work-load cycle ergometer exercise interventions of varying 
intensity, but equal total work done. We hypothesise that mean , HR and rate of 
oxygen uptake divided by heart rate ( /HR) data obtained from moderate, heavy and 
very heavy domain cycle ergometer exercise trials would parallel those obtained during 
a max test. 
 
3.3. Methods 
 
Methodological information directly pertinent to this chapter is summarised briefly 
below. Chapter 2. ‘General methods’, provides a detailed reference resource, 
documenting the procedures employed in collecting the data presented in this thesis. 
Relevant sections in Chapter 2 will be referenced in the text by index number, e.g. [2.2.1.] 
refers to the section 2.2.1. ‘Ethical approval’. 
 
3.3.1. Study design 
 
A schematic representation of the interlinking studies presented in this thesis is provided 
in figure 2.4 [2.5.1.8.1.]. The data presented in this chapter relate to Exercise studies 1 
and 2. 
 
3.3.2. Participants [2.2.] 
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3.3.3. Maximal oxygen uptake determination protocol [2.3.1.] 
 
3.3.4. Determination of exercise trial intensity and duration [2.5.1.5. & 2.5.1.7.] 
 
3.3.5. Exercise trial protocols [2.5.1.8] 
 
3.3.6. Statistical analyses [2.8.] 
 
Participant descriptive data. Independent-samples t-Tests were performed to determine 
if age, body mass, stature, Body mass index (BMI), max, Power output at max 
(POmax), and Heart rate at max (HRmax) were significantly different between the 
participant groups in exercise study 1 and exercise study 2. 
 
Participant cardio-respiratory data. Repeated-measures analysis of variance (ANOVA) 
with as within factor ‘study’ and between factor ‘work-load’ were run to determine 
whether there were significant differences between the two studies (Study 1 vs. Study 2) 
and three work-loads (moderate (80 % GET), heavy (30 % Delta ()) and very heavy (60 
% ) intensity exercise) for PO, , HR and /HR. If significant effects were 
observed, post-hoc Bonferroni-corrected one-way ANOVA were run to identify the 
differences. 
 
Exercise trial comparison analyses. Pearson’s product-moment correlation coefficients 
were computed to assess the relationship between , HR and /HR data for 
moderate (80 % GET), heavy (30 % ) and very heavy (60 % ) intensity exercise 
determined from max tests and data measured directly during the exercise trials. 
Paired samples t-Tests were performed to determine if , HR and /HR data for 
moderate (80 % GET), heavy (30 % ) and very heavy (60 % ) intensity exercise, 
determined from max tests, varied significantly from data measured directly during 
the exercise trials. 
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3.4. Results  
 
3.4.1. Participant descriptive data 
 
Studies 1 and 2 were linked by heavy intensity exercise trials to link them, i.e. the studies 
were designed so participants in both studies 1 and 2 performed heavy intensity exercise 
of equivalent duration, ensuring equal work was performed within each study and 
between both trials. 
 
No statistically significant differences were evident between the participant groups in 
study 1 and 2, and the mean max values suggest excellent aerobic fitness (table 3.1) 
(Heyward 1998). 
 
Table 3.1. Participant descriptive and maximal exercise cardio-respiratory data 
 
  
     
Participant details 
Study 1: Moderate (60 
min) and Heavy (equal 
work) exercise 
Study 2: Heavy (30 
min) and Very Heavy 
(equal work) exercise 
Statistical analyses 
(main effect) 
       
    
Gender, n male, 6  male, 7  - 
Age (yrs.) 28 ± 5 26 ± 7 P = 0.57 
Body mass (kg) 81.1 ± 14.6 82.9 ± 14.3 P = 0.83 
Stature (m) 1.79 ± 0.03 1.84 ± 0.07 P = 0.15 
BMI (kg/m2) 25 ± 4 25 ± 4 P = 0.78 
      
max (ml/min) 4630 ± 581 4242 ± 874 P = 0.38 
POmax (W) 334 ± 43 326 ± 71 P = 0.80 
HRmax (b/min) 180 ± 11 181 ± 14 P = 0.90 
       
 
  
  
˙ V O
2
  
˙ V O
2
  83 
3.4.2. Participant moderate, heavy and very heavy domain exercise cardio-respiratory 
data 
 
Participant cardio-respiratory data indicate that there were no statistically significant 
differences between heavy (30 % Δ) intensity exercise (Study 1 vs. Study 2) for the 
variables analysed (table 3.2). There were no significant differences in total work done. 
A significant work-load effect was observed, with heavy (30 % Δ) intensity exercise 
eliciting a greater response than moderate (80 % GET) intensity exercise, and very heavy 
(60 % Δ) intensity exercise eliciting a greater response than heavy (30 % Δ) intensity 
exercise for PO (P = 0.01) and  (P = 0.02). Similarly, heavy (30 % Δ) intensity 
exercise elicited a greater response than moderate (80 % GET) intensity exercise for HR 
(P < 0.001) and /HR (P = 0.003). However, in these cases there were no statistically 
significant differences between heavy (30 % Δ) and very heavy (60 % Δ) intensity 
exercise. These data confirm exercise intensity significantly impacts cardio-respiratory 
responses. 
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Table 3.2. Participant moderate, heavy and very heavy domain exercise cardio-respiratory data 
 
       
Exercise variables Study 1 Study 2 Statistical analyses 
 
Moderate  
(60 min) 
Heavy (equal 
work) 
Heavy  
(30 min) 
Very Heavy 
(equal work) 
Study 1 vs. 
 Study 2 
Work-load 
       
       
Trial time (min:s) 60:00 ± 00:00 27:48 ± 02:31 30:00 ± 00:00 22:29 ± 01:31 - - 
PO (W) 84 ± 15 182 ± 19 184 ± 51 244 ± 57 NS 
P = 0.01 
M < H < VH 
 (ml/min) 1541 ± 188 2644 ± 231 2768 ± 670 3467 ± 723 NS 
P = 0.02 
M < H < VH 
HR (b/min) 101 ± 10 135 ± 13 134 ± 19 152 ± 12 NS 
P = 0.001 
M < H, VH 
/HR (ml/b/min) 15 ± 1 20 ± 3 19 ± 4 23 ± 5 NS 
P = 0.003 
M < VH 
Total work done (KJ) 303 ± 53 304 ± 53 303 ± 92 331 ± 93 NS NS 
       
 
M – moderate, H – heavy, VH – very heavy, NS - Not statistically significant. 
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3.4.3. Exercise trial comparison analyses 
 
Having ascertained the relevant cardio-respiratory data, we next wished to establish 
whether a relationship existed between exercise intensity determined from max tests 
and constant work-load exercise trials, for relevant output measures ( , HR and 
/HR data). To this end, Pearson’s product-moment correlation coefficients indicated 
significant, positive correlations for  (r = 0.944, n = 25, P < 0.001; figure 3.1), HR (r 
= 0.903, n = 24, P < 0.001; figure 3.2) and /HR data (r = 0.824, n = 24, P < 0.001; 
figure 3.3) between moderate (80 % GET), heavy (30 % ) and very heavy (60 % ) 
intensity exercise. No significant differences were revealed between data for  (P = 
0.16), HR (P = 0.50) and /HR (P = 0.42) determined from max tests and 
measured directly during subsequent exercise trials at moderate (80 % GET), heavy (30 
% ) and very heavy (60 % ) intensities. 
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Figure 3.1. Correlation between  for moderate (80 % GET), heavy (30 % ) and very heavy (60 % ) intensity exercise during a max test and  measured during constant 
work-load exercise trials at those intensities (r = 0.944, n = 25, P < 0.001). 
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Figure 3.2. Correlation between HR for moderate (80 % GET), heavy (30 % ) and very heavy (60 % ) intensity exercise during a max test and HR measured during constant 
work-load exercise trials at those intensities (r = 0.903, n = 24, P < 0.001). 
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Figure 3.3. Correlation between /HR for moderate (80 % GET), heavy (30 % ) and very heavy (60 % ) intensity exercise during a max test and /HR measured during 
constant worload exercise trials at those intensities (r = 0.824, n = 24, P < 0.001). 
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3.5. Discussion 
 
3.5.1. Study design and participant descriptive data 
 
Two independent studies were designed and linked by the inclusion of heavy domain 
constant work-load cycle ergometry trials. Within each study, exercise duration was 
carefully considered to ensure equal total work done between trials and relative 
commonality between the duration of exercise performed within the heavy domain. 
Linking two studies in this way enabled them to run in tandem. Successfully recruited 
participants were allocated to the two studies, thus reducing the required commitment and 
potentially influencing adherence to and completion of the study protocols in what would 
otherwise have been a highly demanding protocol for a single study group, while also 
increasing the number of participants completing heavy domain exercise and avoiding 
ethical and methodological issues associated with multiple biopsies over a short period 
of time. Independent-samples t-Tests suggested there were no significant differences 
between the two participant groups in terms of age (P = 0.57), body mass (P = 0.83), 
stature (P = 0.15), BMI (P = 0.78), max (P = 0.38), POmax (P = 0.80) and HRmax 
(P = 0.90) (table 3.1). The participants from the heavy domain trial could therefore be 
considered as a single representative group, indicating that data from these two trials can 
be pooled. 
 
3.5.2. Methodological considerations 
 
Good practice was followed in that the cycle ergometry performed using a Jaeger 
Ergoline ER800 electronically-braked cycle ergometer was employed throughout data 
collection, and participants presented themselves at the laboratory rested, fasted and 
euhydrated at the same time of day for each session. Detection of the GET, and therefore 
precise assignment of moderate domain (80 % GET) exercise, was made possible by the 
use of continuous, breath-by-breath, analyses of expired gas during a fine incremental 
ramp from the low intensity baseline to the point of volitional exhaustion. This allows the 
 and the rate of carbon dioxide production ( ) profiles to be recorded in 
sufficient resolution to accurately establish the GET via the V-slope method. This is in 
direct contrast to traditional discontinuous protocols utilising Douglas bag expired gas 
collection methods (Hill and Lupton, 1923; Hill et al., 1924; Astrand, 1967) that at best 
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provide single mean  and  datum values from prolonged collection periods 
lasting 30 s or more. 
 
The protocol for establishing Maximal lactate steady state (MLSS) typically involves 5 - 
6 exercise trials of 20 - 30 min duration conducted at increasing work-loads and with 
sufficient rest (24 hrs.) to ensure complete recovery. Finger-prick blood samples are also 
usually collected at 5 minute intervals and analysed for Blood lactate (BLa) to establish 
the highest constant work-load at which BLa is elevated above that at rest, but maintained 
at a constant level (Beneke and von Duvillard, 1996; Jones and Doust, 1998). Undertaking 
this additional work would have greatly prolonged the testing and the participants’ 
involvement, potentially negatively impacting participant recruitment and adherence to 
and completion of the study protocols. Pringle and Jones (2002) identified MLSS 
occurred at ~ 54 %  during cycle ergometry performed by healthy individuals (n = 8; 
age, 25  3 yrs.; body mass, 72.1  8.2 kg; stature, 1.76  8.2 m; max, 3730  844 
ml/min). With reference to this finding, heavy domain exercise trials were conducted at 
30 %  with very heavy domain exercise conducted at 60 % , and no further sessions 
were deemed necessary to establish MLSS in each participant. 
 
3.5.3. Criteria for successful determination of max 
 
Organisations such as The British Association of Sport and Exercise Sciences (BASES) 
and American College of Sports Medicine (ACSM) have produced clear guidelines on 
maximal exercise testing, which include suggested assessment criteria for determining 
whether or not a participant attained true maximum. The literature is divided between 
those that do adopt such criteria and those that do not. It appears many studies choose 
simply to accept the highest  value attained before volitional exhaustion as max. 
The most widely accepted criterion is a plateau in the  response with increasing work-
load, a ceiling effect. The numerous secondary criteria that have been used in the literature 
appear to have been developed in response to an apparent lack of a plateau in  
response, a phenomenon brought about in part by the use of discontinuous protocols in 
which Douglas bags are used to collect expired gas samples, thus providing a low 
resolution description of the  response. Such criteria have received heavy criticism 
(Howley et al., 1995; Poole et al., 2008; Midgley et al., 2007). The wide natural variability 
in the measurements themselves is cited as an argument questioning the validity of such 
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criteria. The result being that by imposing such criteria we may potentially exclude 
participants that have attained max and include those that have not. The use of a 
verification stage has been suggested as a suitable criterion (Poole et al., 2008; Midgley 
et al., 2007; Midgley et al., 2009). In performing a verification stage a participant is 
required to exercise at a work-load in excess of that at which volitional exhaustion 
occurred. The procedure is typically performed following a short rest, after the max 
test. If max was achieved during the max test, the  value measured after the 
verification stage will be no higher. If a higher  value is measured during the 
verification stage that value can be accepted as max or further verification stages can 
be performed at increased work-loads until max is verified. Verification stages were 
not employed in the present investigation.  
 
The criteria formulated and adopted in the present investigation are as follows: 1) primary 
criterion - a plateau in  data with increasing work-load, 2) secondary criteria - 
attainment of age predicted HRmax within 10 b/min, predicted using the equation 205.8 
– 0.685 x age (Inbar et al., 1994), 3) attainment of a Respiratory exchange ratio (RER) of 
1 or greater, and 4) a Rating of perceived exertion (RPE) of 18 or greater. A re-test was 
performed if the primary criterion (a plateau in the  data with increasing work-load) 
was not observed, and two out of the three secondary criteria were not met. The  
plateau is the principle on which the verification stage procedure is founded, and as such 
is still the criterion by which attainment of max can be assessed. The use of modern 
breath-by-breath expired gas analysis systems allow high resolution  and  data 
to be recorded, facilitating the detection of a  plateau. Equations for the prediction of 
HRmax have been reviewed by Robergs and Landwehr (2002). Robergs and Landwehr 
(2002) suggested that the widely used equation 220 – age, attributed to Fox and 
colleagues (Fox et al., 1971), has no scientific merit for use in exercise physiology and 
related fields as it was not developed from original research, but resulted from observation 
based on data from 11 references consisting of published research or unpublished 
scientific compilations. Robergs and Landwehr (2002) also suggested that although at 
present there is no acceptable equation for the prediction of HRmax, the formula 
presented by Inbar et al., (1994) provides the most accurate general equation. We have 
chosen to substitute this equation rather than the traditional 220 – age in our assessment 
criteria with regard to attainment of HR within 10 b/min of age predicted HRmax. In 
reviewing max test criteria Poole et al., (2008) suggested that in some participants 
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V O
2
  
˙ V CO
2
  
˙ V O
2
  
˙ V O
2
  92 
RER may not increase above 1 (Sidney and Shephard, 1977), whereas in others it may 
exceed 1.4 (Buchfuhrer et al., 1983). Poole et al., (2008) also suggested that adopting an 
RER criterion > 1 clearly excludes participants that may have achieved max. 
Achieving an RER of 1 indicates that the exercise intensity was great enough to require 
some respiratory buffering of lactic acid-derived Hydrogen ions (H+), and thus suggests 
that the test was not ended due to lack of participant motivation. The reporting of RPE 
values (Borg, 1982; 1970) is highly subjective. However, attainment of level 18 on the 
RPE scale has been used as a criterion for achieving max (Tanaka et al., 1997). This 
criterion provides a method by which the participant can demonstrate that they felt as 
though they were nearing or applying maximum effort. Participants in the present 
investigation attained max determined by the criteria specified. The max test is 
a fundamental measure of exercise physiology. However, it is clear that a universally 
acceptable criteria indicating true attainment of max has not been reached. Further 
research is warranted to achieve such a criteria, which should be universally adopted in 
exercise studies. 
 
3.5.4. Participant moderate, heavy and very heavy domain exercise cardio-respiratory 
analyses 
 
Data from the two feasibility studies (data not reported) suggested the intensity and 
duration of all exercise trials would be well tolerated and would stimulate changes in the 
systemic concentration of a number of hormones and cytokines that could be quantified 
in our laboratory, via Enzyme-linked immunosorbent assay (ELISA), for further analyses. 
This was found to be the case. Exercise trials were well tolerated by the participants. The 
results show significant differences between moderate (80 % GET), heavy (30 % ) and 
very heavy (60 % ) exercise, but no significant effect of ‘study’ on the investigated 
parameters. These data confirm significant differences exist between exercise trials. 
Further, no significant differences were observed between overlapping exercise trials 
conducted in the heavy domain (heavy (equal work), Study 1 and heavy (30 min), study 
2), indicating the pooling of data from these two trials is appropriate. However, data 
suggests that no significant differences are present in HR for exercise trials conducted in 
the heavy (30 % ) and very heavy (60 % ) exercise domains (P = 0.07), and /HR 
for exercise trials conducted in the moderate (80 % GET) and heavy (30 % ) exercise 
domains (P = 0.07), and heavy (30 % ) and very heavy (60 % ) exercise domains (P = 
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0.19). The lack of statistically significant differences in the post-hoc analyses across trials 
for variables HR and /HR can be accounted for by the variability in HR resulting 
from the diversity of fitness levels of the participants, compounded by the effect of the 
-slow component (Jones et al., 1999) and the influence of cardio-vascular drift (Coyle 
and González-Alonso, 2001). Mean values representing the metabolic cost of constant 
work-load exercise trials were calculated from  and HR data during the periods (a) 
between 2 and 3 min following the onset of the exercise trial work-load, and (b) during 
the final 60 s. These sample periods were chosen as (a) represents the steady state 
component, the point at which the  response plateaus at the end of the primary 
component phase, and (b) takes into account any increase in the  attributed to the 
slow component present in exercise in the heavy and very heavy domains (Whipp and 
Wasserman, 1972; Whipp et al., 1982), thus providing an account of exercise trial oxygen 
cost regardless of exercise trial duration. 
 
3.5.5. Exercise trial comparison analyses 
 
A measure of the accuracy of assigning constant work-load exercise from a max test 
is provided by the Pearson’s product-moment correlation coefficients and paired samples 
t-Tests, computed to assess the relationship between data calculated from the cycle 
ergometer max test and that measured directly during the constant work-load 
exercise trials. Strong positive correlation coefficients were obtained for , HR and 
/HR (figures 3.1, 3.2 and 3.3) suggesting strong agreement between the two data sets. 
The results of the paired samples t-Tests suggest that there are no significant differences 
between the data sets. 
 
3.5.6. Summary and conclusion 
 
In line with the objective of this chapter, to compare data from a cycle ergometer 
max test, conducted using principles and techniques associated with oxygen uptake 
dynamics research, with that from three acute ‘domain-based’ constant work-load cycle 
ergometer exercise interventions of varying intensity, but equal total work done, we have 
presented evidence comparing an alternative method with which constant work-load 
cycle ergometry exercise can be accurately assigned from a max test. This represents 
a departure from the traditional and widely used approach in exercise physiology research 
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of assigning constant work-load exercise in groups of participants with reference to a 
percentage of the maximum rate of oxygen uptake (% max), a percentage of heart 
rate at max (% HRmax), or a target HR derivative of a % max value, as is the 
case with the Karvonen formula (Karvonen and Vuorimaa, 1988), in favour of an exercise 
‘domain-based’ classification. We hypothesised that mean , HR and /HR data 
obtained from equal work (varying duration) moderate (80 % GET) (M), heavy (30 % ) 
(H) and very heavy (60 % ) (VH) domain cycle ergometer exercise trials would parallel 
those obtained during a max test. The data support a conclusion that constant work-
load cycle egometer exercise trials, performed at a power output identified during a 
incremental exercise test carried out with regard to the principals and methods of oxygen 
uptake dynamics research, yield similar cardio-respiratory characteristics. We can 
therefore continue and test our hypothesis that the constant work-load cycle ergometer 
exercise trials developed would result in significant differences in the mRNA expression 
of selected hormones and cytokines despite the measures taken to ensure equal work 
done. 
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Chapter 4. Changes in mRNA expression in skeletal muscle and subcutaneous adipose 
tissue: response to exercise intensity 
 
4.1. Abstract 
 
In the previous chapter we concluded that the equal work (varying duration) moderate 
(M), heavy (H) and very heavy (VH) constant work-load cycle ergometer exercise trials 
performed yielded physiological data ( , HR and /HR) parallel to those obtained 
during a max test at the same power output. We were confident that the trials would 
produce hormone and cytokine responses characteristic of the exercise domain in which 
they reside in the recreationally active young participant group, and could therefore 
progress with the analyses of gene expression. We hypothesised that the constant work-
load cycle ergometer exercise trials developed in the previous chapter would result in 
significant differences in the mRNA expression of selected hormones and cytokines 
despite the measures taken to ensure equal work done. We analysed the expression of 
hormone and cytokine mRNA in skeletal muscle and subcutaneous adipose tissue bioptic 
material collected at baseline (B) and following the M, H and VH exercise trials. Absolute 
expression at B of PGC-1α (P = 0.02), leptin (P < 0.001) and adiponectin (P < 0.001) 
were found to be greater in subcutaneous adipose tissue than skeletal muscle. Conversely, 
expression of TNFα (P = 0.003), TRIM72 (P < 0.001), SOCS3 (P = 0.003) and 
housekeeping gene GAPDH (P < 0.001) were found to be significantly greater in skeletal 
muscle than subcutaneous adipose tissue. Post exercise, increased expression (GAPDH 
normalised) of IL-6: B vs. M (P = 0.006), H (P < 0.001) and VH (P < 0.001) and M vs. 
VH (P = 0.02); TNFα: B vs. VH (P = 0.04) and SOCS3: B vs. M (P = 0.02), and VH (P 
= 0.04) was observed. Exercise was without effect on gene expression in subcutaneous 
adipose tissue. We concluded that our data confirm the importance of skeletal muscle as 
a source of endurance exercise responsive hormones and cytokines, and highlight 
exercise intensity and duration as a mechanisms regulating the expression of IL-6, TNFα 
and SOCS3, proteins with metabolic, inflammatory and cytokine suppressive roles 
respectively, in the tissue. 
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4.2. Introduction 
 
Pedersen (2009) suggested the beneficial effects of endurance exercise are due to the anti-
inflammatory effects of regular exercise, through a reduction in adipose tissue mass and/or 
induction of an anti-inflammatory environment with each acute bout of endurance exercise. 
Myokines, cytokines and other peptides released by skeletal muscle fibres as a result of 
contractile activity (Pedersen et al., 2003), are thought to play a role in mediating the 
beneficial effects of exercise (Pedersen, 2009; Pedersen and Febbraio, 2012). Adipokines, 
secreted from adipose tissue regulate energy metabolism (Yu and Ginsberg, 2005; Ronti 
et al., 2006) and have been implicated in related pathological conditions such as chronic 
low-grade systemic inflammation (Tilg and Moschen, 2006; Arai et al., 2011). Cross-talk 
between these two tissues, ‘the adipose-muscular axis’, may function to satisfy metabolic 
demand during and post-exercise. The mechanisms however require clarification. The 
objective of this chapter is therefore to establish the changes in the Messenger ribonucleic 
acid (mRNA) expression of selected hormones and cytokines that occur locally in skeletal 
muscle and subcutaneous adipose tissue as a function of our acute ‘domain-based’ 
constant work-load cycle ergometer exercise interventions in recreationally active young 
males. We hypothesise that the constant work-load cycle ergometer exercise trials 
developed in the previous chapter will result in significant differences in the mRNA 
expression of selected hormones and cytokines despite the measures taken to ensure equal 
work done. 
 
4.3. Methods 
 
Methodological information directly pertinent to this chapter is summarised briefly 
below. Chapter 2. ‘General methods’, provides a detailed reference resource, 
documenting the procedures employed in collecting the data presented in this thesis. 
Relevant sections in Chapter 2 will be referenced in the text by index number, e.g. [2.2.1.] 
refers to the section 2.2.1. ‘Ethical approval’. 
 
4.3.1. Study design 
 
A schematic representation of the interlinking studies presented in this thesis is provided 
in figure 2.4 [2.5.1.8.1.]. The data presented in this chapter relate to Exercise studies 1 
and 2.  
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4.3.2. Participants [2.2.] 
 
Participant descriptive and exercise cardio-respiratory data are provided in Chapter 3, 
Tables 3.1. and 3.2. 
 
4.3.3. Determination of exercise trial intensity and duration [2.5.1.5. & 2.5.1.7.] 
 
4.3.4. Exercise trial protocols [2.5.1.8.] 
 
4.3.5. Skeletal muscle and subcutaneous adipose tissue sampling [2.7.] 
 
Skeletal muscle and subcutaneous adipose tissue samples were obtained post-exercise via 
conchotome technique (Dietrichson et al., 1980; 1987). The procedure was performed by 
a suitably qualified, General Medical Council registered, medical doctor experienced in 
the extraction of skeletal muscle and adipose tissue. Skeletal muscle samples were 
obtained from the Vastus Lateralis through a small incision following preparation of the 
skin surface and local anaesthesia of the skin and immediate underlying tissue. 
Immediately after harvesting the skeletal muscle tissue sample, a sample of subcutaneous 
adipose tissue was obtained from the adipose tissue bed surrounding the site of the 
incision. Wound closure was undertaken using sterile adhesive strips and overlayed with 
a sterile compressive dressing. Participants were advised when to remove the dressing 
and how to care for the wound, to refrain from exercise for at least 4 days and to inform 
the principal investigator and their general practitioner should the wound become 
infected. 
 
Skeletal muscle tissue and subcutaneous adipose tissue samples were transferred to a 
Class II Biological Safety Cabinet, washed in ice-cold phosphate buffered saline to 
remove blood and then divided for tissue culture studies and for detection of mRNA 
expression. Samples were transferred to 1.2 ml cryovials rapidly frozen and stored in 
liquid nitrogen to await further analyses. 
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4.3.6. Skeletal muscle and adipose tissue homogenisation [2.7.2.] and ribonucleic acid 
isolation [2.7.3.] 
 
Cryovials containing the skeletal muscle and adipose tissue samples were removed from 
liquid nitrogen and homogenised in the presence of Trizol (TRI®) Reagent Solution 
before being returned to storage at -80 °C for one freeze thaw cycle before Ribonucleic 
acid (RNA) isolation. Samples were supplemented with 0.2 ml Chloroform and mixed 
vigorously for 20 s prior to centrifugation at 12000 g for 16 min at 4 ˚C. The aqueous 
phase was transferred into a 1.5 ml RNase-free microcentrifuge tube. Care was taken not 
to disturb the interface Deoxyribonucleic acid (DNA) layer. Ribonucleic acid was 
precipitated from the aqueous phase using Isopropanol. Samples were mixed by inversion 
twice prior to being centrifuged at 12000 g for 10 min at 4 °C. The supernatant was 
carefully removed and the RNA pellet was washed with 75 % ethanol prior to 
centrifugation at 8500 g for 6 min at 4 ˚C. Ethanol was removed and RNA pellets were 
left to air dry before being re-suspended in 100 µl RNA storage solution. Ribonucleic 
acid was returned to -80 °C for storage until further analyses. 
 
4.3.7. Oligonucleotide primer design and synthesis [2.7.4.] 
 
The Genome Bioinformatics Group of UC Santa Cruz website genome browser (no date) 
was used to identify the DNA sequences for the selected genes of investigation. 
Oligonucleotide primers were designed using Beacon Designer version 5.11. 
Oligonucleotide primers were designed to yield products spanning exon-intron 
boundaries to avoid genomic DNA contamination. The inclusion of three or more GC 
base pairs in the last 5 base pairs at the 3’ end of the primer was avoided in order to 
minimise nonspecific amplification. All primers had a nucleotide base length of between 
18 and 22 base-pair sequences. Beacon Designer version 5.11 was also used to perform 
searches for secondary structure or inter/intra-molecular interactions such as hairpins, 
self-dimers and cross-dimers within the primer. Sequence homology searches were 
performed against the National Center for Biotechnology Information (NCBI) Genbank® 
database to ensure specific amplification of the associated target gene. Custom 
oligonucleotide primers were purchased from Sigma-Genosys or from QIAGEN. 
 
4.3.8. Reverse transcription-polymerase chain reaction method and data analysis [2.7.5.] 
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Ribonucleic acid concentration and purity were assessed via ultraviolet spectroscopy 
from the optical density at 260 and 280 nm using a spectrophotometer (WPA Biowave II, 
Biochrom Ltd., Cambridge, UK). Seventy ng RNA were used per Reverse transcription-
polymerase chain reaction (RT-PCR) (7 µl of RNA at a concentration of 10 ng/µl). 
Amplification of target genes via RT-PCR was performed using a commercially available 
Power SYBR Green RNA-to-CT 1 step kit and 96-well RT-PCR plates. The custom RT-
PCR protocol was controlled using a Chromo4TM DNA engine interfaced with a laptop 
computer running Opticon Monitor version 3.1.32. Opticon Monitor version 3.1.32 
constructs a graphical representation of fluorescence yield against RT-PCR cycle. The 
cycle number at which fluorescence yield crossed a threshold line (C(t)) was obtained by 
manually positioning a threshold line at a point along the exponential rise in the 
fluorescence/cycle curve. The data were exported to an Excel® version 12.2.0 
spreadsheet (Microsoft® Excel® 2008 for Mac, Microsoft Corporation, Redmond, WA, 
USA) for analyses. The Delta delta (ΔΔ) C(t) equation (Livak Method) was used to 
determine normalised gene expression. 
 
Sterile technique was implemented throughout. RNase contamination from work surfaces 
and equipment reserved for molecular techniques was minimised prior to use by exposure 
to RNase Zap. Fluid transfer activities were performed using pipettes reserved 
exclusively for molecular biology techniques. These were used with sterile Aerosol 
Resistant (ART®) pipette tips. 
 
4.3.9. Statistical analyses [2.8.] 
 
Absolute Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in skeletal 
muscle and adipose tissue comparison. Paired samples t-Tests were performed to assess 
whether there was a significant difference between absolute expression of the house-
keeping gene GAPDH in skeletal muscle compared with adipose tissue. 
 
Heavy exercise-induced local mRNA expression trial comparisons. Independent samples 
t-Tests were performed to assess whether there were significant differences in local 
mRNA expression induced by heavy exercise performed in study 1 and study 2. Where 
data were non-normally distributed, and could not be successfully log or inversely 
transformed, non-parametric Mann-Whitney U statistical analyses were performed. A 
repeated-measures Analysis of variance (ANOVA) was subsequently performed, 
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incorporating baseline and post-heavy exercise Suppressor of cytokine signaling 3 
(SOCS3) data with as within factor ‘time’ and between factor ‘study’ to check for a ‘time 
x study interaction’. 
 
Baseline absolute mRNA expression in skeletal muscle and adipose tissue. Paired samples 
t-Tests were performed to assess whether there were significant differences between 
baseline absolute mRNA expression in skeletal muscle compared with adipose tissue. 
 
Moderate, heavy and very heavy exercise-induced local mRNA abundance. Repeated-
measures ANOVA with as within factor ‘time’ and between factor ‘work-load’ were run 
to determine whether there were significant differences between local mRNA expression 
induced by moderate, heavy and very heavy exercise. If significant effects were observed, 
post-hoc Bonferroni-corrected one-way ANOVA were run to identify the difference. 
Where data were non-normally distributed, and could not be successfully log or inversely 
transformed, non-parametric Kruskal Wallis statistical analyses were run to determine 
whether there were significant differences. If significant effects were observed, post-hoc 
Mann-Whitney U tests for individual data set pairs were performed to locate the 
difference. Bonferroni-corrections were applied to identify true significance. 
 
4.4. Results 
 
4.4.1. Variation in the reference gene GAPDH and the effect of ‘study’ 
 
The expression of GAPDH in skeletal muscle tissue was higher than that in adipose tissue 
(P < 0.001; figure 4.1). Furthermore, absolute expression of GAPDH was unchanged as 
a consequence of the exercise interventions in both skeletal muscle and adipose tissue 
(data not shown). 
 
Gene expression induced by heavy (30 % Δ) exercise performed in study 1 and study 2 
was analysed for an effect of ‘study’. There were no significant differences for most of 
the investigated proteins. SOCS3 was the exception and mRNA levels were lower in 
study 1 than study 2 (mean ± SD, Study 1 1.03 ± 0.06, Study 2 1.10 ± 0.04; P = 0.02). 
However, heavy exercise induced a similar increase in SOCS3 gene expression in study 
1 and 2, as reflected by an absence of a ‘time x study interaction’ (P = 0.24). The mRNA 
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data from heavy exercise trials performed in study 1 and study 2 were therefore grouped 
and analysed as one trial. 
 
4.4.2. Baseline and exercise-induced changes in local mRNA expression in skeletal 
muscle and adipose tissue 
 
Baseline absolute gene expression of Peroxisome proliferator-activated receptor γ 
coactivator-1α (PGC-1α) (P = 0.02), leptin (P < 0.001) and adiponectin (P < 0.001) were 
found to be greater in adipose tissue than in skeletal muscle. Conversely, expression of 
Tumour necrosis factor-alpha (TNFα) (P = 0.003), Tripartite motif-72 (TRIM72) (P < 
0.001), and SOCS3 (P = 0.003) were found to be significantly greater in skeletal muscle 
than adipose tissue (figure 4.1). 
 
Significant exercise-induced increases were evident in skeletal muscle following GAPDH 
normalisation for Interleukin-6 (IL-6) (P < 0.001), TNFα (P = 0.02), and SOCS3 (P = 
0.006; figure 4.2). Post-hoc Bonferroni corrected comparisons identified significant 
increases in IL-6 expression between baseline and moderate (P = 0.006), heavy (P < 
0.001) and very heavy (P < 0.001) exercise, also moderate and very heavy (P = 0.02) 
exercise. A significant increase in TNFα expression was revealed between baseline and 
very heavy exercise (P = 0.04). A significant increase in SOCS3 expression was revealed 
between baseline and moderate (P = 0.02), and very heavy (P = 0.04) exercise. No 
significant exercise-induced changes in gene expression were evident in adipose tissue 
(figure 4.3). 
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Figure 4.1. Baseline absolute gene expression in skeletal muscle tissue and subcutaneous adipose tissue. * Significantly different (P < 0.05). Data are (mean  SEM). 
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Figure 4.2. Normalised gene expression in skeletal muscle tissue at baseline and in response to moderate (60 min), heavy (27:48  2:31 min) and very heavy (22:29  1:31 min) domain 
cycle ergometer exercise. * - Significant effect of ‘trial’: IL-6 (P < 0.001); Post-hoc analyses, baseline vs. moderate (P = 0.006; a), heavy (P < 0.001; b) and very heavy (P < 0.001; c). 
Moderate vs. very heavy (P = 0.02; d). TNF (P = 0.02); baseline vs. very heavy (P = 0.04; c). SOCS3 (P = 0.006); Post-hoc analyses, baseline vs. moderate (P = 0.02; a) and very 
heavy (P = 0.04; d). Data are (mean  SEM).  
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Figure 4.3. Normlised gene expression in subcutaneous adipose tissue at baseline and in response to moderate (60 min), heavy (27:48  2:31 min) and very heavy (22:29  1:31 min) 
domain cycle ergometer exercise. No significant effect of ‘trial’. Data are (mean  SEM). 
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4.5. Discussion 
 
4.5.1. Baseline absolute expression 
 
The absolute C(t) values of 30 or greater for PGC-1α, IL-6, Interleukin-15 (IL-15), TNFα, 
TRIM72 and Adiponectin receptor 1 (AdipoR1) suggest that their mRNA was expressed 
at low levels in both tissues. Of these, PGC-1α was more abundant in adipose tissue while 
TNFα and TRIM72 were more abundant in skeletal muscle. The absolute C(t) values of 
30 or less for Leptin, adiponectin, SOCS3, Insulin-like growth factor-I receptor (IGF-IR), 
GAPDH, and Insulin-like growth factor-I (IGF-I) suggest that their mRNA was expressed 
at higher levels. Of these, leptin and adiponectin were more abundant in adipose tissue, 
while SOCS3 and GAPDH were more abundant in skeletal muscle. Insulin-like growth 
factor-I and IGF-IR were expressed at a similar level in both tissues. The expression of 
SOCS3 at this level suggests the importance of regulatory signalling in skeletal muscle 
in response to exercise (Babon and Nicola, 2012; Yoshimura et al., 2012; Carow and 
Rottenberg, 2014). The relatively high expression of the reference gene GAPDH in 
skeletal muscle compared to adipose tissue supports the findings of Barber et al., (2005), 
in which expression in skeletal muscle and adipose tissue were ranked 1st and 58th 
respectively, in order of GAPDH mRNA abundance, from 72 human tissues analysed. 
The relatively high and uniform tissue expression of IGF-I and IGF-IR highlights the 
importance of the roles that these proteins play, e.g. survival, cell growth and 
differentiation in both tissue types (Stewart and Rotwein, 1996; Kurmasheva and 
Houghton, 2006; Puche and Castilla-Cortázar, 2012). 
 
4.5.2. Local gene expression adaptations 
 
No significant exercise-induced changes in gene expression were found in adipose tissue. 
In skeletal muscle, exercise induced a significant increase in the expression of IL-6 
following all trials. Only after very heavy exercise was TNFα elevated. The expression 
of SOCS3 in skeletal muscle increased in response to moderate and very heavy exercise. 
We suggest that the changes in IL-6 reflect the metabolic environment within working 
skeletal muscle, and in association with TNFα, potentially activation of repair 
mechanisms. Up-regulation of SOCS3 serves to inhibit and therefore guard against 
inflammatory/catabolic influence of excessive IL-6 and TNFα. 
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4.5.2.1. Exercise-induced adaptations normalised to GAPDH 
 
In addition to myocytes, skeletal muscle contains smooth muscle cells, fibroblasts, 
endothelial cells, and macrophages. These cells have all been shown to produce IL-6 
(Podor et al., 1989; Cicco et al., 1990; Klouche et al., 1999; De Rossi et al., 2000). It is 
possible that the changes in gene expression observed in the present study may have been 
due to increased mRNA expression in cells other than myocytes in the skeletal muscle 
biopsy samples obtained. In the present study we measured changes in mRNA expression 
and not the rate of gene transcription. It is possible that data reflect an increase in 
transcription and/or increases in mRNA stability, or a combination of both. However, 
Keller et al., (2001) demonstrated that the rate of IL-6 gene transcription closely matches 
IL-6 mRNA abundance during exercise. We are therefore confident that our results reflect 
the rate of IL-6 gene transcription. In line with previous studies, we found that acute 
endurance exercise promoted an increase in IL-6 mRNA expression within human 
skeletal muscle (Ostrowski et al., 1998a; Keller et al., 2001; Starkie et al., 2001) and that 
acute very heavy domain exercise resulted in significantly greater IL-6 mRNA 
expression, compared to acute moderate domain exercise. It is recognised that the 
magnitude of the IL-6 response is related to the intensity and duration of exercise 
(Fischer, 2006). Evidence suggests that Calcium (Ca2+) release during Excitation-
contraction coupling (ECC) (Calderón et al., 2014) is related to skeletal muscle IL-6 
transcriptional activity. Stimulation of human primary skeletal myotubes with the Ca2+ 
ionophore ionomycin increased IL-6 mRNA time- and dose-dependently, an effect that 
was blunted by ~ 75 % in the presence of Cyclosporin A (CSA), an inhibitor of the 
eukaryotic Ca2+ and calmodulin-dependent serine/threonine protein phosphatase 
calcineurin (Keller et al., 2002; Keller et al., 2006). Similar findings have been observed 
in animal models (Holmes et al., 2004; Allen et al., 2010). Whitham et al., (2012) 
established further support for Ca2+-dependent regulation of IL-6, and identified c-Jun 
NH2-terminal kinase (JNK)/Activator protein-1 (AP-1) as a novel transcription pathway 
in skeletal muscle. To mimic exercise conditions Whitham et al., (2012) mechanically 
stimulated murine C2C12 myotubes via Electrical pulse stimulation (EPS) and compared 
the responses with those from stimulation with the pharmacological Ca2+ carrier 
calcimycin (A23187) and the classical IL-6 IKappa-B kinase kinase complex 
(IKK)/Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
inflammatory response (De Waal Malefyt et al., 1991; Kreutz et al., 1997) elicited by 
Hydrogen peroxide (H2O2). Neither calcimycin- nor EPS-induced IL-6 mRNA 
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expression was found to be under the transcriptional control of NFκB. Electrical pulse 
stimulation increased the phosphorylation of JNK and the reporter activity of the 
downstream transcription factor AP-1. In addition, JNK inhibition abolished the EPS-
induced increase in IL-6 mRNA and protein expression. Importantly, an exercise-induced 
increase in both JNK phosphorylation and IL-6 mRNA expression in the dissected whole 
mixed hind limb muscles of mice was observed following 30 min of treadmill running, 
whereas no increase was observed in skeletal muscle specific JNK-deficient mice 
(Whitham et al., 2012). Therefore, although we do not have a precise mechanism for the 
regulators of increased IL-6 mRNA in skeletal muscle in response to exercise, there 
maybe a role for calcium, which warrants further investigation. 
 
During endurance exercise the contribution to energy provision from the various 
metabolic pathways is determined by the relative intensity of the exercise bout. At low 
exercise intensities, glucose derived from hepatic glycogenolysis or oral ingestion, and 
free fatty acids from adipose tissue lipolysis are the primary fuel sources supplying 
skeletal muscle. With increasing exercise intensity, muscle utilisation of systemic free 
fatty acids declines, whereas utilisation of circulating glucose and intramuscular glycogen 
progressively increases. Glucose derived from skeletal muscle glycogenolysis is the 
predominant carbohydrate fuel source during intense exercise (Coyle, 1995; Houten and 
Wanders, 2010; Egan and Zierath, 2013). Calculation of carbohydrate oxidation as a 
percentage of total substrate oxidation (Péronnet and Massicotte, 1991) during moderate 
(mean  SEM: 30  9 %), heavy (69  10 %) and very heavy (92  3 %) exercise trials 
support these statements. The design of the present study was such that the exercise 
intensity and duration were manipulated to ensure equal work done in all trials. 
Expression of IL-6 mRNA in skeletal muscle was greater following an acute bout of very 
heavy exercise compared to an acute bout of moderate exercise. The lack of a significant 
difference between heavy and very heavy exercise maybe due to the trade off between 
intensity and duration in accomplishing equal total work done, or an increasing 
dependence on intramuscular glycogen stores that do not require Glucose transporter type 
4 (GLUT4) translocation. This is in agreement with the suggestion that the primary role 
of IL-6 during exercise is to support glucose uptake with increasing rates of carbohydrate 
oxidation (Pal et al., 2014). 
 
It has also been suggested that IL-6 functions as a key stimulator of lipid mobilisation 
and metabolism, to spare muscle glycogen (Lyngso et al., 2002; van Hall et al., 2003; 
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Petersen et al., 2005). Recent evidence suggests IL-6 may even have a role in modulating 
the choice of substrate in skeletal muscle during exercise by altering Pyruvate 
dehydrogenase (PDH) complex via Adenosine monophosphate-activated protein kinase 
(AMPK) (Biensø et al., 2014). It is therefore somewhat surprising that we found no 
increase in IL-6 mRNA in adipose tissue. The reason for this maybe the relatively short 
exercise duration in the present study, and the lack of repeated tissue sampling post-
exercise. Keller et al., (2003a) identified different IL-6 mRNA induction kinetics in 
skeletal muscle and adipose tissue; a significant increase in skeletal muscle IL-6 mRNA 
was observed immediately post- and 1.5 hrs. post-cycle ergometer exercise of 3 hrs. 
duration at 60 % of the maximum rate of oxygen uptake ( max), whereas adipose 
tissue IL-6 mRNA was significantly increased at 1.5 hrs. post-exercise only. Further, 
subcutaneous adipose tissue lipolysis in the lower limbs has been shown to contribute less 
to whole body lipolytic rate than that of abdominal subcutaneous adipose tissue (Arner et 
al., 1990; Horowitz and Klein, 2000; Horowitz, 2003). 
 
Data from the present study show increased SOCS3 mRNA expression in human skeletal 
muscle in response to acute endurance exercise. Increased SOCS3 mRNA has previously 
been observed in the skeletal muscle of Sprague-Dawley rats following treadmill 
endurance training (Steinberg et al., 2004; Spangenburg et al., 2006) and in human 
skeletal muscle following resistance exercise (Trenerry et al., 2007; 2008; 2011; Toth et 
al., 2011). The expression of SOCS3 mRNA in skeletal muscle was increased after 
moderate and very heavy exercise. The SOCS3 is a potent inhibitor of IL-6 signalling by 
exerting negative feedback control on the Janus kinase (JAK)/Signal transducer and 
activator of transcription (STAT) pathway. Classical IL-6 signalling, via the 
phosphorylated tyrosine residue Tyr759 of its signal transducer GP130, results in 
activation of the JAK/STAT signalling pathway and the rapid induction of SOCS3 (Naka 
et al., 1997; Starr et al., 1997; Nicola and Greenhalgh, 2000; Fischer et al., 2004). 
Additionally, IL-6 is targeted for proteasomal degradation through the E3 ubiquitin-ligase 
complex bound to the ‘SOCS box’ motif (Starr et al., 1997; Hilton et al., 1998). 
Paradoxically, the greatest increase in SOCS3 mRNA expression in skeletal muscle was 
induced by moderate exercise, whereas the greatest increase in IL-6 mRNA expression 
was induced by heavy and very heavy exercise. However, evidence indicates that elevated 
systemic concentrations of IL-6 result in increased expression of SOCS3 protein in 
skeletal muscle (Rieusset et al., 2004; Carey et al., 2006; Holmes et al., 2008). We have 
shown that, under conditions of equal total work done, the greatest increase in systemic 
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IL-6 concentration occurred in response to moderate exercise (data presented in Chapter 
5). Interleukin-6 release from skeletal muscle has been shown to account for the exercise-
induced increase in systemic concentrations (Steensberg et al., 2000). Therefore, we 
suggest that the increase in skeletal muscle SOCS3 mRNA expression in response to 
moderate exercise in the present study maybe due, at least in part, to systemic 
accumulation of IL-6 over the relatively greater duration of the moderate exercise bout. 
 
Given the suggested importance of IL-6 activation of AMPK in metabolism and insulin 
sensitivity, inhibition of IL-6 signalling by SOCS3 appears a negative consequence of 
exercise. Sarvas et al., (2013) argues that context determines the negative consequences 
of SOCS3 inhibition. The transient nature of SOCS3 induction in response to exercise 
has a limited effect on the beneficial metabolic and insulin sensitising effects promoted 
by exercise-induced IL-6. Chronically elevated IL-6, such as in obesity and Type 2 
diabetes mellitus (T2DM), leads to increased and sustained expression of SOCS3 proteins 
in skeletal muscle, adipose tissue and in the liver, and inhibitory effects on insulin 
signalling and glucose metabolism (Rui et al., 2002; Ueki et al., 2004; 2005; Shi et al., 
2006), as well as leptin adipostat function (Bjørbaek et al., 1999; Lubis et al., 2008; 
Fuentes et al., 2010). Further, Sarvas et al., propose the concept of ‘IL-6 resistance’. 
Similar to leptin resistance, in which SOCS3 is induced by and binds to the leptin receptor 
thereby limiting leptin action, chronically elevated IL-6 results in sustained SOCS3 
activity, diminished AMPK activity and increased insulin resistance (Sarvas et al., 2013). 
 
Data from the present study show an increase in TNFα mRNA expression in human 
skeletal muscle relative to baseline, only in response to very heavy exercise. In 
comparison to the prototypical myokine IL-6, relatively little is known about exercise-
induced TNFα mRNA expression in skeletal muscle. However, TNFα is generally 
considered an inflammatory cytokine generated by the immune system in response to 
infection or inflammation. Traditionally, TNFα has been associated with muscle 
pathology, originally designated ‘cachectin’ in recognition of its catabolic action. In 
humans skeletal muscle catabolism has been attributed to TNFα in various diseases that 
showed muscle loss in combination with chronically elevated levels of TNFα, most 
notably cancer (Argilés and Lopez-Soriano, 1999; Tisdale, 1999). However, evidence 
from a study by Petersen et al., (2009) suggested TNFα per se does not increase skeletal 
muscle protein loss in vivo in humans, but that skeletal muscle loss might be attributed to 
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high TNFα concentrations mediating catabolism via an enhanced effect on the levels of 
other cytokines and catabolic hormones. 
 
Skeletal muscle TNFα mRNA is increased in the elderly (Greiwe et al., 2001), in obesity 
(Ferrier et al., 2004) and in patients with T2DM (Saghizadeh et al., 1996). In contrast to 
IL-6, the exercise-induced increase in skeletal muscle TNFα mRNA is very small and 
results in little if any measurable increase in systemic concentration indicating a local role 
in skeletal muscle (Steensberg et al., 2002; Febbraio et al., 2003). A complete explanation 
of the mechanisms involved remains elusive, but a direct effect of TNFα on insulin 
sensitivity in skeletal muscle has been demonstrated in vitro (Hotamisligil et al., 1996), 
in vivo in animals (Miles et al., 1997) and in vivo in humans (Plomgaard et al., 2005). 
Tumour necrosis factor-alpha inhibits insulin signalling through key regulatory proteins 
Insulin receptor substrate-1 (IRS1) and Protein kinase B (PKB) substrate 160 in human 
skeletal muscle in vitro (Bouzakri and Zierath, 2007) and in vivo (Plomgaard et al., 2005). 
These data show that elevated TNFα plays a direct pathogenic role in glucose metabolism 
and the pathological conditions associated with insulin resistance. In addition, TNFα has 
been shown to increase lipolysis without enhancing skeletal muscle fat metabolism in 
vivo in humans, highlighting a role in dyslipidemia and the development of lipid-induced 
insulin resistance (Plomgaard et al., 2008). The mechanism is suggested to be direct 
inhibition of AMPK signalling through Protein phosphatase 2C (PP2C) activation 
(Steinberg et al., 2006; 2009). 
 
Systemically, exercise is suggested to promote an anti-inflammatory environment in 
which TNFα concentrations generally do not increase (Pedersen and Hoffman-Goetz, 
2000; Brandt and Pedersen, 2010) due, in part, to the inhibitory effects of IL-6 on TNFα 
and Interleukin-1 (IL-1) through IL-6 induction of Soluble tumour necrosis factor 
receptors (sTNFrs), Interleukin-1 receptor antagonist (IL-1ra) and Interleukin-10 (IL-10) 
(Ostrowski et al., 1999; Starkie et al., 2003; Steensberg et al., 2003). However, skeletal 
muscle TNFα mRNA increases in response to 3 hrs. of treadmill running and cycle-
ergometer exercise at ~ 70 and 75 % max, respectively (Nieman et al., 2003, 2005) 
and 30 min of treadmill running at 75 % max (Louis et al., 2007). Our data supports 
the findings of these studies and further suggests that high intensity endurance exercise 
promotes an increase in skeletal muscle TNFα mRNA expression, regardless of duration. 
In the latter study IL-6 and TNFα mRNA expression relative to GAPDH followed a 
similar profile in the 24 hrs. post-exercise. Specifically, a significant increase 
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immediately post-exercise followed by a decline and peak 8 hrs. post-exercise. At 24 hrs. 
post-exercise IL-6 and TNFα mRNA concentrations remained elevated at a concentration 
similar to that observed immediately post-exercise (Louis et al., 2007). Despite similar 
post-exercise induction profiles, Keller et al., (2006) demonstrated differential IL-6 and 
TNFα mRNA expression in a primary human skeletal muscle cell model in response to 
the calcium ionophore ionomycin, mimicking contraction-mediated Ca2+ release from the 
sarcoplasmic reticulum. Interleukin-6 mRNA increased in a time- and dose-dependent 
fashion with ionomycin stimulation. The effect was blunted by ~ 75 % by calcineurin 
phosphatase inhibitor CSA. In contrast, TNFα mRNA expression decreased by ~ 70 % in 
response to ionomycin, but increased in response to the addition of CSA. As previously 
stated, the calcineurin pathway appears to play a major role in the Ca2+-induced IL-6 
response. However, IL-6 and TNFα appear to be regulated differently in skeletal muscle 
cells in response to a Ca2+ stimulus. Further, as low glycogen levels have been associated 
with decreased re-uptake of Ca2+ into the sarcoplasmic reticulum (Booth et al., 1997), 
these data may provide an explanation for increased exercise-induced IL-6 mRNA 
expression when skeletal muscle glycogen concentrations are low (Keller et al., 2001; 
Steensberg et al., 2001; Hiscock et al., 2004). These data fail, however, to provide an 
explanation for the significant increase in skeletal muscle TNFα mRNA expression 
following acute very heavy exercise in the present study, in what the data from Keller et 
al., (2006) suggested should be an environment inhibiting TNFα mRNA expression. 
 
4.5.3. Summary and conclusion 
 
In line with the objective of this chapter, to establish the changes in the mRNA expression 
of selected hormones and cytokines that occur locally in skeletal muscle and 
subcutaneous adipose tissue as a function of our acute ‘domain-based’ constant work-
load cycle ergometer exercise interventions in recreationally active young males, we 
analysed the expression of hormone and cytokine mRNA in skeletal muscle and 
subcutaneous adipose tissue bioptic material collected at baseline and following the 
moderate, heavy and very heavy domain exercise trials. We hypothesised that the constant 
work-load cycle ergometer exercise trials would result in significant differences in 
mRNA expression despite the measures taken to ensure equal work done in each. We 
found significant increases in the mRNA expression (normalised to GAPDH) in skeletal 
muscle of IL-6 following all trials immediately post-exercise, whereas increases in 
SOCS3 mRNA were observed following moderate and very heavy domain exercise only. 
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TNFα mRNA increased immediately post-very heavy domain exercise only. No effects 
on gene expression in subcutaneous adipose tissue were observed immediately post-
exercise. We conclude that our data confirm the importance of skeletal muscle as a source 
of exercise responsive hormones and cytokines, and highlight exercise intensity and 
duration as a mechanisms regulating the expression of IL-6, TNFα and SOCS3, proteins 
with acknowledged metabolic, inflammatory and cytokine suppressive roles respectively, 
in the tissue. Using this approach we can proceed with testing our hypothesis that acute 
‘domain-based’ constant work-load cycle ergometer exercise interventions will result in 
significant changes in the systemic abundance of the selected hormones and cytokines 
under investigation. 
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Chapter 5. Changes in systemic hormone and cytokine abundance: response to exercise 
intensity 
 
5.1. Abstract 
 
In the previous chapter we concluded that exercise intensity and exercise duration, rather 
than equal work done, were potent drivers behind IL-6 in particular, but also TNFα and 
SOCS3 mRNA expression in skeletal muscle, confirming the importance of this tissue as 
a source of exercise responsive hormones and cytokines. Again, confident that the trials 
would produce hormone and cytokine responses characteristic of the exercise domain in 
which they reside, we wished to supplement these local data by investigating systemic 
responses to equal work (varying duration) moderate (M) heavy (H) and very heavy (VH) 
exercise in the recreationally active, young participant group. We hypothesised that the 
constant work-load cycle ergometer exercise trials developed in chapter 3 would result in 
significant systemic changes despite the relative differences in trial duration, manipulated 
to ensure equal work done. A workload comparison (baseline (B) vs. End of Exercise) 
indicated only IL-6 increased in response to M (1.08 – 5.05 pg/ml, P = 0.001). In response 
to M, H and VH, IL-6 increased and remained elevated for 24 hrs. (P = 0.03). IGF-I and 
cortisol concentrations declined by 60 min post-exercise (P = 0.001 and P = 0.04, 
respectively). GH increased to peak at the end of exercise (P < 0.001) before declining 
sharply. We concluded that endurance exercise promotes significant changes in the 
systemic abundance of hormones and cytokines. The changes strongly suggest activation 
of mechanisms of metabolic rather than anabolic control in our young participant group, 
specifically, the mobilisation of energy from fat stores.  
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5.2. Introduction 
 
Pedersen (2009) suggested the beneficial effects of endurance exercise are due to the anti-
inflammatory effects of regular exercise, through a reduction in adipose tissue mass and/or 
induction of an anti-inflammatory environment with each acute bout of endurance exercise. 
Analysis of systemic changes in the abundance of selected hormones and cytokines 
(myokines and adipokines) with roles thought to contribute to the regulation of adipose 
tissue accumulation and inflammation may provide clarification of the mechanisms 
conferring the beneficial effects of endurance exercise. The objective of this chapter is 
therefore to establish the changes that occur systemically in the abundance of selected 
hormones and cytokines, therefore supplementing data gathered previously in skeletal 
muscle and adipose tissue, as a function of our acute ‘domain-based’ constant work-load 
cycle ergometer exercise interventions in recreationally active young males. We 
hypothesise that the constant work-load cycle ergometer exercise trials developed in 
Chapter 3 will result in significant systemic changes despite the relative differences in 
trial duration, manipulated to ensure equal work done. 
 
5.3. Methods 
 
Methodological information directly pertinent to this chapter is summarised briefly 
below. Chapter 2. ‘General methods’, provides a detailed reference resource, 
documenting the procedures employed in collecting the data presented in this thesis. 
Relevant sections in Chapter 2 will be referenced in the text by index number, e.g. [2.2.1.] 
refers to the section 2.2.1. ‘Ethical approval’. 
 
5.3.1. Study design 
 
A schematic representation of the interlinking studies presented in this thesis is provided 
in figure 2.4 [2.5.1.8.1.]. The data presented in this chapter relate to Exercise studies 1 
and 2. 
 
5.3.2. Participants [2.2.] 
 
Participant descriptive and exercise cardio-respiratory data are provided in Chapter 3, 
Tables 3.1. and 3.2.  
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5.3.3. Determination of exercise trial intensity and duration [2.5.1.5. & 2.5.1.7.] 
 
5.3.4. Exercise trial protocols [2.5.1.8.] 
 
5.3.5. Blood sampling [2.6.] 
 
Samples were obtained pre-, during and post-exercise via indwelling venous cannula. A 
needle and syringe were used to collect blood samples 24 hrs. post-exercise. Samples 
were transferred to ice cold S-Monovette® tubes and then centrifuged. The serum was 
aliquoted into 2 ml Eppendorf® tubes and frozen at -80 C until analysed. Serum samples 
were assayed for specific proteins via Enzyme-linked immunosorbent assay (ELISA). 
Pre-coated, 96-well ELISA kits were purchased for determination of specific protein 
concentrations in human serum. 
 
5.3.6. Statistical analyses [2.8.] 
 
Maximal exercise-induced hormonal adaptations. Paired t-Tests were performed to 
determine if systemic Growth Hormone (GH), Insulin-like growth factor-I (IGF-I), 
cortisol and Interleukin-6 (IL-6) concentrations measured post-cycle ergometry 
maximum rate of oxygen uptake ( max) test were significantly different to 
concentrations measured at baseline. 
 
Heavy exercise-induced hormonal adaptations, trial comparisons. Repeated-measures 
Analysis of variance (ANOVA) with as within factor ‘time’ (4 levels; Baseline, End of 
exercise, Post-exercise (60 min) and Post-exercise (24 hrs.)) and between factor ‘study’ 
(2 levels; Study 1 and Study 2) were run to determine whether there were significant 
differences between systemic protein abundance induced by heavy exercise performed in 
Study 1 and Study 2. If significant effects were observed, post-hoc Bonferroni-corrected 
one-way ANOVA were run to identify the difference. 
 
Work-load comparison, Baseline vs. End of exercise. Repeated-measures ANOVA with 
as within factor ‘time’ (2 levels; Baseline and End of exercise) and between factor ‘work-
load’ (3 levels; moderate, heavy and very heavy) were run to determine whether there 
were significant differences between systemic protein abundance induced by moderate, 
heavy and very heavy exercise, immediately post-exercise. If a significant ‘time’ x ‘work-
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load’ interaction was observed, the data file was split on between factor ‘work-load’ and 
independent t-tests were performed to locate the difference. Post-hoc Bonferroni-
corrections were applied. 
 
Moderate, heavy and very heavy exercise-induced hormonal adaptations. Repeated-
measures ANOVA with as within factor ‘time’ (4 levels; Baseline, End of exercise, Post-
exercise (60 min) and Post-exercise (24 hrs.)) and between factor ‘work-load’ (3 levels) 
were run to determine whether there were significant differences between systemic 
protein abundance induced by moderate, heavy and very heavy exercise. If significant 
effects were observed, post-hoc Bonferroni-corrected one-way ANOVA were run to 
identify the difference. 
 
5.4. Results 
 
5.4.1. Exercise-induced hormonal adaptations 
 
Maximal exercise induced a significant increase in the systemic concentrations of IL-6, 
IGF-I and GH, and a decrease in the concentration of cortisol, immediately post-exercise 
(figure 5.1). 
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Figure 5.1. Maximal exercise-induced hormonal adaptation. Significant effect of ‘time’. (a) Pre-max vs. 
Post-max IGF-I (P = 0.01; a) and Cortisol (P = 0.02; b), and (b) IL-6 (P = 0.005; c) and GH (P = 0.008; d). 
Data are (mean ± SEM). 
 
No significant differences were found between the systemic protein concentrations 
induced by heavy (30 % Δ) exercise performed in study 1 and study 2 (effect of ‘study’) 
for cortisol (P = 0.37), IL-6 (P = 0.15), GH (P = 0.86) or IGF-I (P = 0.27). The data from 
the heavy exercise interventions were therefore pooled and analysed as a single heavy 
exercise trial. 
 
The results of the comparison to determine the effect of work-load on exercise-induced 
hormonal adaptations pre-post-exercise (Baseline vs. End of exercise) indicate moderate 
exercise promoted a significant increase in IL-6 (P = 0.001; figure 5.2.). Heavy and very 
heavy exercise-induced responses were not significantly different. No effect of work-load 
was observed on IGF-I, GH or cortisol.  
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Figure 5.2. Work-load comparison, Baseline vs. End of Exercise. IL-6 (P = 0.001; a) (a), IGF-I (b), Cortisol 
(c) and GH (d). Data are (mean ± SEM).  
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5.4.1.1. Interleukin-6 
 
Systemic IL-6 concentrations increased significantly above that at baseline in response to 
all exercise trials (significant effect of ‘time’ P < 0.001; figure 5.3). Post-hoc analyses 
indicated the IL-6 concentrations remained elevated above baseline for approximately 24 
hrs. Analyses conducted to establish the effect of work-load (Baseline vs. End of exercise) 
indicated that moderate exercise promoted the greatest increase in IL-6 concentration at 
the end of exercise (P = 0.001). 
Figure 5.3. Systemic IL-6 response to moderate (60 min), heavy (27:48  2:31 min) and very heavy (22:29 
 1:31 min) domain cycle ergometer exercise. Significant effect of ‘time’ (P < 0.001). Post-hoc analyses, 
Baseline vs. End of exercise (P = 0.003; a); Post-exercise (60 min) (P = 0.002; b); Post-exercise (24 hrs.) 
(P = 0.03; c). Baseline vs. End of exercise: moderate significantly different to heavy and very heavy (P = 
0.001; d). Data are (mean ± SEM). 
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5.4.1.2. Insulin-like growth factor-I 
 
When monitoring the impact of exercise intensity and duration on IGF-I profiles, it was 
evident that a temporal adaptation occurred. Indeed, statistical analyses identified a 
significant effect of ‘time’ on IGF-I (P < 0.001; figure 5.4). Post-hoc analyses indicate 
the variation in the systemic concentration of IGF-I became significant following the 
cessation of exercise, during which time the concentration declined after all trials. No 
effect of ‘work-load’ (P = 0.6) or ‘work-load’ x ‘time’ interaction (P = 0.7) was observed 
indicating the lack of variation in systemic IGF-I abundance in response to the exercise 
trials, further highlighted by overlapping Standard error of the mean (SEM) error bars at 
all time points. 
Figure 5.4. Systemic IGF-I response to moderate (60 min), heavy (27:48  2:31 min) and very heavy (22:29 
 1:31 min) domain cycle ergometer exercise. Significant effect of ‘time’ (P < 0.001). Post-hoc analyses, 
Baseline vs. Post-exercise (60 min) (P = 0.001; a) and Post-exercise (24 hrs.) (P = 0.009; b), End of exercise 
vs. Post-exercise (60 min) (P < 0.001; c) and Post-exercise (24 hrs.) (P < 0.001; d). Data are (mean ± SEM).  
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5.4.1.3. Growth hormone 
 
Statistical analyses identified a significant effect of ‘time’ on GH (P < 0.001; figure 5.5 
Post-hoc analyses indicated systemic GH concentrations increased significantly in 
response to all exercise trials above baseline to peak at the end of exercise. Growth 
hormone concentrations decreased significantly following the end of exercise, but 
remained significantly elevated above that at baseline 60 min post-exercise. Data 
presented as mean  SEM belie the variability in the GH response observed in the present 
study. Despite a ~ 4-fold greater increase in systemic concentrations of GH at the end of 
heavy and very heavy exercise relative to that following at the end of moderate exercise, 
significance was not achieved due to the variation in participant response. 
Figure 5.5. Systemic GH response to moderate (60 min), heavy (27:48  2:31 min) and very heavy (22:29 
 1:31 min) domain cycle ergometer exercise. Significant effect of ‘time’ (P < 0.001). Post-hoc analyses, 
Baseline vs. End of exercise (P < 0.001; a) and Post-exercise (60 min) (P = 0.008; b), End of exercise vs. 
Post-exercise (60 min) (P < 0.001; c) and Post-exercise (24 hrs.) (P < 0.001; d).  
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5.4.1.4. Cortisol 
 
Once again, there was a significant effect of ‘time’ on the systemic concentration of 
cortisol (P = 0.04; figure 5.6). Post-hoc analyses indicated cortisol concentrations were 
lower at 60 min post-exercise than at baseline and at the end of exercise. 
Figure 5.6. Systemic cortisol response to moderate (60 min), heavy (27:48  2:31 min) and very heavy 
(22:29  1:31 min) domain cycle ergometer exercise. Significant effect of ‘time’ (P = 0.04). Post-hoc 
analyses, Baseline vs. Post-exercise (60 min) (P = 0.04; a), End of exercise vs. Post-exercise (60 min) (P = 
0.01; b). 
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5.4.1.5. The Growth hormone/Cortisol ratio 
 
All trials induced a significant increase in the GH to cortisol ratio (significant effect of 
‘time’, P < 0.001; figure 5.7), which peaked at the end of exercise and remained elevated 
above that at baseline at 60 min post-exercise. 
Figure 5.7. Systemic GH to cortisol ratio response to moderate (60 min), heavy (27:48  2:31 min) and 
very heavy (22:29  1:31 min) domain cycle ergometer exercise. Significant effect of ‘time’ (P < 0.001). 
Post-hoc analyses, Baseline vs. End of exercise (P < 0.001; a) and Post-exercise (60 min) (P < 0.001; b), 
End of exercise vs. Post-exercise (60 min) (P = 0.002; c) and Post-exercise (24 hrs.) (P < 0.001; d), Post-
exercise (60 min) vs. Post-exercise (24 hrs.) (P < 0.001; e). Data are (mean ± SEM). 
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5.5. Discussion 
 
5.5.1. Endocrine adaptations to exercise interventions 
 
It is acknowledged that high intensity exercise can elicit damage (Córdova Martínez et 
al., 2014) with associated systemic increases in inflammatory cytokines (Zaldivar et al., 
2006). We found no changes in circulating Tumour necrosis factor-alpha (TNF), 
Interleukin-1-beta (IL-1) and Interleukin-1-alpha (IL-1); indeed the levels remained 
below the detection threshold of the ELISA kits (data not shown), as observed by others 
(Ullum et al., 1994; Drenth et al., 1995; Brüünsgaard et al., 1997). The systemic 
concentration of IL-6 in resting, healthy individuals is ~ 1 pg/ml or lower (Brüünsgaard 
et al., 1997; Ostrowski et al., 1998a; Knudsen et al., 2008). The findings from the present 
study support this. Acute exercise resulted in a significant increase in the systemic 
concentration of IL-6 above baseline, which remained elevated up to 24 hrs. post-
exercise. It is well established that systemic concentrations of IL-6 are increased in 
response to exercise (Northoff and Berg, 1991; Fischer, 2006). Data from 74 exercise 
trials involving ~ 800 participants (Fischer, 2006) suggested that the variation in the IL-
6 increase is especially dependent on duration, and that exercise of 60 min duration 
typically yields < 10-fold increase in the systemic concentration of IL-6, regardless of 
exercise mode. Further, IL-6 has been suggested to be a key modulator of lipid 
homeostasis and metabolism, connected with the substrate availability and glycogen 
sparing (van Hall et al., 2003; Wolsk et al., 2010). Compared to heavy or very heavy 
domain exercise, where oxidative phosphorylation alone is unable to satisfy energy 
demands and where blood flow to adipose tissue depots maybe restricted, long duration 
and low intensity moderate domain exercise performed in the present study had the 
greatest potential to benefit metabolism of free fatty acids derived from adipose tissue 
(Fischer, 2006; Frayn, 2010). Although the greatest increase in systemic IL-6 
concentrations in response to moderate (~ 5-fold) compared to heavy and very heavy 
exercise bouts (~ 2-fold increase) supports this notion, the absence of a difference 
between heavy and very heavy exercise, together with a large increase following maximal 
exercise, challenges the prime importance of duration. It suggests that besides duration, 
intensity also impacts systemic concentrations of IL-6, at least in cycling. Interestingly, 
the IL-6 levels remained ~ 3-fold higher for up to 24 hrs. after exercise, irrespective of 
intensity or duration. Given the reported emphasis of exercise duration and intensity on 
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IL-6 levels, it is important to note that the conclusions which are drawn maybe influenced 
by the timing of sampling following exercise cessation. 
 
Baseline GH concentrations in the present study are within the range of those reported by 
Drobny et al., (1983). Roth et al., (1963) first described the marked increase in GH in 
response to exercise, which has subsequently been well documented in endurance, sprint 
and resistance exercise (Godfrey et al., 2003; Stokes, 2003; Gibney et al., 2007; Gilbert 
et al., 2008) and can occur as early as 15 min after the onset of exercise (Lassarre et al., 
1974; Raynaud et al., 1981). Studies suggest that endurance exercise above the Anaerobic 
threshold (ATh) elicits the most marked increase in GH (Felsing et al., 1992; Pritzlaff et 
al., 1999; Wahl et al., 2010; 2013) which positively correlates with exercise duration 
performed at 70 % peak rate of oxygen uptake ( peak) (Wideman et al., 2006). In line 
with this, we observed that systemic GH concentrations increased more in response to 
heavy and very heavy than moderate exercise, though this did not reach significance. 
Growth hormone concentrations peak at the end of exercise and return to baseline after 
approximately 60 min. (Lassarre et al., 1974; Raynaud et al., 1981; Viru et al., 1992; 
Zaldivar et al., 2006). The findings from the present study support this also. 
 
In line with previous studies (Kanaley et al., 2005; Eliakim et al., 2006; Zaldivar et al., 
2006; Nindl et al., 2009; 2010; Wahl et al., 2010) we found no change in IGF-I at end of 
exercise. However, a significant decline in IGF-I was observed at 60 min and up to 24 
hrs. post-exercise. These observations occurred irrespective of exercise intensity and 
duration. Data from short-term training studies identified that systemic IGF-I 
concentrations decline with training (Eliakim et al., 1996; 1998; Nishida et al., 2010). In 
the study by Nishida et al., (2010), the decline in IGF-I was accompanied by a decrease 
in basal glucose and insulin concentrations and an increase in Insulin-like growth factor 
binding protein-1 (IGFBP-1), without a change in Insulin-like growth factor binding 
protein-3 (IGFBP-3). The authors suggested the decline in IGF-I maybe an adaptive 
response to prevent hypoglycemia following insulin-sensitising training. Thus, changes 
in systemic IGF-I concentrations in response to an acute bout of exercise may reflect 
regulatory behaviour priming glucose homeostasis. 
 
The systemic concentrations of IGF-I increased significantly in response to the max 
test. These data support the findings of others (De Palo et al., 2008; Zebrowska et al., 
2009). Although it appears sub-maximal exercise does not elicit an elevation in IGF-I 
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levels, the increase following maximal exercise would imply an environment more 
conducive to anabolic adaptation. The relationship between local and systemic IGF-I in 
mediating the outcomes of exercise are still not fully understood and further investigation 
is required to confirm whether local production and release from skeletal muscle 
augments systemic concentrations following maximal exercise. Given the widely 
acknowledged regulatory links between GH and IGF-I, it is interesting to note that the 
peak in systemic GH concentrations induced by the three exercise-trials is not reflected 
in the IGF-I response, thus representing an uncoupling of the Growth hormone/Insulin-
like growth factor-I (GH/IGF-I) axis. Zaldivar et al., (2006) observed similar results in 
which no change in systemic IGF-I was observed in response to 30 min of heavy domain 
cycle ergometer exercise, despite a peak in systemic GH. Frystyk (2010) suggested the 
uncoupling maybe due to the transient nature of the exercise-induced systemic GH 
response as administration with recombinant growth hormone (rhGH), eliciting a similar 
peak but longer-lasting increase in systemic GH concentration, has been shown to elevate 
the systemic concentrations of IGF-I within 4 hrs. post-administration (Lee et al., 1997; 
Stokes et al., 2005). 
 
Baseline systemic cortisol concentrations in the present study appear lower than those 
observed by others (Silverman and Mazzeo, 1996; Del Corral et al., 1998; Hill et al., 
2008; Wahl et al., 2010; Rosa et al., 2012). However, several studies reported a decline 
in cortisol prior to exercise (Del Corral et al., 1998; Hill et al., 2008; Wahl et al., 2010). 
These lower concentrations more closely resemble baseline values in the present study. 
It has been shown that exercise above 60 % max induces an increase in systemic 
cortisol concentrations, whilst exercise below this intensity resulted in a decline in 
cortisol (Davies and Few, 1973; Bloom et al., 1976). The duration of exercise at a specific 
intensity then determines the final cortisol concentrations (Hill et al., 2008). The findings 
of the present study do not support this. Maximal exercise induced a reduction in systemic 
cortisol concentrations, which suggests either a lack of Hypothalamic-pituitary-adrenal 
(HPA) axis stimulation or a rate of cortisol uptake into target tissues outweighing that of 
release from the adrenal gland. Systemic cortisol concentrations remained unchanged as 
a result of the three exercise trials, but had declined significantly at 60 min post-exercise. 
The cortisol responses in our study were too small to have an impact on the GH to cortisol 
ratio. The small cortisol responses were independent of exercise intensity and duration.  
5.5.2. Summary and conclusion 
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In line with the objective of this chapter, to establish the changes that occur systemically 
in the abundance of selected hormones and cytokines as a function of our acute ‘domain-
based’ constant work-load cycle ergometer exercise interventions in recreationally active 
young males, we analysed the systemic abundance of IL-6, IGF-I, cortisol and GH at 
baseline, end of exercise and at 60 minutes and 24 hrs. post-moderate, heavy and very 
heavy domain exercise trials. We hypothesised that the constant work-load cycle 
ergometer exercise trials would result in significant systemic changes despite the relative 
differences in trial duration, manipulated to ensure equal work done. We observed an 
increase in IL-6 during moderate exercise only, but significant increases post-heavy and 
very heavy exercise that remained elevated for 24 hrs. We observed an uncoupling of GH 
and IGF-I with GH increasing to peak at the end of exercise before declining sharply. No 
such increase was observed in IGF-I, which declined post-exercise and remained 
significantly below baseline concentrations for 24 hrs. Cortisol displayed a similar profile 
of decline. We conclude that endurance exercise promotes significant changes in the 
systemic abundance of hormones and cytokines. The changes strongly suggest activation 
of mechanisms of metabolic rather than anabolic control, specifically, the mobilisation of 
energy from fat stores. We feel confident in our ‘domain-based’ approach and will 
therefore proceed with testing our hypothesis that ageing will be reflected in systemic 
hormone and cytokine temporal and/or abundance variations in older participant groups. 
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Chapter 6. Age-related changes in systemic protein abundance: response to heavy domain 
cycle ergometry 
 
6.1. Abstract 
 
In the previous chapters we established the impact of equal work (varying duration) 
moderate, heavy and very heavy domain constant work-load cycle ergometer exercise on 
local (mRNA expression in skeletal muscle and subcutaneous adipose tissue) and 
systemic (protein abundance) responses of selected hormones and cytokines in 
recreationally active young male participants. We wish to augment the data from the 
heavy domain (30 % ) (H) exercise trial with those from a wider age range (20 - 60 yrs.). 
We hypothesised that ageing would be reflected in systemic hormone and cytokine 
temporal and/or abundance variations in the older participant groups. Four groups of 
recreationally active male participants (Study 3: 20 - 30 yrs., n = 8; body mass, 79.5 ± 
10.1 kg; stature 1.78 ± 0.04 m; BMI, 25 ± 2 kg/m2. 30 - 40 yrs., n = 10; body mass, 79.0 
± 13.1 kg; stature 1.78 ± 0.07 m; BMI, 25 ± 3 kg/m2. 40 - 50 yrs., n = 8; body mass, 75.6 
± 18.9 kg; stature 1.74 ± 0.10 m; BMI, 23 ± 5 kg/m2. 50 - 60 yrs., n = 8; body mass, 80 ± 
13 kg; stature 1.74 ± 0.10 m; BMI, 26 ± 3 kg/m2) performed 30 min of heavy domain (30 
% ) (H) constant work-load cycle ergometer exercise. In all groups IL-6 displayed a 
similar bi-phasic profile, with an increase during exercise at 10 min and subsequently at 
60 min post-exercise (P < 0.001). Insulin and leptin declined in all groups during exercise 
(P < 0.001 and P = 0.002, respectively). Exercise was without effect on adiponectin. GH 
increased similarly in all groups to peak again at the end of exercise (P < 0.001), although 
the peak appears depressed in the 40 - 60 yr. age range. IGF-I was unchanged, but 
concentrations were consistently higher in the 20 – 30 yr. age group at all time points (P 
= 0.001). Cortisol concentrations declined similarly in all groups post-exercise (P < 
0.001). We concluded that systemic IGF-I concentrations clearly decline between the 3rd 
and 6th decades of life, and that age (20 - 60 yrs.) is not reflected by temporal and/or 
abundance variations in systemic insulin, leptin, adiponectin, IL-6, GH, IGF-I or cortisol 
in response to an acute 30 min bout of heavy domain cycle ergometer exercise.  
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6.2. Introduction 
 
Evidence suggests endurance exercise may serve a function as an exercise component in 
therapeautic interventions targeted at ageing individuals, to help address age-related 
skeletal muscle functional decline by reducing visceral and ectopic (in skeletal muscle 
and organs) adipose tissue accumulation, and therefore, potentially, systemic and chronic 
inflammation. Although not the focus of the present work, it is also envisaged that 
incorporating endurance exercise into such an intervention may provide additional 
benefits such as improvements in cardio-respiratory fitness and minor improvements in 
or maintenance of skeletal muscle strength and power, potentially promoting functional 
improvements in the performance of activities of daily living. Our data suggest cycle 
ergometer exercise in the heavy domain, specifically, exercise above the Gas exchange 
threshold (GET) but below Maximal lactate steady state (MLSS), might present such an 
endurance exercise component. The mechanisms however require clarification. The 
objective of this chapter is therefore to establish the impact of age (20 - 60 yrs.) on the 
systemic hormone and cytokine response to an acute, 30 min, heavy domain constant 
work-load cycle ergometer exercise intervention in recreationally active males. We 
hypothesise that, even in this relatively young and recreationally active cohort, that ageing 
will be reflected in systemic hormone and cytokine temporal and/or abundance variations 
in the older participant groups. 
 
6.3. Methods 
 
Methodological information directly pertinent to this chapter is summarised briefly 
below. Chapter 2. ‘General methods’, provides a detailed reference resource, 
documenting the procedures employed in collecting the data presented in this thesis. 
Relevant sections in Chapter 2 will be referenced in the text by index number, e.g. [2.2.1.] 
refers to the section 2.2.1. ‘Ethical approval’. 
 
6.3.1. Study design 
 
A schematic representation of the interlinking studies presented in this thesis is provided 
in figure 2.4 [2.5.1.8.1.]. The data presented in this chapter relate to Exercise study 3. 
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6.3.2. Participants [2.2.] 
 
Participant descriptive and exercise cardio-respiratory data are provided in Table 6.1. and 
6.3. 
 
6.3.3. Determination of exercise trial intensity and duration [2.5.1.5. & 2.5.1.7.] 
 
6.3.4. Exercise trial protocols [2.5.1.8.] 
 
6.3.5. Blood sampling [2.6.] 
 
Samples of whole blood were obtained from the fingertip capillary bed via finger prick pre- 
and post-exercise to enable measurements of glucose and lactate concentrations. Samples 
of whole blood were collected via venepuncture from veins in proximity to the cubital 
fosse of the non-dominant arm. Samples were obtained pre-, during and post-exercise via 
indwelling venous cannula. Samples were transferred to ice cold S-Monovette® tubes 
and centrifuged. The serum was aliquoted into 2 ml Eppendorf® tubes and stored at -80 
C until analysed. Serum samples were assayed for specific proteins via Enzyme-linked 
immunosorbent assay (ELISA). Pre-coated, 96-well ELISA kits were purchased for 
determination of specific protein concentrations in human serum. 
 
6.3.6. Statistical analyses [2.8.] 
 
Participant descriptive and maximal exercise cardio-respiratory data. One-way Analysis 
of variance (ANOVA) were run to determine if age, body mass, stature, Body mass index 
(BMI), maximum rate of oxygen uptake ( max), Power output at max (POmax) 
and Heart rate at max (HRmax) were significantly different between participant 
groups 20 - 30 yrs., 30 - 40 yrs., 40 - 50 yrs. and 50 - 60 yrs. Where data did not satisfy 
the assumptions of parametricity, the Kruskal-Wallis test was performed. 
 
Participant heavy domain exercise cardio-respiratory data. One-way ANOVA were run 
to determine if Power output (PO), rate of oxygen uptake ( ), Heart rate (HR), rate of 
oxygen uptake divided by heart rate ( /HR), and Total work done were significantly 
different for heavy domain exercise trials between participant groups 20 - 30 yrs., 30 - 40 
yrs., 40 - 50 yrs. and 50 - 60 yrs. Data were log transformed where applicable. 
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Heavy domain exercise trial comparison analyses. Pearson’s product-moment correlation 
coefficients were computed to assess the relationship between , HR and /HR 
data for heavy domain exercise determined from max tests and data measured 
directly during subsequent heavy domain exercise trials. Paired samples t-Tests were 
performed to determine if , HR and /HR data for heavy domain exercise, 
determined from max tests, varied significantly from data measured directly during 
subsequent heavy domain exercise trials. 
 
Blood lactate and blood glucose analyses. Repeated-measures ANOVA with as within 
factor ‘time’ and between factor ‘group’ were run to determine whether there were 
significant time and age effects. If significant effects were observed post-hoc Bonferroni-
corrected one-way ANOVA were run to identify the difference. 
 
Maximal and heavy domain exercise-induced hormonal adaptation analyses. Repeated-
measures ANOVA with as within factor ‘time’ and between factor ‘group’ were run to 
determine whether there were significant time and age effects. If significant effects were 
observed post-hoc Bonferroni-corrected one-way ANOVA were run to identify the 
difference. 
 
Delta analyses. In the case of a significant ‘time’ x ‘group’ interaction, a post-hoc 
ANOVA was run on the absolute delta values to identify the different responses between 
age groups. 
 
6.4. Results 
 
6.4.1. Participant descriptive and maximal exercise cardio-respiratory data 
 
No statistically significant differences were evident between the participant groups for 
body mass, stature, BMI, max or POmax. HRmax, not unexpectedly, was higher in 
the 20 - 30 yr. olds compared to the other age groups (table 6.1). 
 
6.4.2. Participant heavy domain exercise cardio-respiratory data 
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There were no significant differences between the participant groups for PO, , 
/HR, or Total work done during the heavy domain exercise. The HR was, however, 
significantly higher in the 20 - 30 vs. the 30 - 40 yr. old participants (table 6.2). 
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Table 6.1. Participant descriptive and maximal exercise cardio-respiratory data 
 
 
 
Post-hoc analyses. Age (*) all groups (P < 0.001), HRmax (**) 20 - 30 yrs. vs. 30 - 40 yrs. (P = 0.03) and 20 - 30 yrs. vs. 40 - 50 yrs. (P = 0.02). 
 
      
Participant details 20 - 30 yrs. 30 - 40 yrs. 40 - 50 yrs. 50 - 60 yrs. 
Statistical analyses 
(main effects) 
      
      
Gender, n male, 8 male, 10 male, 8 male, 8 - 
Age (yrs.) 22 ± 2 34 ± 3 45 ± 3 57 ± 4 P < 0.001 * 
Body mass (kg) 79.5 ± 10.1 79.0 ± 13.1 75.6 ± 18.9 80 ± 13 P = 0.91 
Stature (m) 1.78 ± 0.04 1.78 ± 0.07 1.79 ± 0.07 1.74 ± 0.10 P = 0.51 
BMI (kg/m2) 25 ± 2 25 ± 3 23 ± 5 26 ± 3 P = 0.33 
      
max (ml/min) 3741 ± 837 3723 ± 807 3456 ± 639 3348 ± 821 P = 0.58 
POmax (W) 272 ± 62 289 ± 53 236 ± 50 247 ± 58 P = 0.17 
HRmax (b/min) 187 ± 14 170 ± 8 169 ± 3 171 ± 14 P = 0.03 ** 
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Table 6.2. Participant heavy domain exercise cardio-respiratory data 
 
 
 
Post-hoc analyses. HR (***) 20 - 30 yrs. vs. 30 - 40 yrs. (P = 0.05). 
 
      
Exercise variables 20 - 30 yrs. 30 - 40 yrs. 40 - 50 yrs. 50 - 60 yrs. Statistical analyses 
      
      
Trial time 
(min:s) 
30:00 ± 00:00 30:00 ± 00:00 30:00 ± 00:00 30:00 ± 00:00 - 
PO (W) 138 ± 35 146 ± 27 121 ± 19 129 ± 24 P = 0.28 
(ml/min) 2076 ± 535 2148 ± 310 2099 ± 372 2148 ± 372 P = 0.93 
HR (b/min) 141 ± 14 123 ± 16 125 ± 8 123 ± 10 P = 0.04 *** 
/HR 
(ml/b/min) 
15 ± 4 18 ± 3 17 ± 2 18 ± 3 P = 0.44 
Total work 
done (KJ) 
248 ± 72 262 ± 49 218 ± 34 233 ± 43 P = 0.28 
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6.4.3. Heavy domain exercise trial comparison analyses 
 
Having examined the relationship between relevant output measures ( , HR and 
/HR data) determined from the max tests and measured directly during subsequent 
exercise trials for moderate, heavy and very heavy domain exercise (Chapter 3. Section 
3.4.3. ‘Exercise trial comparison analyses’), we wished to build on the findings and 
examine the relationship between these output measures established from participants in 
the present study. To this end, Pearson’s product-moment correlation coefficients 
indicated significant positive correlations for  (r = 0.828, n = 34, P < 0.001; figure 
6.1), HR (r = 0.729, n = 30, P < 0.001; figure 6.2) and /HR (r = 0.877, n = 30, P = 
0.001; figure 6.3) in participants between the 20 - 60 yrs. of age, performing heavy 
domain exercise. Comparison of , HR and /HR data determined from max 
tests with that measured during heavy domain exercise revealed no significant differences 
for HR (P = 0.06) and /HR (P = 0.48). A significant difference was observed for  
(P = 0.02), reflecting the higher  values measured in response to the heavy domain 
exercise trial. 
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Figure 6.1. Correlation between  measured during max tests and heavy (30 % ) intensity exercise trials in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males (r = 0.828, n = 
34, P < 0.001). 
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Figure 6.2. Correlation between HR measured during max tests and heavy (30 % ) intensity exercise trials in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males (r = 0.729, n = 
30, P < 0.001). 
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Figure 6.3. Correlation between /HR measured during max tests and heavy (30 % ) intensity exercise trials in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males (r = 0.877, 
n = 30, P = 0.001). 
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6.4.4. Blood lactate and blood glucose analyses 
 
Blood lactate (BLa) increased significantly during both maximal and heavy domain 
exercise (P < 0.001) (figure 6.4), with 3.5 - 4-fold greater increases in BLa in response to 
maximal exercise. The significant effect of ‘group’ observed in response to both maximal 
(P < 0.001) and heavy domain (P = 0.008) exercise highlights the greater post-exercise 
BLa concentrations in the older individuals. A significant ‘group’ x ‘time’ interaction (P 
= 0.02) highlights the greater increase in BLa in 40 - 50 vs. 20 - 30 and 30 - 40 yr. old 
participants, during maximal exercise, which is supported by post-hoc comparison data 
(P = 0.001). Post-hoc comparison data from heavy domain exercise support a similar 
finding, with lower BLa values in the 30 - 40 vs. 40 - 50 (P = 0.04) and 50 - 60 (P = 0.02) 
yr. olds. A significant increase in Blood glucose (BGlu) was observed only during 
maximal exercise (P < 0.001). Post-hoc analyses were unable to locate the difference 
despite a significant effect of ‘group’ (P = 0.04). However, the greatest and similar 
increases were observed in the 20 - 30 and 30 - 40 yr. old participants. No significant 
effects were observed with regard to heavy domain exercise. 
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Figure 6.4. Maximal and heavy domain cycle ergometer exercise adaptation. Blood lactate (Bla) (a) and 
blood glucose (BGlu) (b). (a) Significant effect of ‘time’. Pre-max vs. Post-max (P < 0.001; a), Pre-heavy 
vs. Post-heavy (P < 0.001; b). Significant effect of ‘group’. Pre-max vs. Post-max (P < 0.001; c), Pre-heavy 
vs. Post-heavy (P < 0.001; d). (b) Significant effect of ‘time’. Pre-max vs. Post-max (P < 0.001; e). 
Significant effect of ‘group’. Pre-max vs. Post-max (P = 0.04; f). Data are (mean ± SEM). 
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6.4.5. Maximal exercise-induced hormonal adaptation 
 
Insulin concentration increased during maximal exercise (figure 6.5 and 6.5, continued). 
A ‘group’ x ‘time’ interaction (P = 0.03) highlights a somewhat attenuated response in 
the 40 - 50 and 50 - 60 yr. old participants. Growth hormone (GH) increased in all age 
groups in response to maximal exercise. Baseline Insulin-like growth factor-I (IGF-I) 
levels were highest in the youngest age group compared with all other groups, which did 
not differ from each other. Maximal exercise resulted in an increase in IGF-I 
concentration, which was attenuated progressively with respect to increasing age (‘group’ 
x ‘time’ interaction, P = 0.002). No differences in cortisol concentration were apparent. 
The Interleukin-6 (IL-6) concentration increased in all age groups in response to maximal 
exercise. 
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Figure 6.5. Maximal exercise-induced hormonal adaptation. IL-6 (a), IGF-I (b) and GH (c). Significant 
effect of ‘time’. Pre-max vs. Post-max (a) (P < 0.001; a), (b) (P < 0.001; b), (c) (P = 0.003; c). Significant 
effect of ‘group’. Pre-max vs. Post-max (b) (P < 0.001; d). Data are (mean ± SEM). 
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Figure 6.5, continued. Maximal exercise-induced hormonal adaptation. Cortisol (d) and Insulin (e). 
Significant effect of ‘time’. Pre-max vs. Post-max (e) (P = 0.02; e). Data are (mean ± SEM). 
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6.4.6. Heavy domain exercise-induced hormonal adaptation 
 
6.4.6.1. Insulin, leptin and adiponectin adaptations 
 
Heavy domain exercise resulted in a decrease in systemic insulin concentration in all age 
groups (figure 6.6). A significant decrease in systemic leptin concentration post-exercise 
was observed, which was similar in all age groups (figure 6.7). No significant differences 
were observed in systemic adiponectin concentration (figure 6.8). 
Figure 6.6. Systemic insulin response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 40 - 50 
and 50 - 60 yr. old males. Significant effect of ‘time’ (P < 0.001; a). Data are (mean ± SEM). 
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Figure 6.7. Systemic leptin response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 40 - 50 
and 50 - 60 yr. old males. Significant effect of ‘time’ (P = 0.002; a). Data are (mean ± SEM). 
Figure 6.8. Systemic adiponectin response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 
40 - 50 and 50 - 60 yr. old males. Data are (mean ± SEM). 
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6.4.6.2. Anabolic adaptations 
 
During heavy domain exercise GH increased significantly in all age groups (figure 6.9). 
Growth hormone returned to baseline levels 60 min after cessation of exercise. The most 
significant variation occurred between GH concentrations at the end of exercise compared 
with those at baseline and 60 min post-exercise. Although post-hoc comparisons revealed 
no significant group differences, the GH response in the older age groups appears reduced 
in comparison with that of the younger age groups. During heavy domain exercise IGF-I 
concentrations did not increase, but were consistently higher in the youngest age group 
(figure 6.10). 
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Figure 6.9. Systemic GH response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males. Significant effect of ‘time’ (P < 0.001). Post-hoc 
analyses, Baseline vs. End of exercise (P < 0.001; a), 10 min vs. 20 min (P = 0.006; b) and End of exercise (P < 0.001; c), 20 min vs. End of exercise (P = 0.02; d) and Post-exercise 
(60 min) (P = 0.01; e), End of exercise vs. Post-exercise (30 min) (P < 0.001; f) and Post-exercise (60 min) (P < 0.001; g), Post-exercise (30 min) vs. Post-exercise (60 min) (P < 0.001; 
h). Data are (mean ± SEM).  
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Figure 6.10. Systemic IGF-I response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males. Significant effect of ‘group’ (P = 0.001). Post-
hoc analyses, 20 - 30 vs. 40 - 50 (P = 0.004; a) and 50 - 60 (P = 0.002; b) yrs. Data are (mean ± SEM). 
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6.4.6.3. Catabolic and metabolic/inflammatory adaptations 
 
During heavy domain exercise cortisol concentrations decreased (figure 6.11). Post-hoc 
analyses indicated the decline in cortisol became significant in the post-exercise period. 
The absence of an effect of ‘group’ and ‘group’ x ‘time’ interaction indicated that the 
decrease in systemic cortisol was similar for all age groups. Heavy domain exercise 
resulted in an increase in IL-6 abundance in the first 10 min of exercise and again post-
exercise (figure 6.12). Post-hoc analyses revealed that all time points differed 
significantly, except at 20 min, where data were similar to baseline. A significant ‘group’ 
x ‘time’ interaction (P < 0.001) was reflected by a greater post-exercise increase in IL-6 
in the 40 - 50 and 50 - 60 yr. age groups. Post-hoc ‘Delta’ analyses indicated a significant 
impact of ‘time’ 60 min post-exercise (P = 0.001). Post-hoc multiple comparisons on 
‘group’ indicate the 30 - 40 yr. old participants differed significantly from those in the 40 
- 50 and 50 - 60 yr. age groups (P = 0.002). The response in the 20 - 30 yr. old participants 
did not differ from any other group. 
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Figure 6.11. Systemic cortisol response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males. Significant effect of ‘time’ (P < 0.001). Post-
hoc analyses, Baseline vs. End of exercise (P = 0.009; a), Post-exercise (30 min) (P < 0.001; b) and Post-exercise (60 min) (P < 0.001; c), 10 min vs. Post-exercise (30 min) (P = 0.007; 
d) and Post-exercise (60 min) (P = 0.001; e), 20 min vs. End of exercise (P = 0.03; f), Post-exercise (30 min) (P = 0.001; g) and Post-exercise (60 min) (P < 0.001; h), End of exercise 
vs. Post-exercise (30 min) (P < 0.001; i) and Post-exercise (60 min) (P < 0.001; j), Post-exercise (30 min) vs. Post-exercise (60 min) (P = 0.001; k). Data are (mean ± SEM).  
0
50
100
150
200
250
300
350
400
450
500
Baseline 10 min 20 min End of exercise
(30 min)
Post-exercise
(30 min)
Post-exercise
(60 min)
S
er
u
m
 C
o
rt
is
o
l 
co
n
ce
n
tr
at
io
n
 (
n
g
/m
l)
 20-30 yrs.  30-40 yrs.  40-50 yrs.  50-60 yrs.
a
b
c
d
e
f
g
h
i
j
k
  
1
5
1
 
Figure 6.12. Systemic IL-6 response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males. Significant effect of ‘time’ (P < 0.001). Post-hoc 
analyses, Baseline vs. 10 min (P < 0.001; a), End of exercise (P = 0.04; b), and Post-exercise (60 min) (P < 0.001; c), 10 min vs. 20 min (P < 0.001; d), End of exercise (P < 0.001; e) 
and Post-exercise (60 min) (P < 0.001; f), 20 min vs. End of exercise (P = 0.004; g), and Post-exercise (60 min) (P < 0.001; h), End of exercise vs. Post-exercise (60 min) (P = 0.001; 
i). Data are (mean ± SEM). 
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6.4.6.4. Systemic protein ratios 
 
During heavy domain exercise the leptin to adiponectin ratio decreased by ~ 0.8 – 0.5-
fold (P = 0.004; figure 6.13) and the GH to cortisol ratio increased by ~ 8.8 - 14-fold (P 
< 0.001; figure 6.14). The GH to cortisol ratio returned to baseline levels 60 min after 
cessation of exercise. 
Figure 6.13. The leptin to adiponectin ratio response to heavy domain cycle ergometer exercise in 20 - 30, 
30 - 40, 40 - 50 and 50 - 60 yr. old males. Data are (mean ± SEM). 
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Figure 6.14. The GH to cortisol ratio response to heavy domain cycle ergometer exercise in 20 - 30, 30 - 40, 40 - 50 and 50 - 60 yr. old males. Significant effect of ‘time’ (P < 0.001). 
Post-hoc analyses, Baseline vs. End of exercise (P < 0.001; a), 10 min vs. 20 min (P = 0.02; b) and End of exercise (P = 0.001; c), 20 min vs. End of exercise (P = 0.05; d), and Post-
exercise (60 min) (P = 0.02; e), End of exercise vs. Post-exercise (30 min) (P < 0.001; f) and Post-exercise (60 min) (P < 0.001; g), Post-exercise (30 min) vs. Post-exercise (60 min) 
(P = 0.007; h). Data are (mean ± SEM). 
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6.5. Discussion 
 
6.5.1. Participant descriptive and cardio-respiratory data 
 
As is commonly observed (Higginbotham et al., 1986; Ogawa et al., 1992) HRmax was 
reduced in the older participant groups. This is in contrast to similar values for body mass, 
stature, BMI, max and POmax across the cohort. These data confirm a healthy 
heterogeneic population with a good level of aerobic fitness (Heyward 1998).  
 
6.5.2. Heavy domain exercise trial comparison analyses 
 
Previously, it was established that there were good correlations between , HR and 
/HR measured during the max tests and during exercise trials for moderate, 
heavy and very heavy domain exercise in young participants (Chapter 3. Section 3.4.3. 
‘Exercise trial comparison analyses’). Correlations from the present study indicate 
agreement over the extended age range. No differences were found between HR and 
/HR. However, a significant difference in  was found. This was due to the effect of 
the  slow component; a gradual increase in  apparent after 10 - 20 min in exercise 
above the GET (Jones et al., 1999). Although not significantly different, HR was also 
elevated in the heavy exercise trial compared to the max test. This maybe due to the 
influence of cardio-vascular drift (Coyle and González-Alonso, 2001) where a 
progressive decline in stroke volume and pulmonary and systemic mean arterial pressures 
is accompanied by a parallel increase in HR in order to maintain cardiac output (Coyle 
and González-Alonso, 2001). The similarity in /HR between the two tests indicates 
comparable increases in both  and HR during the exercise trials. 
 
6.5.3. Blood lactate and blood glucose analyses 
 
Blood lactate concentrations increased during both maximal and heavy domain exercise. 
The concentration of BLa was greater in response to maximal exercise due to a greater 
anaerobic influence. The younger age groups appeared to have lower BLa concentrations 
at baseline than the older age groups (~ 0.5 vs. 1.3 mmol/l), and in response to both 
maximal (~ 8.1 vs. 10 mmol/l) and heavy domain (~ 2.3 vs. 3.1 mmol/l) exercise 
respectively, despite the similar relative physiological demands of the heavy domain 
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exercise bout. Lower skeletal muscle oxidative capacity maybe responsible for the higher 
BLa concentrations in the older individuals (Chisari et al., 2002). Blood glucose 
concentration is maintained within a narrow range. Deviations from this normal range 
(hypo/hyper-glycaemia) can have neurological consequences, such as light-headedness, 
confusion, and if unchecked, can result in coma. Fasted baseline BGlu concentrations 
were within the normal range (3.9 - 5.5 mmol/l) (Diabetes.co.uk, no date). Blood glucose 
increased during maximal exercise. However, while the data show a similar response in 
the two younger age groups, the increase was somewhat attenuated in the older age 
groups. The reason for this uncoupling is unclear. Blood glucose concentrations remained 
similar to baseline concentrations during heavy domain exercise. These variations in the 
BGlu response can broadly be explained by changes in the mechanisms of Glucose 
utilisation (GU) and Glucose production (GP) with exercise intensity (Marliss and 
Vranic, 2002). 
 
6.5.4. Insulin, leptin and adiponectin adaptations 
 
Fasting concentrations of leptin (Liu et al., 1999), adiponectin (Antuna-Puente et al., 
2008) and insulin (Kahn et al., 1997) were within previously established normal ranges. 
During maximal exercise insulin increased, while during heavy domain exercise insulin 
decreased. Leptin decreased significantly also during heavy exercise. Exercise was 
without effect on adiponectin concentration. An increase in insulin during maximal 
exercise would promote glucose uptake in skeletal muscle, adipose tissue and the liver, 
and fatty acid uptake and lipogenesis in adipose tissue. Insulin reduces the release of 
glucose from the liver by inhibiting hepatic glycogenolysis and the expression of key 
gluconeogenic enzymes (Wahren and Ekberg, 2007). In addition to the primary role of 
maintaining glucose homeostasis, insulin mediates other cellular events including 
regulation of ion and amino-acid transport, lipid metabolism, glycogen synthesis, gene 
transcription and Messenger ribonucleic acid (mRNA) turnover, protein synthesis and 
degradation in liver and muscle, and Deoxyribonucleic acid (DNA) synthesis (Cheatham 
and Kahn, 1995). Impaired processing of pro-insulin to insulin has been suggested as a 
mechanism for the age-related decline in insulin release (Bryhni et al., 2010). Data from 
the present study show fasted baseline insulin concentrations to be lowest in the oldest 
age group and highest in the youngest age group, thus broadly supporting this hypothesis. 
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During maximal exercise insulin increased in a parallel manner in all age groups. The 
decrease in insulin during heavy domain exercise was most pronounced in the youngest 
age group. The contrasting insulin responses can be explained by the variation in the 
intensity of exercise and the relative requirements for BGlu (Marliss and Vranic, 2002). 
During heavy domain exercise characteristic of that in the present study there is an 
increase in demand for glucose by the exercising muscles. This promotes a response that 
increases GP to match GU precisely, and insulin secretion is inhibited to below fasting 
levels through α-adrenergic receptor activation (Robertson et al., 1976; Broadstone et al., 
1987). Inhibition of insulin secretion increases GP by the liver by increasing sensitivity 
to glucagon (Vranic et al., 1976; Issekutz and Vranic, 1980; Zinker et al., 1994). The 
decrease in insulin with either no change or an increase in glucagon accounts for the 
corresponding increases in GP (Wasserman et al., 1989a; 1989b). Thus, the ratio of 
glucagon to insulin is the main determinant of GP during heavy domain exercise 
characteristic of that in the present study (Issekutz and Vranic, 1980; Wasserman et al., 
1984). Maximal, exhaustive exercise, promotes rapid hepatic glycogenolysis. In contrast 
to the ‘feedback’ signal at lower exercise intensities, this has been suggested to be a 
beneficial ‘feed forward’ loop (Kjaer et al., 1986; 1993). It has been proposed that the 
relatively greater magnitude of the catecholamine response in maximal exercise, 
compared to that at lower intensity, is the prime regulator of GP (Marliss et al., 1991; 
1992; Sigal et al., 1996; Marliss and Vranic, 2002; Kreisman et al., 2000; 2001; 2003). 
The result is that GP is increased above the rate of GU. Systemic insulin, however, 
remains relatively stable as high catecholamine concentrations (acting through a 
dominant α-adrenergic effect) prevent glucose stimulation of insulin secretion. Post-
exercise, systemic insulin increases in response to the net increase in blood glucose as 
epinephrine and norepinephrine rapidly decline (Marliss et al., 1992; Sigal et al., 1996; 
Marliss and Vranic, 2002). Thus, exercise-induced changes in insulin abundance 
observed in the present study appear to be related to blood glucose homeostasis as 
described above, although further experiments would be required for confirmation, with 
no indication of insulin resistance. 
 
Ageing is associated with increased adiposity, most notably central adiposity. 
Interestingly, although not significantly different, the highest baseline leptin 
concentrations were observed in the oldest age group who possessed the greatest BMI 
value. Similarly, this group possessed the highest baseline adiponectin concentrations, 
broadly suggesting that they maybe benefiting from the anti-inflammatory and anti-
  157 
atherogenic effects of this protein also. Systemic leptin concentrations have been linked 
to energy expenditure, and shown to decline as a result of both acute exercise (Duclos et 
al., 1999; Zaccaria et al., 2013; Rosa et al., 2012) and exercise training (Simsch et al., 
2002; Olmedillas et al., 2011). This finding is supported by data from the present study 
in which leptin concentrations declined during heavy domain exercise. Further, heavy 
domain exercise resulted in a decrease in the leptin/adiponectin ratio, potentially 
offsetting the negative effects of increasing circulating leptin concentrations known to 
increase with accumulating adipose tissue mass. Age was without effect on the 
leptin/adiponectin ratio. Adiponectin has been shown to be inversely correlated with 
fasting insulin (Park et al., 2004). Our data support this and we note that adiponectin 
appears to inversely reflect the changes in insulin during heavy domain exercise. These 
findings support a role for insulin in blood glucose homeostasis during exercise where 
insulin resistance is not apparent, reflected by basal abundance of insulin, and show acute 
heavy domain exercise is able to bring about positive changes in the systemic abundance 
of adipokines leptin and adiponectin. 
 
6.5.5. Anabolic adaptations 
 
Baseline GH concentrations in the present study are similar to the 0.8 ng/ml (2.42 µIU/ml) 
baseline concentrations reported by Drobny et al., (1983). Elevation above this figure is 
likely to be due in part to the fasting state of the participants (Ho et al., 1988) and variation 
in peak pulsatile secretion with sample time. In the present study fasting IGF-I 
concentrations were within the normal range established previously, with the greatest 
concentration (~ 100 ng/ml greater) in the youngest age group (Yamamoto et al., 1991). 
Basal systemic IGF-I concentrations in 207 normal adults (103 males and 104 females), 
aged 21 to 80 years suggested a significant decline in basal IGF-I with age, which is linear 
in males (Yamamoto et al., 1991). Insulin-like growth factor-I is suggested to be primarily 
responsible for the anabolic response to exercise (Velloso, 2008). Growth hormone is the 
principal regulator of the hepatic synthesis of IGF-I and Insulin-like growth factor binding 
protein-3 (IGFBP-3), the major Insulin-like growth factor carrier and modulator of 
systemic IGF-I action (Frystyk, 2004; 2010). Local IGF-I may augment systemic 
concentrations of hepatic origin acting in a paracrine fashion (Adams, 2002; Berg and 
Bang, 2004; Nindl, 2010). The Growth hormone/Insulin-like growth factor-I (GH/IGF-I) 
axis exerts short- and long-term metabolic effects on exercise (Gibney et al., 2007; 
Widdowson et al., 2009). The marked exercise-induced GH response first described by 
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Roth et al., (1963) has since been well documented with regard to endurance, sprint and 
resistance exercise (Godfrey et al., 2003; Gibney et al., 2007; Gilbert et al., 2008). 
Endurance exercise above the Anaerobic threshold (ATh) is considered to elicit the most 
marked increase in GH (Pritzlaff et al., 1999; Godfrey et al., 2003; Gilbert et al., 2008; 
Wahl et al., 2010; 2013). The exercise-induced increase in systemic GH concentration is 
suggested to spare blood glucose by increasing gluconeogenesis and mobilising free fatty 
acids from adipose tissue (Hunter et al., 1965a; 1965b). However, it is thought that the 
latter maybe restricted during very strenuous exercise due to reduced blood flow to 
adipose tissue depots. Systemic IGF-I is involved in the feedback inhibition of GH release 
(Frystyk, 2004; 2010) and therefore enhancement of insulin action and glucose 
homeostasis (Clemmons, 2006b). Data from the present study support previous findings 
that endurance exercise above the ATh results in a significant increase in systemic GH 
concentration within the first 20 min (Felsing et al., 1992), and that the response is 
attenuated in middle-aged men (Gilbert et al., 2008). Both maximal and heavy domain 
exercise resulted in a significant increase in systemic GH in all groups. Similar to the 
findings of others, GH concentrations were significantly increased within 20 min of the 
onset of heavy domain exercise, peaked at the end of exercise and returned to baseline 
levels within 60 min (Lassarre et al., 1974; Raynaud et al., 1981; Viru et al., 1992; 
Zaldivar et al., 2006). The most significant variation occurred between GH concentrations 
at the end of exercise compared with those at baseline and post-exercise (60 min), which 
were highly comparable. Although post-hoc comparisons revealed no significant group 
differences, the GH response to both maximal and heavy domain exercise appears very 
much dampened in the older compared with that of the younger age groups.  
 
In the present study maximal exercise induced a significant increase in systemic 
concentrations of IGF-I, which were progressively attenuated with increasing age. A 
significant increase in systemic concentrations of IGF-I was shown by De Palo et al., 
(2008) in young male participants (n = 20, mean age 19 ± 2 yrs.) in response to two 
exhaustive cycling exercise trials lasting 25 and 40 min. No significant exercise-induced 
increase in IGF-I was observed in response to heavy domain exercise. We note here again, 
similar to the response reported in Chapter 3., that the heavy domain exercise-induced 
peak in systemic GH abundance is not reflected in the IGF-I response, thus representing 
an uncoupling of the GH/IGF-I axis. This finding, also observed by Zaldivar et al., (2006), 
is interesting given the widely acknowledged regulatory links between GH and IGF-I. 
Frystyk (2010) suggested the uncoupling maybe due to the transient nature of the 
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exercise-induced systemic GH response. 
 
It has been shown that systemic IGF-I abundance follows a similar age-related decline to 
that of GH (Corpas et al., 1993). Given the evidence that locally produced IGF-I maybe 
capable of augmenting systemic concentrations, it is hypothesised that the age-related 
reduction in systemic IGF-I shown here is also due to a reduced contribution of locally 
produced IGF-I. Further, one might also argue that this contributes to the reduced capacity 
for exercise-induced skeletal muscle hypertrophy in older individuals. Data from the 
present study suggests that neither acute maximal nor heavy domain exercise can 
compensate for the age-related decline in the systemic abundance of these two key 
anabolic proteins.  
 
6.5.6. Catabolic and metabolic/inflammatory adaptations 
 
Baseline systemic cortisol concentrations were comparable to those found by others 
(Silverman and Mazzeo, 1996; Del Corral et al., 1998; Hill et al., 2008; Wahl et al., 2010; 
Rosa et al., 2012). Increased basal systemic cortisol concentrations have been reported in 
older individuals (Pavlov et al., 1986; Van Cauter et al., 1996). However, data from the 
present study do not support this. Age-related temporal alterations in cortisol pulsatile 
secretion dynamics have also been reported (Sherman et al., 1985; Bergendahl et al., 
2000). The small variation in the baseline systemic cortisol concentration data may reflect 
this. 
 
The pulsatile secretion of cortisol, the end product of the Hypothalamic-pituitary-adrenal 
(HPA) axis, is tightly controlled via a complex regulatory mechanism incorporating 
negative feedback (Lightman et al., 2008; Russell et al., 2010). In addition, perceived or 
actual physical or psychological stress induces transient activation of HPA and cortisol 
secretion; the fight or flight response, an essential mechanism that promotes adaptation 
and survival via responses of the neural, cardio-vascular, autonomic, immune and 
metabolic systems (Charmandari et al., 2005). It is widely acknowledged that the HPA 
axis mediates the relationship between stressful life experiences and health outcomes, and 
evidence suggests that HPA axis activity contributes to biological ageing through 
inappropriate or excessive glucocorticoid secretion (Krøll, 2010; Aguilera, 2011; 
Lucassen et al., 2013). The effects of chronic hypercortisolism (excessive cortisol 
secretion) can be observed in Cushing’s Disease. As such, hypercortisolism has been 
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linked with muscle weakness, increased central adiposity/obesity (Medline Plus, no date) 
and insulin resistance in otherwise healthy individuals (Cree et al., 2010). Currently, 
research suggests a bi-phasic model of glucocorticoid regulation in which the normal 
diurnal secretion profile of cortisol supports the activity of defense mechanisms, 
including innate immune inflammation, while greater, stress-induced, concentrations act 
to acutely suppress inflammation, thus preventing tissue injury from an excessive or 
prolonged inflammatory response (Yeager et al., 2011). 
 
The max test was without effect on systemic cortisol concentrations. During heavy 
domain exercise there was a reduction in systemic cortisol concentrations in all age 
groups. Although not supported by a significant effect of ‘group’ or ‘group x time 
interaction’, the greatest reduction in systemic cortisol concentration during exercise 
appeared to be in the youngest age group, with comparable further post-exercise 
reductions across age groups. Our findings support those of others (Rosa et al., 2011; 
2012) who observed no increase in systemic cortisol abundance in response to exercise. 
During heavy domain exercise reported in our study, systemic cortisol decreased and GH 
increased. This promoted an increase in the ratio of GH to cortisol, theoretically 
promoting a systemic environment conducive to improving insulin sensitivity and gains 
in skeletal muscle mass. 
 
It is well known that exercise is a potent stimulus for IL-6 (Pedersen and Febbraio, 2012). 
Systemic abundance of this cytokine has been shown to increase over 100-fold in 
response to ‘strenuous’ exercise (marathon running) of long duration (Ostrowski et al., 
1999), although less dramatic increases are typical. The systemic concentration of IL-6 
in resting, healthy individuals is ~ 1 pg/ml or lower (Brüünsgaard et al., 1997; Ostrowski 
et al., 1998a; Knudsen et al., 2008). The findings from the present study broadly support 
this. However, the baseline concentration in the youngest age group was ~ 2 pg/ml. The 
large error bars present at all time points in both maximal and heavy domain exercise 
highlight the great variability in the systemic abundance of IL-6 within this group. Both 
maximal and heavy domain exercise resulted in significant differences in systemic IL-6 
abundance. During heavy domain exercise systemic IL-6 abundance varied significantly 
at all time points except at 20 min, which was not significantly different to baseline. The 
similarity between the secretion profile of all groups suggests the variability in the 
youngest age group is not as a result of the exercise trials, but reflective solely of the 
systemic state of individuals in this group. Fischer (2006) suggested that reduced basal 
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systemic IL-6 abundance, as well as in response to exercise, is a characteristic of the 
normal adaptation to training, whereas high basal systemic IL-6 abundance is closely 
associated with physical inactivity. Indeed, life-long endurance activity has been shown 
to be associated with a significant reduction in inflammatory markers C-reactive protein 
(CRP) and IL-6 (Mikkelsen et al., 2013). All of the participants recruited for the study 
were apparently healthy, with many engaged in some form of recreational physical 
activity/training. It is entirely possible that for some of the older participants physical 
activity has been a life-long pursuit; potentially indicated by their descriptive and cardio-
respiratory measures. Therefore, it is also possible that the exercise-induced systemic 
abundance of IL-6 maybe reduced in these older groups compared with the potentially 
less trained, younger cohort. The finding of a significant ‘group’ x ‘time’ interaction (P 
< 0.001), and post-hoc ‘Delta’ analyses showing a significant impact of ‘time’ at post-
exercise (60 min) (P = 0.001), highlights the significant difference in the post-exercise 
secretion profiles between the younger 20 - 40 yr. old and older 40 - 60 yr. old 
participants. Interleukin-6 concentrations in the 30 - 40 yr. old participants remained 
below 1 pg/ml, which was significantly lower than those in the 40 - 50 and 50 - 60 yr. old 
age groups (P = 0.002). These data suggest a potential uncoupling of the response during 
and post-exercise. 
 
6.5.7. Summary and conclusion 
 
In line with the objective of this chapter, to establish the impact of age (20 - 60 yrs.) on 
the systemic hormone and cytokine response to an acute, 30 min, heavy domain constant 
work-load cycle ergometer exercise intervention in recreationally active males, we 
analysed the systemic abundance of insulin, leptin, adiponectin, IL-6, IGF-I, cortisol and 
GH in four groups of recreationally active males at baseline and in response to heavy 
domain exercise. We hypothesised that ageing would be reflected in systemic hormone 
and cytokine temporal and/or abundance variations in the older participant groups. IL-6 
displayed a similar bi-phasic profile, with an increase during exercise at 10 min and 
subsequently at 60 min post-exercise in all groups. A decline in both insulin and leptin 
was observed in all groups during exercise, while exercise was without effect on 
adiponectin. In all groups the peak in systemic GH occurred at the end of exercise, 
although the peak appeared to be somewhat depressed in the 40 - 60 yr. age range. 
Exercise was without effect on IGF-I, but concentrations were consistently higher in the 
20 – 30 yr. age group. In all groups cortisol concentrations declined post-exercise. We 
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conclude that systemic IGF-I concentrations clearly decline between the 3rd and 6th 
decades of life, and that age (20 - 60 yrs.) is not reflected by temporal and/or abundance 
variations in systemic insulin, leptin, adiponectin, IL-6, GH, IGF-I or cortisol variations 
in response to an acute 30 min bout of heavy domain cycle ergometer exercise. 
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Chapter 7. Discussion and future directions 
 
7.1. Achievement of overall aim and objectives 
 
Our overall aim was to implement an empirically informed, palatable acute endurance 
exercise intervention that elicits beneficial hormonal responses with the potential for 
improved health/quality of life across the lifespan. We envisage such an intervention 
might eventually form an exercise component in a multimodal lifestyle approach 
incorporating physical activity (endurance/aerobic and strength/power), nutrition (optimum 
calorific quantity and nutritional makeup) and key pharmaceutical therapies targeted to 
improving the performance of activities of daily living in older individuals through 
improvements in cardio-respiratory fitness, skeletal muscle quality and function, and 
reductions in adiposity and systemic inflammation. Our objectives were: 1) to develop, 
with regard to the principles and techniques associated with oxygen uptake dynamics 
research, acute ‘domain-based’ constant work-load cycle ergometer exercise 
interventions of varying intensity, but equal total work done by varying exercise duration, 
2) to establish the changes in the mRNA expression of selected hormones and cytokines 
that occur locally in skeletal muscle and subcutaneous adipose tissue and 3) systemically, 
as a function of our acute ‘domain-based’ constant work-load cycle ergometer exercise 
interventions in recreationally active young males, and 4) to establish the the impact of 
age (20 - 60 yrs.) on the systemic hormone and cytokine response to an acute heavy 
domain constant work-load cycle ergometer exercise intervention in recreationally active 
males. 
 
In Chapter 3 we satisfied our first objective by comparing data collected from the cycle 
ergometer maximum rate of oxygen uptake ( max) test, conducted using principles 
and techniques associated with oxygen uptake dynamics research, with that from three 
acute ‘domain-based’ constant work-load cycle ergometer exercise trials of varying 
intensity, but equal work done. In support of this alternative approach, which takes into 
account skeletal muscle metabolic threshold events rather than assigning constant work-
load exercise in groups of participants with reference to a percentage of the maximum 
rate of oxygen uptake (% max), a percentage of heart rate at max (% HRmax), 
or a target Heart rate (HR) derivative of a % max value such as is the case with the 
Karvonen formula (Karvonen and Vuorimaa, 1988), we observed no significant 
differences between mean rate of oxygen uptake ( ), HR and rate of oxygen uptake 
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divided by heart rate ( /HR) data obtained from the constant work-load cycle 
ergometer exercise trials and the max tests. This indicates that the exercise trials were 
conducted at the same ‘domain-based’ intensity identified during the max tests. 
 
In Chapters 4 and 5 we satisfied our second and third objectives by establishing the 
changes in Messenger ribonucleic acid (mRNA) expression in skeletal muscle and 
subcutaneous adipose tissue and systemic abundance, respectively, of selected hormones 
and cytokines with suggested key anabolic/catabolic/metabolic and inflammatory roles 
resulting from our alternative, exercise ‘domain-based’ approach. We discussed our 
findings within the context of mechanisms behind the hormone and cytokine responses 
to endurance exercise suggested in the existing literature. We suggest that our findings in 
young and apparently healthy participants appear predominantly to reflect mechanisms 
of metabolic control responding to the demands of the exercise trials. 
 
In Chapter 6 we satisfied our final objective and broadly achieved our overall aim. We 
established how the systemic abundance of selected hormones and cytokines with 
suggested key anabolic/catabolic/metabolic and inflammatory roles varied in response to 
an acute 30 min heavy domain constant work-load cycle ergometer exercise intervention. 
It has been suggested that the beneficial effects of endurance exercise are due to the anti-
inflammatory effects of regular exercise, through a reduction in fat mass and/or induction of 
an anti-inflammatory environment with each acute bout of exercise. We therefore suggest 
that heavy domain exercise may represent an effective endurance exercise component in 
a multimodal lifestyle approach targeted to improving the performance of activities of daily 
living in older individuals through improvements in cardio-respiratory fitness, skeletal 
muscle quality and function, and reductions in adiposity and systemic inflammation. Again, 
we discussed our findings within the context of pertinent existing literature, and again, 
our findings in apparently healthy participants between 20 and 60 yrs. age appear 
predominantly to reflect mechanisms of metabolic control responding to the demands of 
the exercise trials. However, our data also appear to show that the systemic abundance of 
markers of anabolism Insulin-like growth factor-I (IGF-I) and Growth hormone (GH) 
decline during this period of life, both basally and in response to acute exercise. 
 
7.2. General discussion 
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Over the last 15 - 20 years, research propelled by the significant socio-economic issues 
presented by obesity and an ageing population (World Health Organization, 2000; 2012; 
2013) has identified links between physical inactivity, metabolism and disease (Egan and 
Zierath, 2013; Pillon et al., 2013; Weigert et al., 2013; Wunderlich et al., 2013; Bosma, 
2014). Our increasingly less active lifestyles and opportunities to obtain sustenance with 
almost no effort facilitate over-nutrition and obesity, resulting in dysregulation of 
metabolism and the progression of a chronic inflammatory state (immunometabolism) 
(Ferrante, 2013; Mathis and Shoelson, 2011) leading to insulin resistance and Type 2 
diabetes mellitus (T2DM) (Sarvas et al., 2013). As we age a similar inflammatory process 
(inflammageing) (Degens, 2010; Cevenini et al., 2013; Franceschi and Campisi, 2014) 
contributes to the decline in the skeletal muscle mass (sarcopenia) and strength 
(dynapenia), eroding functional capability and quality of life. This appears to be further 
compounded by a progressive decline in anabolic potential, and therefore the ability to 
affect positive change. Through the mechanism of excitation-transcription coupling 
(Gundersen, 2011), skeletal muscle functions as a secretory organ. This provides the basis 
for a new paradigm for understanding the communication between skeletal muscle and 
other tissues and organs such as adipose tissue and the liver, and explains why a lack of 
physical activity appears to be involved in a network of diseases termed ‘The diseasome 
of physical inactivity’ (Pedersen, 2009). Exercise appears to be an effective therapy to 
correct metabolic function and reduce ectopic excess nutrient storage (Bosma, 2014), 
thereby reducing the associated low-grade systemic and tissue specific inflammation 
consequent to over-nutrition in obesity, sarcopenic obesity and dynapenic obesity (Egan 
and Zierath, 2013). 
 
7.2.1. Exercise trial design 
 
In contrast to traditional approach in which exercise intensity is expressed in terms of a 
% max, we favoured an approach more closely aligned with oxygen uptake dynamics 
research, and the concept of exercise domains (Whipp et al., 2005) as described in detail 
in Chapter 2 ‘General methods’. Section 2.5.1. ‘Methodological considerations: an 
oxygen uptake dynamics approach’. It is our view that the former could result in markedly 
different physiological stress characteristics at what would appear to be identical relative 
exercise intensities. Here we have demonstrated the precision with which constant work-
load exercise can be assigned, with reference to the profiles of the muscle metabolic and 
pulmonary gas exchange responses, from maximal incremental exercise in a domain-
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based manner in males between 20 and 60 yrs. of age. It is suggested that this should 
become the preferred method for assigning constant work-load exercise as it facilitates a 
closer alignment of groups of participants in terms of physiological stress, therefore 
excluding potentially confounding variables. This is particularly important given the 
mounting evidence linking the exercise-induced hormone and cytokine response with the 
complex mechanisms of metabolic control. In the present work two independent studies 
were linked by the inclusion of heavy domain constant work-load cycle ergometry trials. 
A schematic (figure 7.1.) describing the relationship between the exercise studies 
performed and the presentation of work throughout the thesis is presented in section 7.3. 
‘Exercise studies and presentation of work schematic’. Exercise duration was set to 
ensure equal total work done between exercise trials in the moderate and heavy domains 
in study 1, and exercise trials in the heavy and very heavy domains in study 2. Statistical 
analyses indicated the pooling of data from the two heavy domain exercise trials was 
appropriate, and that the participants could be considered as a single representative group. 
 
7.2.2. Exercise intensity and local and systemic cytokine responses 
 
An emerging theory suggests skeletal muscle has a physiological function as a sensor and 
responder to stress and that Interleukin-6 (IL-6) gene expression in muscle responds to a 
wide variety of internal and external stressors (Welc and Clanton, 2013; Bustamante et 
al., 2014). In the context of exercise, the requirement for energy represents a potent 
stressor (Pedersen, 2012). Exercise intensity influences the relative contributions from 
carbohydrate and lipid sources, and circulating (extra-muscular) and intramuscular fuel 
stores, to adenosine triphosphate provision (Coyle, 1995; Houten and Wanders, 2010; 
Egan and Zierath, 2013). It has been suggested that IL-6 expression mediates the response 
to this stress and increased expression mainly stimulates skeletal muscle glucose uptake, 
but also the mobilisation of substrate in anticipation of a prolonged exercise bout (Pal et 
al., 2014). Our data support this and show that even relatively short duration endurance 
exercise increases both expression of the IL-6 gene in skeletal muscle and systemic 
abundance of the protein. We have shown that under conditions of equal work done, acute 
very heavy domain exercise, requiring the most forceful contractions of all of the acute 
exercise trials investigated in the present work, stimulated the greatest increase in IL-6 
mRNA expression in skeletal muscle. Acute moderate domain exercise, requiring the 
least forceful contractions, promoted the greatest systemic accumulation of IL-6. Given 
the variation in exercise duration between these two trials, we speculate that although 
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moderate exercise appears to induce a lesser rate of IL-6 transcription and release, the 
greater exercise duration facilitates systemic accumulation of the protein. Given the 
evidence indicating a role for IL-6 in lipid homeostasis and metabolism (Lyngso et al., 
2002; van Hall et al., 2003; Petersen et al., 2005), we further speculate that systemic 
accumulation of IL-6 promotes greater access to adipose tissue depots, including those 
within skeletal muscle as an intermediary step (Kelly et al., 2004; Al-Khalili et al., 2006; 
Carey et al., 2006; Wolsk et al., 2010), and therefore mobilisation of fuel via endocrine 
and/or paracrine signalling for prolonged exercise bouts. 
 
We suggest the increased expression of Suppressor of cytokine signalling-3 (SOCS3) 
mRNA in skeletal muscle is in response to the exercise-induced increase in skeletal 
muscle IL-6 mRNA and systemic concentrations of IL-6 (Rieusset et al., 2004; Carey et 
al., 2006; Holmes et al., 2008). In this context the elevation of SOCS3 functions to prevent 
the effects of a chronic IL-6 response to exercise by negative feedback inhibition of the 
Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) signalling 
pathway (Babon and Nicola, 2012). In contrast to the contribution of chronically elevated 
SOCS3 to leptin and insulin resistance, the transient nature of the SOCS3 response to 
exercise-induced IL-6 is suggested to have limited effect on the beneficial metabolic and 
insulin sensitising effects of endurance exercise (Sarvas et al., 2013). Interestingly, a 
reduction in SOCS3 protein was found in the skeletal muscle of older (~ 67 yrs.) 
compared to that of younger (~ 20 yrs.) individuals 2 hrs. after an acute bout of resistance 
training (Trenerry et al., 2008). The implications of this remain to be fully elucidated. 
However, the authors speculate that this signalling potentiation by IL-6 maybe involved 
in impaired muscle regenerative capacity observed in older adults through the 
establishment of a pro-inflammatory state. It is possible that this mechanism is 
responsible for the increased systemic concentration of IL-6 from 40 - 60 yr. old males at 
60 min post-heavy exercise in comparison to that from the 20 - 40 yr. old participants, 
indicated by our data. 
 
In contrast to IL-6, the exercise-induced increase in skeletal muscle Tumour necrosis 
factor-alpha (TNFα) mRNA is suggested to be very small and to result in little if any 
measurable increase in systemic concentrations, indicating a local role in skeletal muscle 
(Steensberg et al., 2002; Febbraio et al., 2003). Exercise is suggested to promote an anti-
inflammatory environment (Pedersen and Hoffman-Goetz, 2000; Brandt and Pedersen, 
2010) due, in part, to IL-6 inhibition of Interleukin-1 (IL-1), TNF, and Interleukin-8 
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(IL-8) expression and systemic abundance (Ostrowski et al., 1999; Starkie et al., 2003; 
Steensberg et al., 2003). However, our data show a significant increase in the expression 
of TNF mRNA in response to acute very heavy domain exercise. These findings add 
support to those from others who have also shown an increase in skeletal muscle TNF 
mRNA in response to endurance exercise above ~ 70 % max (Nieman et al., 2003; 
2005; Louis et al., 2007). Unfortunately, we are unable to identify the exact cellular 
source of the TNF mRNA due to the use of homogenate, which in addition to skeletal 
muscle tissue may also include inflammatory cells. This does however lend itself to 
skeletal muscle repair and regeneration as a plausible explanation for the increased 
expression of this pro-inflammatory cytokine, as a local immune response shortly after 
the cessation of exercise forms the initial step in the regeneration process and activates 
Muscle satellite cells (MuSCs) (Seene and Kaasik, 2013; Madaro and Bouché, 2014). 
Interestingly, data from Al-Shanti et al., (2008) from the murine C2C12 muscle cell line, 
suggests TNF-α and IL-6 function positively and potentially also co-operatively with the 
Insulin-like growth factor system to achieve the maximal beneficial effect on skeletal 
myoblast numbers. We speculate that these data may indicate TNFα and IL-6 working 
synergistically to enhance skeletal muscle regeneration following very heavy exercise. 
However, it must be remembered that elevated TNFα has been shown to play a direct 
pathogenic role in conditions associated with skeletal muscle insulin resistance 
(Hotamisligil et al., 1996; Plomgaard et al., 2005; Bouzakri and Zierath, 2007), 
dyslipidemia, the development of lipid-induced insulin resistance (Steinberg et al., 2006; 
Plomgaard et al., 2008; Steinberg et al., 2009) and has been identified as a biomarker of 
peripheral muscle fatigue (Finsterer, 2012) and inflammation (Zelová and Hošek, 2013). 
Although highly speculative, considering these findings collectively, it is counter-
intuitive to advocate a therapeutic role for endurance exercise in addressing age-related 
skeletal muscle functional decline, obesity or systemic inflammation at an intensity 
shown to promote an increase in expression of TNFα. 
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7.2.3. Exercise and the Growth hormone/Insulin-like growth factor-I axis 
 
The present work addresses, in part, the absence of exercise dose-response reference data 
relating to systemic hormone and cytokine adaptations to acute endurance exercise in 
apparently healthy males between 20 – 60 yrs. of age. Our data support the view that the 
systemic abundance of markers of anabolism decline during this period of life 
(Baumgartner et al., 1999; Chahal and Drake, 2007; Giovannini et al., 2008), both basally 
and in response to acute exercise. Universally, systemic IGF-I concentrations were 
greatest in the youngest age group. This group demonstrated the greatest acute increase 
in response to maximal exercise and maintained the greatest concentration in response to 
acute heavy exercise. Further, our data suggest the decline in IGF-I becomes significant 
after 40 yrs. of age. In all studies GH peaked at the end of exercise and returned 
approximately to baseline concentrations by 60 min post-exercise. Although not 
statistically significant, our data show a decline in the exercise-induced peak in the 
systemic concentrations of GH. Similar to the decline in IGF-I, this is most apparent after 
40 yrs. of age. The reduction in the GH to cortisol ratio peak at the end of heavy domain 
exercise in the 50 - 60 yr. age group further supports this. Systemically, our data show an 
uncoupling of the GH/IGF-I axis during exercise at sub-maximal intensities, similar to 
that observed by Zaldivar et al., (2006), where the exercise-induced peak in systemic GH 
abundance is not reflected in the IGF-I response. This has been suggested to be due to the 
transient nature of the exercise-induced GH response (Frystyk, 2010) and emphasises a 
metabolic rather than anabolic role (Møller and Jørgensen, 2009). 
 
Interestingly, and in addition to increased systemic IL-6, GH and insulin concentrations, 
our data show significant increases in systemic IGF-I concentrations in all studies 
regardless of age in response to maximal exercise, supporting the findings of others (De 
Palo et al., 2008; Zebrowska et al., 2009). In contrast, but also regardless of age, no 
significant increases in systemic IGF-I, or IGF-I and Insulin-like growth factor-I receptor 
(IGF-IR) mRNA expression were observed in response to sub-maximal exercise. 
Increased expression of IGF-I in skeletal muscle has been shown with unchanged 
systemic levels (LeRoith et al., 2001; Velloso, 2008; Gatti et al., 2012) suggesting that 
local IGF-I may augment systemic concentrations (Adams, 2002; Berg and Bang, 2004; 
Nindl, 2010). This suggests the possibility for potential anabolic gain from acute 
endurance exercise at intensities that elicit maximal oxygen uptake in individuals of less 
than 60 yrs. of age. High intensity exercise training has recently been advocated as a 
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potential therapy with beneficial effects on glycaemic control, as an alternative to low 
intensity high volume training (Adams, 2013; Roberts et al., 2013; Wahl et al., 2013), and 
this maybe an avenue worthy of further investigation. 
 
7.3. Exercise studies and presentation of work schematic 
 
A schematic representation of the relationship between the exercise studies performed 
and the presentation of work throughout the thesis is provided in figure 7.1. For additional 
information pertaining to the exercise trial timelines and exercise trial protocols, the 
reader is directed to Chapter 2. Section 2.5.1.8.1. ‘Overview of exercise studies’. 
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Figure 7.1. Schematic describing the relationship between the exercise studies performed and the presentation of work throughout the thesis. Heavy domain exercise trials link all three 
studies. Sd - significantly different, NS - no significant differences, B – baseline, MAX -  max test, S - significant increase, S - significant decrease, m – male. 
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7.4. Limitations 
 
The following is a discussion of what could be perceived as limitations of the work 
presented in this thesis. Limitations specific to each data chapter are first summarised and 
then discussed. 
 
Chapter 3 limitations: 1) a departure from traditional methods of aligning exercise 
intensity i.e. % max, % HRmax, or a similar method such as by use of the Karvonen 
formula (Karvonen and Vuorimaa, 1988), in favour of an exercise ‘domain-based’ 
approach, 2) the division of work into two independent studies, linked by the inclusion of 
heavy domain constant work-load cycle ergometry trials, 3) generalisation, based on the 
findings of Pringle and Jones (2002), rather than direct measurement of Maximal lactate 
steady state (MLSS) to define the boundary between heavy and very heavy domain 
exercise, 4) deviation from The British Association of Sport and Exercise Sciences 
(BASES) and American College of Sports Medicine (ACSM) criteria for successful 
determination of max, and 5) the lack of a verification stage to indicate conclusively 
attainment of max. 
 
By departing from traditional methods of aligning exercise intensity and adopting 
methods common to oxygen uptake dynamics research, we have been able to specify 
exercise intensity and measure the resulting variation in hormone and cytokine responses 
in our participants with regard to common threshold events in their individual muscle 
metabolic and pulmonary gas exchange responses. We feel that skeletal muscle metabolic 
threshold events such as the Anaerobic threshold (ATh), or in oxygen uptake dynamics 
research terminology the Gas exchange threshold (GET), maybe important in defining 
the hormone and cytokine response to exercise, and consequently this approach may help 
clarify the many and varied roles these proteins play. Simply aligning exercise intensity 
in groups of participants by % max, % HRmax, or a target HR derivative of a % 
max value, as is the case with the Karvonen formula (Karvonen and Vuorimaa, 1988), 
could result in markedly different physiological stress characteristics at what would 
appear to be identical relative exercise intensities, i.e. exercise at 70 % max, in a 
group of participants varying in aerobic fitness might mean that some participants are 
working below their ATh while others maybe working above their ATh. 
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The division of work into two independent studies, linked by the inclusion of heavy 
domain constant work-load cycle ergometry trials allowed us to implement a protocol 
which would otherwise have been highly demanding, potentially influencing adherence 
to and completion, and ethically questionable in terms of the invasive nature of the 
procedures for a single study group. The results of the statistical tests comparing data 
from the two participant groups described previously indicate that the decision to proceed 
with this study design has not compromised the integrity of the findings. Similarly, direct 
measurement of MLSS, conclusively defining the boundary between the heavy and very 
heavy exercise domains would have significantly increased the demand on the 
participants. Informed by the findings of Pringle and Jones (2002) described previously 
we chose not to measure MLSS directly, but to perform the heavy domain exercise trial 
at a power output which elicited a 30 %  response and the very heavy domain exercise 
trial at a power output which elicited a 60 %  response, thus avoiding the MLSS and 
placing the respective trials firmly within each exercise domain. 
 
We chose to deviate from established BASES and ACSM guidelines for the successful 
determination of max in favour of a set of criteria determined by ourselves with 
reference to the existing literature. Our reasons for this were two-fold. Firstly, due to the 
use of a breath-by-breath expired gas analysis system, we were confident in our ability to 
identify our primary criterion, a plateau in the  data with increasing work-load. 
Secondly, in the face of literature criticising secondary deterministic criteria, it appears 
contrary to the scientific process to fail to acknowledge limitations and not to push for 
improvement in methods and techniques. Given our confidence in being able to 
accurately determine max, we felt that implementing a verification stage to indicate 
conclusively attainment of max was not required and would be ethically questionable 
when testing the older participant groups. 
 
Chapter 4 limitations: 1) timing of biopsy sampling immediately post-exercise may 
provide an incomplete picture of mRNA expression, 2) the presence of cells such as 
smooth muscle cells, fibroblasts, endothelial cells, and macrophages in the bipotic 
material, which may have contributed to mRNA expression data, and 3) the measurement 
of the changes in mRNA expression and not the rate of gene transcription. 
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A single biopsy collected immediately post-exercise will not provide a complete picture 
of the exercise-induced changes in mRNA expression. As previously discussed, it is 
entirely possible that the timing of the biopsy, immediately post exercise, is the reason no 
significant changes in mRNA expression were detected in subcutaneous adipose tissue. 
However, our data document the changes in skeletal muscle relative to a lack of change 
in subcutaneous adipose tissue immediately post-exercise. Further post-exercise biopsies 
may have provided interesting information and clarified our understanding of the 
temporal characteristics of the exercise response in these tissues. Due to the sample 
method, it is entirely possible that the changes in gene expression observed in the present 
study may be due, at least in part, to increased mRNA expression in cells other than 
skeletal muscle myocytes. However, it is therefore logical to assume that these cells make 
an important contribution to the local hormone and cytokine milieu, which we feel 
justifies the inclusion and the use of the biopsy technique. It is important to acknowledge 
that we measured changes in mRNA expression and not the rate of gene transcription. It 
is entirely possible that data reflect an increase in transcription and/or increases in mRNA 
stability, or a combination of both. 
 
Chapter 5 limitations: 1) timing of blood sampling may provide an incomplete picture of 
the changes in systemic abundance of the selected hormones and cytokines, 2) the 
influence of natural circadian variation and the pulsatile nature of GH and cortisol 
secretions, and 3) the effect of fasting on systemic hormone and cytokine abundance. 
 
Blood samples were taken at baseline, immediately post-exercise, and at 60 minutes and 
24 hrs. post-exercise. To gain a complete picture of the changes in the systemic abundance 
profiles of the selected hormones and cytokines in response to the exercise trials over the 
24 hr. period a far greater frequency of sampling would be required. Quite apart form the 
cost implication, an analysis of this depth was not possible within the scope of the thesis. 
However, our data document the changes in the systemic abundance profiles of the 
selected hormones and cytokines relative to each other in response to the exercise trials, 
and have provided some interesting information and clarified our understanding of the 
temporal characteristics of the exercise response. As far as is reasonably practicable we 
have controlled for circadian effects and the pulsatile nature of GH and cortisol secretions 
from the anterior pituitary and the adrenal glands, respectively, by ensuring the 
homogeneity of our participants and that all tests were performed in a similar 
physiological state, e.g. rested, fasted, euhydrated and at the same time of day. However, 
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the changes in the GH and cortisol systemic abundance profiles will reflect not only the 
GH and cortisol response to the exercise trials, but also the underlying natural circadian 
and pulsatile secretion dynamics. Future investigations into the GH and cortisol response 
to exercise could choose to first assess the ‘normal’ 24 hr. GH and cortisol secretion 
dynamics as a control measure prior to an acute exercise bout. All of the data collected 
was from participants in the fasted state. Evidence suggests that compared to the fed state, 
acute exercise in the fasted state promotes altered metabolic regulation, and is therefore 
both an important methodological consideration with a potentially significant impact on 
the results. It is therefore probable that the systemic hormone and cytokine responses 
reflect what is suggested in the literature to be a predisposition to metabolic control 
favouring pathways geared towards mobilizing and utilising stored fat. Future 
investigations could choose to control nutrient intake by supplying a standardised meal 
prior to data collection. The conclusions drawn from the data presented in this chapter, 
e.g. the likelihood that IL-6 functions metabolically during sub-maximal exercise to 
mobilise fat stores, are suggested with reference to the evidence presented in the 
literature. Within the scope of a single study, or indeed this thesis, it is not possible to 
examine completely the activation of the intricate signaling mechanisms that would 
provide proof beyond doubt. Future investigations could choose to focus on examining 
in detail downstream signalling events that may provide such evidence. 
 
Chapter 6 limitations: 1) the use of recreationally active and apparently healthy 
participants between 20 and 60 yrs. age, 2) the lack of an assessment of habitual physical 
activity as a measure of participant training status, and 3) the use of alternative equipment 
for the determination of Blood lactate (BLa) and Blood glucose (BGlu) in 40 – 60 yr. old 
vs. 20 – 40 yr. old participants. 
 
Recreationally active and apparently healthy participants between 20 and 60 yrs. age. 
were recruited for the work presented in Chapter 6. We felt that by employing a study 
design in which participants were arranged into four groups, with each group displaying 
variations in systemic hormone and cytokine abundance characteristic of healthy ageing 
between the 3rd and 6th decades of life, would allow us to augment the local and systemic 
data gathered previously (Chapters 4 and 5, respectively) in 18 – 40 yr. old participants 
while potentially highlighting early age-related changes in hormone and cytokine 
abundance. The ethical and methodological constraints of maximal exercise testing in 
older individuals were also considered. 
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Levels of habitual physical activity were not quantified in our recreationally active 
participants. It is probable that the exercise-induced systemic abundance of the hormones 
and cytokines was influenced by habitual physical activity or ‘training’. For some of the 
older participants physical activity may have been a life-long pursuit, and this may have 
had a disproportionate influence on exercise-induced systemic hormone and cytokine 
responses in comparison to the younger, potentially less ‘trained’, participants. Future 
investigations may choose to quantify participant habitual physical activity, e.g. through 
the use of questionnaires (Baecke et al., 1982). Quantification of habitual physical activity 
would have allowed basic information regarding the activity levels of each of the 
participant age groups to be compiled and a comparison between them performed. Such 
as comparison may have informed the discussion of the data and the conclusions drawn. 
 
Due to the relocation of laboratory facilities, two different analysers had to be employed 
in the measurement of BLa and BGlu during data collection (equipment described 
previously in Chapter 2. Sections 2.6.2.1. ‘Blood lactate’ and 2.6.2.2. ‘Blood glucose’, 
respectively). Despite performing daily calibration checks to ensure accurate readings, 
the lower BLa concentrations at baseline measured in the younger participants in response 
to both maximal and heavy domain exercise, despite the similar relative physiological 
demands of heavy exercise, maybe due to the unavoidable substitution of equipment and 
variation in measurement methods. 
 
Notwithstanding the limitations discussed above, we feel that the data presented in this 
thesis adds clarity to the research regarding the hormone and cytokine response to 
endurance exercise, and highlights what we feel is an important methodological 
consideration in this field of research. Specifically, the alignment of exercise intensity 
with regard to skeletal muscle metabolic threshold events, given the important endocrine 
activity of the tissue, rather than by reference to % max, % HRmax or a similar 
method such as by use of the Karvonen formula (Karvonen and Vuorimaa, 1988), which 
could result in markedly different physiological stress characteristics at what would 
appear to be identical relative exercise intensities (Whipp et al., 2005). 
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7.5. Conclusion 
 
We adopted techniques and methods associated with oxygen uptake dynamics research 
and, based on comparisons of cardio-respiratory data, successfully aligned exercise 
intensity relative to the skeletal muscle metabolic threshold events characteristic of exercise 
in the moderate, heavy and very heavy exercise domains. In comparison to equal work done 
moderate (80 % GET) exercise, heavy (30 % ) exercise, promotes a favourable exercise-
induced systemic change in the GH to cortisol ratio while avoiding the potentially 
negative inflammatory consequences of increased skeletal muscle TNFα mRNA 
expression, which we have shown occurs in response to very heavy (60 % ) exercise. 
Although skeletal muscle IL-6 mRNA is expressed at a similar level in equal work done 
heavy and very heavy exercise, we suggest that the greater duration of the former 
promotes systemic IL-6 accumulation with the metabolic role of mobilising free fatty 
acids from adipose tissue with the potential for positive effects on adipose tissue mass 
and associated inflammation. Further, heavy exercise of 30 min duration is palatable in 
males up to 60 yrs. age, and whilst the systemic abundance of IGF-I at baseline clearly 
declines between the 3rd and 6th decades of life, increasing age was not reflected by 
significant exercise-induced variations in systemic insulin, leptin, adiponectin, IL-6, GH, 
IGF-I or cortisol. We suggest the lack of age-related significant variations in the systemic 
abundance of the selected hormones an cytokines analysed is due to the health and fitness 
of our our recreationally active participants. 
 
It has been suggested that the beneficial effects of endurance exercise are due to the anti-
inflammatory effects of regular exercise, through a reduction in fat mass and/or induction of 
an anti-inflammatory environment with each acute bout of exercise. Our overall aim was to 
implement an empirically informed, palatable acute endurance exercise intervention that 
elicits beneficial hormonal responses with the potential for improved health/quality of life 
across the lifespan. We achieved this aim by implementing a bout of heavy domain 
exercise in recreationally active apparently healthy males of 20 – 60 yrs. age. However, 
a great deal of further work would clearly be required to identify and optimise an 
endurance exercise intervention for older individuals. We envisage such an intervention 
might eventually form an important exercise component in an multimodal lifestyle 
approach incorporating physical activity (endurance/aerobic and strength/power), nutrition 
(optimum calorific quantity and nutritional makeup) and key pharmaceutical therapies 
targeted to improving the performance of activities of daily living in older individuals 
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through improvements in cardio-respiratory fitness, skeletal muscle quality and function, 
and reductions in adiposity and systemic inflammation. 
 
Finally, it is our opinion that given the evidence for skeletal muscle endocrine activity 
and adipose tissue cross-talk in order to satisfy metabolic demand during and post-
exercise, exercise-induced hormone and cytokine research should adopt the techniques 
and methods associated with oxygen uptake dynamics research, which ensure alignment 
of relative exercise intensity with regard to skeletal muscle metabolic threshold events. 
 
7.6. Future directions 
 
Given that recent evidence suggests major roles for exercise-induced myokines and 
adipokines in metabolic regulation, future investigations should be performed with 
metabolic-demand-driven hypotheses in accordance with a central guiding principle that 
exercise places demands on the body that ultimately benefits health. The benefits of 
exercise are realised through: (a) impedance of the propagation of adipose tissue mediated 
inflammation and associated co-morbidities by control of adipose tissue mass, and (b) 
positive effects on the functional capacity of skeletal muscle, determined largely by 
exercise stimulus. 
 
1) The experimental design in the present work provided the opportunity to directly 
compare exercise intensity (contractile force) in the completion of equal work done 
exercise trials, through manipulation of exercise trial duration. We were therefore unable 
to draw conclusions regarding the effect of exercise duration. Further work should be 
performed to explore the effect of varying exercise duration intra-domain. We propose 
three initial consolidation studies. Cycle ergometer exercise at each of the three exercise 
intensities with a second trial increasing the duration by 50 % as follows: 60 and 90 min 
at moderate (80 % GET), 30 and 45 min at heavy (30 % ), and 15 and 22 min at very 
heavy (60 % ). 
 
2) We suggest addressing the translation from acute exercise-induced responses to 
chronic exercise training-induced adaptations, comparing the benefits of endurance and 
resistance training in sedentary young-adult and older participants. We propose a cross-
over training study to investigate the effects of 12 weeks of endurance and 12 weeks of 
resistance training in apparently healthy sedentary males (n = 20 in each age group 20 - 
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30, 30 - 40, 40 - 50, 50 - 60, 60 – 70 yrs. of age). Participants would be randomly assigned 
within each age group to experimental group 1 or 2, and progress through the study as 
shown in figure 7.2. The findings may help to identify the extent to which relevant and 
supervised exercise interventions might impact health over an extended age range. 
 
3) Given ethical constraints, it is not feasible to investigate mechanisms in vivo, and 
therefore the model of acute and chronic adaptations should be extended to incorporate 
cell culture and/or animal studies. Studies in human cells cultured from bioptic material 
obtained in 1 and 2 above could be used to compare and contrast stem cell behavior 
(growth, differentiation, survival, senescence, injury repair) across the age groups, pre- 
and post- acute and chronic interventions. The impact of serum (acute and chronic) from 
across the age groups could also be investigated. Specific questions would further the 
work of Al-Shanti et al., (2008; 2012) and the relationships between IL-6, TNF and 
IGF-I, given the hypothesised effects of IL-6 on satellite cell mobilisation and 
hypertrophy (Serrano et al., 2008; McKay et al., 2009; Washington et al., 2011; Pedersen 
and Febbraio, 2012). 
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Figure 7.2. A cross-over training study to investigate the effects of 12 weeks of endurance and 12 weeks of resistance training. DEXA - Dual-energy X-ray absorptiometry, MRI - 
Magnetic resonance imaging, ADL – Activities of daily living, RM – Repetition maximum, SM&A - Skeletal muscle and subcutaneous adipose tissue biopsy. 
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Appendix A: Chemicals and reagents 
 
Chemical/reagent Manufacturer/supplier 
 
Betadine surgical scrub Purdue Pharma LP, Stamford, 
  Connecticut, USA. 
Chloroform (99 %), C2432-500ml Sigma-Aldrich Company Ltd., 
  Poole, UK. 
DEPC treated water, 75-0024 Invitrogen, Paisley, UK. 
ELISA kits: 
 IL-6, 850.035.096 IDS Ltd., Tyne and Wear, UK. 
 IL-1, 583301 Cayman Chemical Company, 
  Michigan, USA. 
 IL-1, 583311 Cayman Chemical Company, 
  Michigan, USA. 
 TNF, 589201 Cayman Chemical Company, 
  Michigan, USA. 
 Cortisol, DX-EIA-1887 IDS Ltd., Tyne and Wear, UK. 
 IL-6, BMS213INST Bender MedSystems GmbH,  
  Vienna, Austria. 
 GH, DX-EIA-3552 IDS Ltd., Tyne and Wear, UK. 
 IGF-I, EL2010 Oxford Biosystems Oxford, UK. 
 Leptin, BMS2039INST Bender MedSystems GmbH, 
  Vienna, Austria. 
 Adiponectin, DEE009 Demeditec Diagnostics GmbH, 
  Kiel, Germany. 
 Insulin, KAP1251 BioSource Europe S.A., Nivelles, 
  Belgium. 
Ethanol (96 %), 10476 VWR International Ltd., 
  Lutterworth, UK. 
Isopropanol (99 %), I9516-500ml Sigma-Aldrich Company Ltd., 
  Poole, UK. 
Lidocaine (2 %), PL01502/0021R Hamlin Pharmaceuticals Ltd., 
  Gloucester, UK. 
Oligonucleotide synthesis: Sigma-Genosys Ltd., Suffolk, UK. 
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  QIAGEN, West Sussex, UK. 
Phosphate Buffered Saline, BR0014G OXOID, Basingstoke, UK. 
Power SYBR Green RNA-to-CT 1-Step Kit, -  Applied Biosystems, Warrington, 
4389986 UK. 
RNase zap, AM9780 Applied Biosystems, Warrington, 
  UK. 
The RNA storage solution, AM7001 Applied Biosystems, Warrington, 
  UK. 
Trizol (TRI®) Reagent Solution, AM9738 Applied Biosystems, Warrington, 
  UK. 
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Appendix B: Equipment 
 
General laboratory plastic and glassware: 
 
Jencons PLS, Leighton Buzzard, UK. 
VWR International Ltd., Lutterworth, UK. 
Fisher Scientific Inc., Loughborough, UK. 
 
Equipment Manufacturer/supplier 
 
Aerosol resistant (ART®) pipette tips Molecular BioProducts Inc., San 
Diego, CA, USA. 
Auto. 96-well plate reader, ELx800UV BIO-TEK Instruments Inc., 
  Winooski, USA. 
Blood glucose analyser 201+,120713 HemoCue AB, Ängelholm, Sweden. 
 Level 2 controls, 146.002.002 HemoCue AB, Ängelholm, Sweden. 
 Microcuvetes, Glucose 201+, 110716 HemoCue AB, Ängelholm, Sweden. 
Blood glucose analyser, Accutrend GC Roche Diagnostics, East Sussex, 
  UK. 
 Glucose reagent strips, Accutest Roche Diagnostics, East Sussex, 
  UK. 
Blood lactate analyser, Lactate Pro Akray KDK, Koyota, Japan. 
 Lactate Pro reagent Strips Akray KDK, Koyota, Japan. 
Blood lactate analyser, YSI 1500 Sport YSI Inc., Yellow Springs, Ohio, 
  USA. 
Bio. safety cabinet, class II, NU-437-400E NuAire Inc., Plymouth, MN, USA. 
Biotech photometer, WPA Biowave II Biochrom Ltd., Cambridge, UK. 
Biopsy conchotome Weil-Blakesley 52-030-50 Gebrüder Zepf Medizintechnik, 
  Tüttlingen, Germany. 
Cardio-pulmonary testing system, K4 b2 COSMED, Rome, Italy. 
Cryovials, 1.2 ml, CRY-100-015A Fisher Scientific Inc., 
  Loughborough, UK. 
Cycle ergometer, Ergoline ER 800 Jaeger, GmbH, Würzburg, 
  Germany. 
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Disposable prep razor, UN2000 Universal Hospital Supplies, 
  Enfield, UK. 
DNA Engine Peltier Thermal Cycler -  BioRad Laboratories Ltd., Hemel 
with Chromo4 RT-PCR Detector Hempstead, UK. 
 PC laptop, Samsung M50 Samsung, Seoul, South Korea. 
Fluid aspiration system 401134 Vaccusafe Comfort, INTEGRA 
  Biosciences AG, Chur, Switzerland. 
Freezer storage:  
 -80 C, NuAire, NU9668 NuAire Inc., Plymouth MN, USA. 
 -80 C, Revco Ultima, RFV-104-020L Fisher Scientific, Loughborough, 
  UK. 
Heart rate monitor, Accurex Plus Polar Electro Oy, Kempele, Finland. 
Hypodermic needle, 21G, NN-2138R Terumo Europe, Leuven, Belgium. 
Hypodermic needle, 25G, NN-2516R Terumo Europe, Leuven, Belgium. 
Ice flaker, Scotsman AF100 Frimont, Milan, Italy. 
Magnetic stirrer/hotplate, IKA Combimag RET IKA-Werke GmbH & Co. KG, 
  Staufen, Germany. 
Micro-centrifuge, Galaxy 16DH, 521-2841 VWR International Ltd., 
  Lutterworth, UK. 
Micro-centrifuge tubes, 0.5 ml, 0030 121.023 Eppendorf AG. Hamburg, Germany. 
Micro-centrifuge tubes, 1.5 ml, 0030 120.086 Eppendorf AG. Hamburg, Germany. 
Micro-centrifuge tubes, 2 ml, 0030 120.094 Eppendorf AG. Hamburg, Germany. 
Optical film sealing kit, MSO-1001 Bio-Rad Laboratories Ltd., Hemel 
  Hempstead, UK. 
Orbital shaker, Vibrax VXR IKA-Werke GmbH & Co. KG, 
  Staufen, Germany. 
RT-PCR Plates, 96-well, HSP-9655 Bio-Rad Laboratories Ltd., Hemel 
  Hempstead, UK. 
pH meter, 410A Thermo Electron Corporation, 
  Beverly, MA, USA. 
Pipette, 12-channel, 5-50 µl, Rainin L12-50 Anachem Ltd., Luton, UK. 
 Pipette tips, 2-250 µl, Rainin SS-L250 Anachem Ltd., Luton, UK. 
Pipette, 12-channel, 50-300 µl, Rainin L12-300 Anachem Ltd., Luton, UK. 
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 Pipette tips, 30-300 µl, Rainin SS-L300 Anachem Ltd., Luton, UK. 
Pipettes, single channel, 10 µl – 5 ml  Gilson Inc., Middleton, WI, USA. 
 Pipette tips, 10 µl – 5 ml Fisher Scientific UK Ltd., 
  Loughborough, UK. 
 Pipette tips, RNase free, barrier, 10 µl 1 ml ART Micropoint, Molecular 
  BioProducts Inc., San Diego, CA, 
  USA. 
Pre-injection wipes, Sterets, 00766691 Seton Healthcare Group plc., 
  Oldham, UK. 
Refrigerated Centrifuge, 3K10 SIGMA Laborzentrifugen GmbH, 
  Osterode am Harz, Germany. 
Refrigerator storage: 
 4 C, Biocold, 2224 Scientific laboratory Supplies, 
  Nottingham, UK. 
S-Monovette tubes, Serum Z/9ml, 02.1063.001 Sarstedt AG & Co, Germany. 
Safety lancets, Haemolance Plus, 7568 HTL Strefa, Inc., Marietta, GA, 
  USA. 
Scales, SECA beam balance, 709 SECA, Hamburg, Germany. 
Serological pipette filler, Powerpette Pro, -  Jencons PLS, Leighton Buzzard, 
 266-185 UK. 
 Serological pipettes, 2 – 25 ml Fisher Scientific UK Ltd., 
  Loughborough, UK. 
Stadiometer, Harpenden with –  Holtain Ltd, Crymych, Wales. 
 Veeder-Root high speed counter 
Sterile adhesive strips, 3M Steri-Strip 3M Healthcare, St. Paul, MN, USA. 
Sterile compressive dressing: 
 Self-Adherent Wrap, 3M Coban, 1584 3M Healthcare, St. Paul, MN, USA. 
 Gauze swab, Vernaid, 28919 Vernon-Carus ltd., Preston, UK. 
Sterile container, 150 ml, FB51778 Fisher Scientific Inc., 
  Loughborough, UK. 
Sterile disposable scalpel, Size 11 Swann-Morton, General Medical, 
  Aldershot, UK. 
Sterile dressing, Mepore Ultra Mölnlycke Health Care AB, 
  Göteborg, Sweden. 
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Sterile procedure pack, Vernaid, 28853 Vernon-Carus ltd., Preston, UK. 
Syringe, 5 ml, SS-05ES Terumo Europe, Leuven, Belgium. 
Syringe, 10 ml, SS-10ES Terumo Europe, Leuven, Belgium. 
Venous cannula, 22G, Venflon IV Blue Beckton Dickinson (BD)  
  Biosciences, Oxford, UK. 
Vortex mixer, Vortex 3, 3340000 IKA-Werke GmbH & Co. KG, 
  Staufen, Germany. 
Water purification system, RIOS3 Millipore, Billerica, MA, USA. 
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Appendix C: Solutions 
 
Solutions were prepared with dH2O unless otherwise indicated. 
 
Ethanol (75 % solution) 
 Ethanol 96 % v/v 
 Add 100 ml of 96 % v/v ethanol to 22 ml dH2O. 
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Appendix D: Gases 
 
Gases were purchased from the British Oxygen Company (BOC) Ltd, Guildford, UK 
unless otherwise specified. 
 
K4 b2 calibration gas - O2 (16 %)/CO2 (5 %) N2 balance. 
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Appendix E: Software 
 
Software Version Designer/Supplier 
 
Opticon Monitor 3.1.32 MJ Geneworks Inc., Waltham,  
   Massachusetts, USA. 
IBM SPSS Statistics 19 - 21 IBM Corporation, New York,  
   USA. 
K4 b2 PC software 8.0b COSMED, Rome, Italy. 
Beacon Designer 5.11 PREMIER Biosoft International,  
   California, USA. 
NCBI Genbank database  NCBI, Maryland, USA. 
Microsoft Office for Mac: 
 Microsoft Excel for Mac 2011 Microsoft Corporation, Redmond, 
   WA, USA. 
 Microsoft Word for Mac 2011 Microsoft Corporation, Redmond, 
   WA, USA. 
